
<html lang="en"     class="pb-page"  data-request-id="fc110c58-accb-43fe-894d-722a0130c2c3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-5;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b01695"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification and Preclinical Pharmacology of ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials" /></meta><meta name="dc.Creator" content="John L.  Gilmore" /></meta><meta name="dc.Creator" content="Hai-Yun  Xiao" /></meta><meta name="dc.Creator" content="T. G. Murali  Dhar" /></meta><meta name="dc.Creator" content="Michael G.  Yang" /></meta><meta name="dc.Creator" content="Zili  Xiao" /></meta><meta name="dc.Creator" content="Jenny  Xie" /></meta><meta name="dc.Creator" content="Lois D.  Lehman-McKeeman" /></meta><meta name="dc.Creator" content="Lei  Gong" /></meta><meta name="dc.Creator" content="Huadong  Sun" /></meta><meta name="dc.Creator" content="Lloyd  Lecureux" /></meta><meta name="dc.Creator" content="Cliff  Chen" /></meta><meta name="dc.Creator" content="Dauh-Rurng  Wu" /></meta><meta name="dc.Creator" content="Marta  Dabros" /></meta><meta name="dc.Creator" content="Xiaoxia  Yang" /></meta><meta name="dc.Creator" content="Tracy L.  Taylor" /></meta><meta name="dc.Creator" content="Xia D.  Zhou" /></meta><meta name="dc.Creator" content="Elizabeth M.  Heimrich" /></meta><meta name="dc.Creator" content="Rochelle  Thomas" /></meta><meta name="dc.Creator" content="Kim W.  McIntyre" /></meta><meta name="dc.Creator" content="Virna  Borowski" /></meta><meta name="dc.Creator" content="Bethanne M.  Warrack" /></meta><meta name="dc.Creator" content="Yuwen  Li" /></meta><meta name="dc.Creator" content="Hong  Shi" /></meta><meta name="dc.Creator" content="Paul C.  Levesque" /></meta><meta name="dc.Creator" content="Zheng  Yang" /></meta><meta name="dc.Creator" content="Anthony M.  Marino" /></meta><meta name="dc.Creator" content="Georgia  Cornelius" /></meta><meta name="dc.Creator" content="Celia J.  D’Arienzo" /></meta><meta name="dc.Creator" content="Arvind  Mathur" /></meta><meta name="dc.Creator" content="Richard  Rampulla" /></meta><meta name="dc.Creator" content="Anuradha  Gupta" /></meta><meta name="dc.Creator" content="Bala  Pragalathan" /></meta><meta name="dc.Creator" content="Ding Ren  Shen" /></meta><meta name="dc.Creator" content="Mary Ellen  Cvijic" /></meta><meta name="dc.Creator" content="Luisa M.  Salter-Cid" /></meta><meta name="dc.Creator" content="Percy H.  Carter" /></meta><meta name="dc.Creator" content="Alaric J.  Dyckman" /></meta><meta name="dc.Description" content="Recently, our research group reported the identification of BMS-986104 (2) as a differentiated S1P1 receptor modulator. In comparison to fingolimod (1), a full agonist of S1P1 currently marketed fo..." /></meta><meta name="Description" content="Recently, our research group reported the identification of BMS-986104 (2) as a differentiated S1P1 receptor modulator. In comparison to fingolimod (1), a full agonist of S1P1 currently marketed fo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 20, 2019" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01695" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01695" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01695" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01695" /></link>
        
    
    

<title>Identification and Preclinical Pharmacology of ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01695" /></meta><meta property="og:title" content="Identification and Preclinical Pharmacology of ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0015.jpeg" /></meta><meta property="og:description" content="Recently, our research group reported the identification of BMS-986104 (2) as a differentiated S1P1 receptor modulator. In comparison to fingolimod (1), a full agonist of S1P1 currently marketed for the treatment of relapse remitting multiple sclerosis (RRMS), 2 offers several potential advantages having demonstrated improved safety multiples in preclinical evaluations against undesired pulmonary and cardiovascular effects. In clinical trials, 2 was found to exhibit a pharmacokinetic half-life (T1/2) longer than that of 1, as well as a reduced formation of the phosphate metabolite that is required for activity against S1P1. Herein, we describe our efforts to discover highly potent, partial agonists of S1P1 with a shorter T1/2 and increased in vivo phosphate metabolite formation. These efforts culminated in the discovery of BMS-986166 (14a), which was advanced to human clinical evaluation. The pharmacokinetic/pharmacodynamic (PK/PD) relationship as well as pulmonary and cardiovascular safety assessments are discussed. Furthermore, efficacy of 14a in multiple preclinical models of autoimmune diseases are presented." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01695"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01695">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01695&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01695&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01695&amp;href=/doi/10.1021/acs.jmedchem.8b01695" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2265-2285</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01303" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.8b01348" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification and Preclinical Pharmacology of ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P<sub>1</sub>) Modulator Advanced into Clinical Trials</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">John L. Gilmore</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John L. Gilmore</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: (609)252-3153. E-mail: <a href="/cdn-cgi/l/email-protection#254f4a4d4b0b424c49484a5740654748560b464a48"><span class="__cf_email__" data-cfemail="fa90959294d49d93969795889fba989789d4999597">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+L.++Gilmore">John L. Gilmore</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0520-8746" title="Orcid link">http://orcid.org/0000-0002-0520-8746</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hai-Yun Xiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hai-Yun Xiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hai-Yun++Xiao">Hai-Yun Xiao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">T. G. Murali Dhar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">T. G. Murali Dhar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=T.+G.+Murali++Dhar">T. G. Murali Dhar</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0738-1021" title="Orcid link">http://orcid.org/0000-0003-0738-1021</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael G. Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael G. Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael+G.++Yang">Michael G. Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2908-4060" title="Orcid link">http://orcid.org/0000-0003-2908-4060</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zili Xiao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zili Xiao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zili++Xiao">Zili Xiao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jenny Xie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jenny Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jenny++Xie">Jenny Xie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lois D. Lehman-McKeeman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lois D. Lehman-McKeeman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lois+D.++Lehman-McKeeman">Lois D. Lehman-McKeeman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Gong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Gong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Gong">Lei Gong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Huadong Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Huadong Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Huadong++Sun">Huadong Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lloyd Lecureux</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lloyd Lecureux</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lloyd++Lecureux">Lloyd Lecureux</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cliff Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cliff Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cliff++Chen">Cliff Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dauh-Rurng Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dauh-Rurng Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dauh-Rurng++Wu">Dauh-Rurng Wu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marta Dabros</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marta Dabros</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marta++Dabros">Marta Dabros</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoxia Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoxia Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoxia++Yang">Xiaoxia Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tracy L. Taylor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tracy L. Taylor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tracy+L.++Taylor">Tracy L. Taylor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xia D. Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xia D. Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xia+D.++Zhou">Xia D. Zhou</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Elizabeth M. Heimrich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Elizabeth M. Heimrich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth+M.++Heimrich">Elizabeth M. Heimrich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rochelle Thomas</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rochelle Thomas</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rochelle++Thomas">Rochelle Thomas</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kim W. McIntyre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kim W. McIntyre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kim+W.++McIntyre">Kim W. McIntyre</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Virna Borowski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Virna Borowski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Virna++Borowski">Virna Borowski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bethanne M. Warrack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bethanne M. Warrack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bethanne+M.++Warrack">Bethanne M. Warrack</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuwen Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuwen Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuwen++Li">Yuwen Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shi">Hong Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul C. Levesque</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul C. Levesque</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+C.++Levesque">Paul C. Levesque</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zheng Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zheng Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Yang">Zheng Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anthony M. Marino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anthony M. Marino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+M.++Marino">Anthony M. Marino</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Georgia Cornelius</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Georgia Cornelius</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Georgia++Cornelius">Georgia Cornelius</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Celia J. D’Arienzo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Celia J. D’Arienzo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Celia+J.++D%E2%80%99Arienzo">Celia J. D’Arienzo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arvind Mathur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arvind Mathur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Mathur">Arvind Mathur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard Rampulla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard Rampulla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard++Rampulla">Richard Rampulla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anuradha Gupta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anuradha Gupta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anuradha++Gupta">Anuradha Gupta</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4211-1441" title="Orcid link">http://orcid.org/0000-0002-4211-1441</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bala Pragalathan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bala Pragalathan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bala++Pragalathan">Bala Pragalathan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ding Ren Shen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ding Ren Shen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ding+Ren++Shen">Ding Ren Shen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mary Ellen Cvijic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mary Ellen Cvijic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ellen++Cvijic">Mary Ellen Cvijic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Luisa M. Salter-Cid</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Luisa M. Salter-Cid</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Luisa+M.++Salter-Cid">Luisa M. Salter-Cid</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Percy H. Carter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Percy H. Carter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Percy+H.++Carter">Percy H. Carter</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Alaric J. Dyckman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alaric J. Dyckman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alaric+J.++Dyckman">Alaric J. Dyckman</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1050-2077" title="Orcid link">http://orcid.org/0000-0002-1050-2077</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01695&amp;href=/doi/10.1021%2Facs.jmedchem.8b01695" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2265–2285</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 20, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 October 2018</li><li><span class="item_label"><b>Published</b> online</span>20 February 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01695" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01695</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2265%26pageCount%3D21%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJohn%2BL.%2BGilmore%252C%2BHai-Yun%2BXiao%252C%2BT.%2BG.%2BMurali%2BDhar%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D5%26contentID%3Dacs.jmedchem.8b01695%26title%3DIdentification%2Band%2BPreclinical%2BPharmacology%2Bof%2B%2528%25281R%252C3S%2529-1-Amino-3-%2528%2528S%2529-6-%25282-methoxyphenethyl%2529-5%252C6%252C7%252C8-tetrahydronaphthalen-2-yl%2529cyclopentyl%2529methanol%2B%2528BMS-986166%2529%253A%2BA%2BDifferentiated%2BSphingosine-1-phosphate%2BReceptor%2B1%2B%2528S1P1%2529%2BModulator%2BAdvanced%2Binto%2BClinical%2BTrials%26numPages%3D21%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2285%26publicationDate%3DMarch%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01695"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3370</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01695" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification and Preclinical Pharmacology of ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;L. Gilmore&quot;},{&quot;first_name&quot;:&quot;Hai-Yun&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;T.&quot;,&quot;last_name&quot;:&quot;G. Murali Dhar&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;G. Yang&quot;},{&quot;first_name&quot;:&quot;Zili&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Jenny&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Lois&quot;,&quot;last_name&quot;:&quot;D. Lehman-McKeeman&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Gong&quot;},{&quot;first_name&quot;:&quot;Huadong&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Lloyd&quot;,&quot;last_name&quot;:&quot;Lecureux&quot;},{&quot;first_name&quot;:&quot;Cliff&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Dauh-Rurng&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Marta&quot;,&quot;last_name&quot;:&quot;Dabros&quot;},{&quot;first_name&quot;:&quot;Xiaoxia&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Tracy&quot;,&quot;last_name&quot;:&quot;L. Taylor&quot;},{&quot;first_name&quot;:&quot;Xia&quot;,&quot;last_name&quot;:&quot;D. Zhou&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;M. Heimrich&quot;},{&quot;first_name&quot;:&quot;Rochelle&quot;,&quot;last_name&quot;:&quot;Thomas&quot;},{&quot;first_name&quot;:&quot;Kim&quot;,&quot;last_name&quot;:&quot;W. McIntyre&quot;},{&quot;first_name&quot;:&quot;Virna&quot;,&quot;last_name&quot;:&quot;Borowski&quot;},{&quot;first_name&quot;:&quot;Bethanne&quot;,&quot;last_name&quot;:&quot;M. Warrack&quot;},{&quot;first_name&quot;:&quot;Yuwen&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;C. Levesque&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;M. Marino&quot;},{&quot;first_name&quot;:&quot;Georgia&quot;,&quot;last_name&quot;:&quot;Cornelius&quot;},{&quot;first_name&quot;:&quot;Celia&quot;,&quot;last_name&quot;:&quot;J. D’Arienzo&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Mathur&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;Rampulla&quot;},{&quot;first_name&quot;:&quot;Anuradha&quot;,&quot;last_name&quot;:&quot;Gupta&quot;},{&quot;first_name&quot;:&quot;Bala&quot;,&quot;last_name&quot;:&quot;Pragalathan&quot;},{&quot;first_name&quot;:&quot;Ding&quot;,&quot;last_name&quot;:&quot;Ren Shen&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ellen Cvijic&quot;},{&quot;first_name&quot;:&quot;Luisa&quot;,&quot;last_name&quot;:&quot;M. Salter-Cid&quot;},{&quot;first_name&quot;:&quot;Percy&quot;,&quot;last_name&quot;:&quot;H. Carter&quot;},{&quot;first_name&quot;:&quot;Alaric&quot;,&quot;last_name&quot;:&quot;J. Dyckman&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;2265-2285&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01695&quot;},&quot;abstract&quot;:&quot;Recently, our research group reported the identification of BMS-986104 (2) as a differentiated S1P1 receptor modulator. In comparison to fingolimod (1), a full agonist of S1P1 currently marketed for the treatment of relapse remitting multiple sclerosis (RRMS), 2 offers several potential advantages having demonstrated improved safety multiples in preclinical evaluations against undesired pulmonary and cardiovascular effects. In clinical trials, 2 was found to exhibit a pharmacokinetic half-life (T1/2) longer than that of 1, as well as a reduced formation of the phosphate metabolite that is required for activity against S1P1. Herein, we describe our efforts to discover highly potent, partial agonists of S1P1 with a shorter T1/2 and increased in vivo phosphate metabolite formation. These efforts culminated in the discovery of BMS-986166 (14a), which was advanced to human clinical evaluation. The pharmacokinetic/pharmacodynamic (PK/PD) relationship as well as pulmonary and cardiovascular safety assessments are di&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01695&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01695" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01695&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01695" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01695&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01695" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01695&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01695&amp;href=/doi/10.1021/acs.jmedchem.8b01695" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01695" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01695" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01695&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01695%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DGilmore%26date%3D2019%26atitle%3DIdentification%2Band%2BPreclinical%2BPharmacology%2Bof%2B%2528%25281R%252C3S%2529-1-Amino-3-%2528%2528S%2529-6-%25282-methoxyphenethyl%2529-5%252C6%252C7%252C8-tetrahydronaphthalen-2-yl%2529cyclopentyl%2529methanol%2B%2528BMS-986166%2529%253A%2BA%2BDifferentiated%2BSphingosine-1-phosphate%2BReceptor%2B1%2B%2528S1P1%2529%2BModulator%2BAdvanced%2Binto%2BClinical%2BTrials%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D5%26spage%3D2265%26epage%3D2285%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291719" title="Redox reactions">Redox reactions</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=290672" title="Phosphates">Phosphates</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/jmcmar.2019.62.issue-5/20190314/jmcmar.2019.62.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Recently, our research group reported the identification of BMS-986104 (<b>2</b>) as a differentiated S1P<sub>1</sub> receptor modulator. In comparison to fingolimod (<b>1</b>), a full agonist of S1P<sub>1</sub> currently marketed for the treatment of relapse remitting multiple sclerosis (RRMS), <b>2</b> offers several potential advantages having demonstrated improved safety multiples in preclinical evaluations against undesired pulmonary and cardiovascular effects. In clinical trials, <b>2</b> was found to exhibit a pharmacokinetic half-life (<i>T</i><sub>1/2</sub>) longer than that of <b>1</b>, as well as a reduced formation of the phosphate metabolite that is required for activity against S1P<sub>1</sub>. Herein, we describe our efforts to discover highly potent, partial agonists of S1P<sub>1</sub> with a shorter <i>T</i><sub>1/2</sub> and increased in vivo phosphate metabolite formation. These efforts culminated in the discovery of BMS-986166 (<b>14a</b>), which was advanced to human clinical evaluation. The pharmacokinetic/pharmacodynamic (PK/PD) relationship as well as pulmonary and cardiovascular safety assessments are discussed. Furthermore, efficacy of <b>14a</b> in multiple preclinical models of autoimmune diseases are presented.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36503" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36503" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite formed through the phosphorylation of sphingosine by sphingosine kinases.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> S1P regulates a multitude of physiological processes including lymphocyte trafficking, cardiac function, vascular development, and inflammation. These biological functions are mediated through the interaction of S1P with five G-protein coupled receptors S1P<sub>1–5</sub>.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Agonism of the S1P<sub>1</sub> receptor has been shown to block lymphocyte trafficking from the thymus and secondary lymph nodes, resulting in immunosuppression.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7 ref8">(4−8)</a> Because of the ability of S1P<sub>1</sub> receptor agonists to suppress lymphocyte egress, they have great potential as therapeutic agents in a variety of autoimmune diseases including rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease.</div><div class="NLM_p">In 2010, fingolimod (<b>1</b>) was approved by the FDA for the treatment of relapsing-remitting multiple sclerosis (RRMS).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Compound <b>1</b> is a nonselective S1P receptor agonist which is dosed as a pro-drug and subsequently metabolized in vivo via phosphorylation to form <b>1-P</b>, in a manner similar to the conversion of sphingosine to S1P.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> It has been reported that <b>1-P</b> induces S1P<sub>1</sub> receptor internalization and degradation on lymphocytes and behaves as a functional antagonist to inhibit S1P induced cell migration.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> As a result, lymphocytes are sequestered in the thymus and secondary lymphoid organs, leading to a marked peripheral lymphopenia. In a variety of S1P<sub>1</sub> functional assays, such as GTPγS, ERK phosphorylation, receptor internalization, cAMP, and calcium mobilization, <b>1-P</b> is a full agonist, eliciting a response comparable to that of the endogenous ligand S1P. Dosing with <b>1</b> has been shown to cause a transient, dose-dependent decrease of heart rate and a decline in pulmonary function in clinical studies.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> While these side effects were originally attributed to the off-target activity at the S1P<sub>3</sub> receptor, recent clinical evaluations of S1P<sub>3</sub>-sparing S1P<sub>1</sub> full agonists have implicated agonism of S1P<sub>1</sub> as contributing to at least the heart rate effects.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">Previous research efforts from our laboratories led to the discovery of the clinical compound BMS-986104 (<b>2</b>).<a onclick="showRef(event, 'cit15a'); return false;" href="javascript:void(0);" class="ref cit15a">(15a)</a> This compound is a novel S1P<sub>1</sub> receptor modulator that demonstrates ligand-biased signaling through S1P<sub>1</sub> and excellent selectivity against S1P<sub>3</sub>. Despite being a partial agonist of S1P<sub>1</sub> in certain S1P1/CHO cell assays such as receptor internalization, <b>2</b> was shown to block S1P induced T cell migration completely in vitro and to induce a level of lymphopenia and efficacy in rodents comparable to <b>1</b>. These results provided evidence that efficacy and lymphopenia can be fully achieved without complete desensitization of the S1P<sub>1</sub> receptor in S1P<sub>1</sub>//CHO cells. More importantly, <b>2</b> is differentiated from <b>1</b> in terms of pulmonary safety based on preclinical rodent studies and in cardiovascular safety based on preclinical studies using human cardiomyocytes.<a onclick="showRef(event, 'cit15a'); return false;" href="javascript:void(0);" class="ref cit15a">(15a)</a> However, <b>2</b> was found to exhibit a <i>T</i><sub>1/2</sub> in human clinical studies longer than was observed for <b>1</b> (18 days vs 7–9 days). Additionally, these clinical studies showed the formation of the active phosphate metabolite, <b>2-P</b>, to be lower than needed to drive the desired level of lymphocyte reduction at the top dose evaluated. Herein, we describe our medicinal chemistry efforts to find novel compounds in this series with a reduced human <i>T</i><sub>1/2</sub> and improved in vivo formation of the active phosphate metabolite while maintaining efficacy as well as an improved safety profile. Our strategy involved using the pharmacokinetic <i>T</i><sub>1/2</sub> and phosphate to parent ratios in rodents along with lymphocyte reduction for the initial selection criteria.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Compound <b>1</b> exhibited greater formation of the active phosphate metabolite in rat when compared to <b>2</b> and was subsequently found to also show a higher ratio in additional nonclinical species and ultimately in humans (see <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). We retained the cyclopentyl amino-alcohol headgroup of <b>2</b> as this moiety has been shown to provide the desired S1P<sub>1</sub> biased agonist profile by us<a onclick="showRef(event, 'cit15a cit15b'); return false;" href="javascript:void(0);" class="ref cit15a cit15b">(15a,b)</a> and others,<a onclick="showRef(event, 'cit15c'); return false;" href="javascript:void(0);" class="ref cit15c">(15c)</a> and we focused on modifications to the hexyl side chain and tetralin framework. Our initial tetralin modifications were previously disclosed,<a onclick="showRef(event, 'cit15b'); return false;" href="javascript:void(0);" class="ref cit15b">(15b)</a> and this work focuses on the evaluation of aryl and heteroaryl replacements for the hexyl side chain (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Previously discovered S1P<sub>1</sub> full agonists, such as <b>BMS-824</b> discovered in our laboratories<a onclick="showRef(event, 'cit15d'); return false;" href="javascript:void(0);" class="ref cit15d">(15d)</a> as well as <b>KRP-203</b> and others,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> established the tolerance for aryl and heteroaryl groups in this region. We commenced an exploration to determine if aryl and heteroaryl modifications would lead to the desired improvements over <b>2</b>.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Incorporation of aryl and heteroaryl side chains.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>8</b>–<b>16</b> is depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Starting from methyl (1<i>R</i>,3<i>S</i>)-amino-3-(4-bromophenyl)cyclopentane-1-carboxylate hydrochloride (<b>3</b>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> reduction of the ester followed by the reaction of the resulting amino alcohol with carbonyldiimidazole (CDI) afforded carbamate <b>4</b>. The bromophenyl group of this carbamate was then reacted with 2-(<i>tert</i>-butoxy)-2-oxoethyl)zinc(II) bromide using a catalyst system of Pd<sub>2</sub>(dba)<sub>3</sub> and 1,2,3,4,5-pentaphenyl-1′-(di-<i>tert</i>-butylphosphino)ferrocene (Q-phos) to give compound <b>5</b>. The <i>tert</i>-butyl ester of <b>5</b> was deprotected with trifluoroacetic acid (TFA), and the resulting acid was converted to the acid chloride using oxalyl chloride. An intramolecular Friedels–Craft alkylation was performed on this acid chloride in the presence of ethylene and aluminum chloride, resulting in the formation of tetralone <b>6</b>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> This tetralone was then converted to an enol triflate using phenyl triflimide. Reaction of enol triflate <b>7</b> with a variety of Grignard reagents using Co(acac)<sub>3</sub> as a catalyst followed by a reduction of the alkene using 10% Pd(OH)<sub>2</sub> yielded various aryl compounds with an alkyl linker of 0, 1, or 2 methylene groups as a mixture of diastereoisomers. Alternatively, triflate <b>7</b> could be coupled with an appropriately substituted terminal alkyne using Sonogashira conditions<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> followed by reduction to yield the desired compounds. Subsequent chiral chromatographic separation of these mixtures followed by basic hydrolysis of the carbamate group afforded the individual diastereoisomers <b>8a</b>–<b>16a</b> and <b>8b</b>–<b>16b</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 6-Substituted-((1<i>R</i>,3<i>S</i>)-1-amino-3-(5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, 91%; (b) CDI, dioxane, 87%; (c) LiHMDS, (2-(<i>tert</i>-butoxy)-2-oxoethyl)zinc(II) bromide, THF; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, Q-phos, 80 °C, 85%; (e) TFA, DCM; (f) oxalyl chloride; (g) ethylene, AlCl<sub>3</sub>, DCM, 92%; (h) LDA, DMPU; (i) PhN(Tf)<sub>2</sub>, THF, −78 to 0 °C, 60% (2 steps); (j) LiHMDS, Co(acac)<sub>3</sub>, THF/NMP, RMgBr, −40 °C or CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, TEA, alkyne; (k) Pd(OH)<sub>2</sub>, MeOH, H<sub>2</sub>; (l) Chiral SFC separation; (m) 1 N NaOH, dioxane.</p></p></figure><div class="NLM_p">An alternate route was devised for the synthesis of compound <b>14a</b> and <b>15a</b> as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. In this route, Heck reaction of <b>4</b> with itaconic acid and reduction of the double bond was followed by cyclization, facilitated using sulfuric acid, and the resulting keto-acid was esterified by the addition of MeOH to the reaction mixture. Pd-catalyzed benzylic deoxygenation under hydrogenation conditions yielded <b>17</b>. Compound <b>17</b> was then separated using chiral SFC conditions. Each of these isomers was reduced to the corresponding alcohols using lithium borohydride and subsequently converted to tosylates <b>18a</b> and <b>18b</b>. The absolute stereochemistry of compound <b>18b</b> was determined to be <i>S</i> at the site of the tosylate attachment by X-ray crystallography.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The <i>R</i>-tosylate (<b>18a</b>) was then coupled with (2-methoxybenzyl)magnesium chloride using copper(I) bromide dimethyl sulfide complex and subsequently hydrolyzed to afford <b>14a</b>. The absolute stereochemistry of <b>14a</b> was also confirmed by X-ray crystallography.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Compound <b>15a</b> was synthesized in a similar manner using (3-methoxybenzyl)magnesium chloride and <b>18a</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternate Synthesis of <b>14a</b> and <b>15a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, P(<i>o</i>-Tol)<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/MeCN, 80 °C; (b) 10% Pd/C, MeOH, H<sub>2</sub>; (c) H<sub>2</sub>SO<sub>4</sub>, 4 h, then MeOH; (d) 10% Pd/C, MeOH, H<sub>2</sub>, 55% yield from <b>4</b>; (e) LiBH<sub>4</sub>, THF, 60 °C, 90%; (f) Chiral SFC separation; (g) TsCl, pyridine, 80–95%; (h) CuBr-DMS, RMgCl, Et<sub>2</sub>O, 93%; (i) 1 N NaOH, dioxane, 57%.</p></p></figure><div class="NLM_p">Compounds <b>22</b>–<b>29</b> were synthesized using routes shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Compound <b>17</b> was first reduced using lithium borohydride then oxidized to the aldehyde (<b>19</b>). This aldehyde was then converted to a terminal alkyne using dimethyl (1-diazo-2-oxopropyl)phosphonate. The terminal alkyne intermediate was separated using chiral SFC conditions to yield <b>20a</b> and <b>20b</b>. The <i>R</i>-alkyne (<b>20a</b>) and <i>S</i>-alkyne (<b>20b</b>)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> intermediates were coupled with an appropriately substituted heteroaryl bromides using Sonogashira conditions.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Subsequent reduction and hydrolysis afforded <b>22</b>–<b>25</b> and <b>29</b>. An alternate route was employed to synthesize <b>27</b> and <b>28</b> using a Julia–Kocienski olefination.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compound <b>18a</b> was coupled with 1-phenyl-1<i>H</i>-tetrazole-5-thiol then oxidized to the sulfone with hydrogen peroxide and ammonium molybdate tetrahydrate. This intermediate was coupled with the appropriately substituted pyrazole aldehyde to give <b>21</b>, which was then reduced and hydrolyzed as previously described to afford <b>27</b> and <b>28</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 6-Substituted-heterophenethyl Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiBH<sub>4</sub>, THF, 60 °C, 90%; (b) Swern oxidation, 84%; (c) K<sub>2</sub>CO<sub>3</sub>, dimethyl (1-diazo-2-oxopropyl)phosphonate, 82%; (d) chiral SFC separation, 30–35% of <b>20a</b> and <b>20b</b>; (e) ArBr, Pd(amphos)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C, 40–50%; (f) 10% Pd(OH)<sub>2</sub>, MeOH, H<sub>2</sub>, 95%; (g) 1 N NaOH, dioxane; (h) 1-phenyl-1<i>H</i>-tetrazole-5-thiol, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 90%; (i) H<sub>2</sub>O<sub>2</sub>, ammonium molybdate tetrahydrate, 0 °C, 99%; (j) pyrazole aldehydes, KHMDS, 30–40% .</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28025" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28025" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Because binding and other in vitro functional assays require the synthesis of the active phosphate metabolite and are not predictive of the compounds’ ability to form the active metabolites in vivo, <b>8a</b>/<b>b</b>, <b>9a</b>/<b>b</b>, and <b>10a</b> were initially assessed using a mouse blood lymphocyte reduction (BLR) pharmacodynamic/pharmacokinetic (PD/PK) model to determine whether these side chain modifications would result in an acceptable amount of circulating lymphocyte reduction (>65%) as well as an in vivo phosphate metabolite to parent ratio which was greater than that of <b>2</b> (ratios of 0.5 at 30 mg/kg and 1.0 at 0.5 mg/kg). The first set of compounds evaluated were derivatives with an alkyl linker of 0, 1, or 2 methylenes and a terminal phenyl group in place of the hexyl side chain (<b>8</b>–<b>10</b>). The results of these studies are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The compounds were evaluated at a low dose (1 mg/kg) and a high dose (15, 30, or 50 mg/kg) for each of the individual isomers, and the lymphocyte count was measured at 4 and 24 h. The two isomers with a directly attached phenyl group (<b>8a</b>, <b>8b</b>) exhibited poor lymphocyte reduction at the 1 mg/kg dose at both time points. At a 30 mg/kg dose, both isomers showed good reduction of lymphocytes at both the 4 and 24 h time points; however, concentrations at 24 h indicated poor formation of the phosphate metabolite with a phosphate to parent ratio of 0.14. Compounds <b>9a</b> and <b>9b</b>,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> which have a benzyl moiety as the side chain, similarly had poor lymphocyte reduction at the lower dose and acceptable levels of reduction at the higher dose for both isomers. The phosphate to parent ratio of <b>9a</b> and <b>9b</b> were both better than that of <b>2</b> at the 30 mg/kg dose with ratios of 1.4 and 1, respectively, versus a ratio 0.5 for <b>2</b>. Lastly, one of the isomers of the phenethyl derivatives (<b>10a</b>)<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> was assessed in the mouse BLR PK/PD assay. At the 1 mg/kg dose, <b>10a</b> exhibited poor lymphocyte reduction at the 4 h time point, however, at the 24 h time point, the compound showed 52% lymphocyte reduction. The high dose for <b>10a</b> demonstrated good lymphocyte reduction at both time points. This compound also demonstrated a phosphate to parent ratio in the range of 2.3 to 2.8, which was a marked improvement over <b>2</b>. Because the benzyl and phenethyl derivatives both demonstrated favorable lymphocyte reduction and phosphate metabolite formation, we chose to further assess derivatives in these series.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effects on Blood Lymphocyte Counts in BALB-c Mice<a class="ref internalNav" href="#t1fn1" aria-label="b">b</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0009.gif" alt="" id="GRAPHIC-d7e1154-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0010.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn2"><div class="footnote" id="t1fn2"><sup><sup>a</sup></sup><p class="last">Blood concentration at the time indicated.</p></div><div class="footnote" id="t1fn1"><sup><sup>b</sup></sup><p class="last">Compounds tested in BALB-c mice (<i>n</i> = 2–4); Lymph Red. = Lymphocyte reduction; Phos. = Phosphate; BLQ = below limit of quantitation</p></div></div><div></div></div><div class="NLM_p">For the next set of benzyl and phenethyl analogues, metabolic “soft spots” were incorporated into the side chain and the compounds were evaluated in a BLR PK/PD study in Lewis rats (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In this study, the percent reduction of circulating lymphocytes was measured at 4 and 24 h post dose (2 mg/kg, po). Additionally, the corresponding levels of parent and active phosphate metabolite were measured at these time points. For compounds with greater than 65% lymphocyte reduction at the 24 h time point, an estimated <i>T</i><sub>1/2</sub> from oral dosing over a period of 72 h was generated. The results from our first clinical compound (<b>2</b>) are shown in the rat PK/PD study for comparative purposes. The next set of analogues in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> are the two isomers of the unsubstituted phenethyl derivative (<b>10a</b> and <b>10b</b>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Of the two isomers, <b>10a</b> was not only more efficacious with lymphocyte reductions of 43% and 82% at 4 and 24 h respectively, but it also demonstrated an extremely favorable phosphate to parent ratio of 6, again significantly better than that of <b>2</b> (ratio of 1.6). However, these analogues exhibited very long in vivo <i>T</i><sub>1/2</sub>s (>75 h). The next three compounds shown are benzyl analogues in which a methoxy group was installed on the phenyl group at the 2, 3, or 4 positions (<b>11</b>–<b>13</b>). In general, these analogues were less effective at reducing circulating lymphocytes. The two most promising compounds in this series were compounds <b>12a</b>, a 3-methoxybenzyl derivative, and <b>13b</b>, a 4-methoxybenzyl derivative. At 24 h, these compounds each reduced the lymphocyte count by 73%, and these analogues exhibited moderate phosphate to parent ratios. The introduction of a methoxy substitution did result in compounds with reduced in vivo <i>T</i><sub>1/2</sub> (15 h for <b>12a</b> and 64 h for <b>13b</b>) when compared to <b>2</b> (<i>T</i><sub>1/2</sub> > 75 h).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Effects on Blood Lymphocyte Counts in Lewis Rats<a class="ref internalNav" href="#t2fn1" aria-label="c">c</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0011.gif" alt="" id="GRAPHIC-d7e1248-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0012.gif" alt="" id="gr10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn2"><div class="footnote" id="t2fn2"><sup><sup>a</sup></sup><p class="last">Compounds dosed at 2 mg/kg unless otherwise noted.</p></div><div class="footnote" id="t2fn3"><sup><sup>b</sup></sup><p class="last">Blood concentration at the time indicated.</p></div><div class="footnote" id="t2fn1"><sup><sup>c</sup></sup><p class="last">Compounds tested in Lewis rat (<i>n</i> = 2); Lymph Red. = Lymphocyte reduction; Phos. = Phosphate; nd = not determined.</p></div></div><div></div></div><div class="NLM_p">The remaining compounds depicted in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> are from the phenethyl series. Compounds <b>14</b>–<b>16</b> are analogues in which a methoxy group was placed on the phenethyl moiety at the 2, 3, or 4 positions. In the 2-methoxy derivatives (<b>14a</b>, <b>14b</b>), both isomers were effective at reducing the lymphocyte count at the 2 mg/kg dose. Isomer <b>14a</b> was the more effective of the two showing robust lymphopenia at 4 h (76% reduction), better phosphate formation (ratio of 5.0), and an estimated in vivo <i>T</i><sub>1/2</sub> of 27 h in the rat PK/PD study. Of the 3-methoxyphenethyl analogues, <b>15a</b> exhibited the more desirable profile of the two isomers, demonstrating a lymphocyte reduction of 69% at 4 h and excellent phosphate formation with phosphate to parent ratio of 6.3. The estimated <i>T</i><sub>1/2</sub> of <b>15a</b> was 31 h. Finally, in this series, the 4-methoxy phenethyl analogues (<b>16a</b>, <b>16b</b>) were studied. The 4-methoxy isomers were much less effective at reducing lymphocytes at 4 h (21% and 31%) although they were quite effective at the 24 h time point (81% and 84%). These isomers did have very short in vivo <i>T</i><sub>1/2</sub>s of 11 and 7 h; however, neither exhibited phosphate formation superior to <b>2</b>.</div><div class="NLM_p">In the phenethyl series, replacement of the aryl moiety with a variety of heteroaryl groups was also explored. For these compounds, a new screening paradigm was developed in which predicted <i>T</i><sub>1/2</sub>s were estimated using a liver microsome assay. This methodology of <i>T</i><sub>1/2</sub> prediction was based on an initial data set of compounds in this series where a correlation was established between predicted <i>T</i><sub>1/2</sub> from rat liver microsome and observed in vivo <i>T</i><sub>1/2</sub> in rats. This gave us the confidence to this methodology for compound screening and progression. Additionally, to determine the compounds’ abilities to form the active phosphate metabolites, the rates of ATP-dependent phosphorylation were determined using recombinant sphingosine kinase 1 and 2.<a onclick="showRef(event, 'ref1 ref24'); return false;" href="javascript:void(0);" class="ref ref1 ref24">(1,24)</a> A variety of pyridyl, pyrimidine, pyrazole, and imidazole analogues were prepared and studied (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In general, these compounds were less efficient at forming the phosphate metabolite as compared to <b>2</b>, for which a relative conversion of 15% was observed, and many also had long predicted human <i>T</i><sub>1/2</sub>. Compounds <b>23a</b> and <b>29</b> were further assessed in a rat PK/PD study, and consistent with the in vitro predictions, neither compound was effective at reducing lymphocytes at a dose of 0.5 mg/kg at either 4 or 24 h. While <b>23b</b> showed an encouraging result in the formation of phosphate metabolite, our focus had turned to the phenethyl analogues (<b>14</b>–<b>16</b>) and we discontinued further exploration of heteroaryl replacements.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Heterocyclic Replacement of Phenyl Moiety<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0013.gif" alt="" id="GRAPHIC-d7e1385-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0014.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Pred. = predicted; Phos. = phosphate</p></div></div><div></div></div><div class="NLM_p">As the phenethyl analogues were the most promising, select compounds from this series were then evaluated for pulmonary toxicity by measuring the level of bronchoalveolar lavage (BAL) protein, a known marker for vascular leakage and pulmonary edema.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> As it has been shown that BAL changes observed with <b>1</b> eventually lead to vascular leak and fibrosis in mice,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> an S1P<sub>1</sub> modulator with reduced pulmonary effects may be a preferred entity in the clinic. The compounds (<b>14</b>–<b>16</b>) were evaluated for BAL elevation at a high dose (10 or 25 mg/kg) and a low dose (2 or 3 mg/kg) for each of the individual isomers, and the results of the BAL protein elevation is reported as both relative to vehicle and relative to an estimated in vivo ED<sub>50</sub> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In addition, the results from a previously disclosed S1P<sub>3</sub> sparing/S1P<sub>1</sub> full agonist, <b>BMS-824</b> (dosed at 1 mg/kg), as well as <b>1</b>, are shown in the study for comparative purposes. At the higher dose, the 2-methoxy (<b>14a</b>/<b>14b</b>) compounds had similar relative increases with a 3.1-fold increase in BAL protein at 100-fold over ED<sub>50</sub> and a 6.4-fold increase in BAL protein at 200-fold over ED<sub>50</sub>, respectively. The 3-methoxy (<b>15a</b>/<b>15b</b>) compounds were both at 200-fold over ED<sub>50</sub> and exhibited a 3.2- and 4.4-fold increase, respectively. The 4-methoxy compounds (<b>16a</b>/<b>16b</b>) were least favorable from the phenethyl series, with a 4.5–4.7-fold increase in BAL levels at 40–50-fold over ED<sub>50</sub>. When evaluated at lower doses, the 2-methoxy and 3-methoxy analogues demonstrated favorable results, with <b>14a</b>, <b>14b</b>, and <b>15b</b> leading to BAL protein increases of less than 2-fold at 30–40-fold over ED<sub>50</sub>. All the 2-methoxy and 3-methoxy compounds exhibited significantly less BAL protein elevation as compared to our S1P<sub>3</sub> sparing/S1P<sub>1</sub> full agonist, <b>BMS-824</b>, which elicited a BAL elevation of 4.3-fold at 10-fold over ED<sub>50</sub>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Effects of Compounds <b>14</b>–<b>16</b> on BAL<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a> Protein Levels<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="×" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">BAL<a class="ref internalNav" href="#t4fn2" aria-label="a">a</a> protein mg/dL (dose)</th><th class="colsep0 rowsep0" align="center" char=".">fold over vehicle<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">rat PD 24 h ED<sub>50</sub> (mg/kg)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="×">fold over ED<sub>50</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">12.5 ± 1.0 (3 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char="×">30×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>BMS-824</b></td><td class="colsep0 rowsep0" align="left">24.3 ± 1.0 (1 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char="×">10×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14a</b></td><td class="colsep0 rowsep0" align="left">14 ± 1.5 (10 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char="×">100×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">8.8 (3 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="×">30×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="4" align="left">     </td><td class="colsep0 rowsep0" align="char" char="×"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14b</b></td><td class="colsep0 rowsep0" align="left">29 ± 0.1 (10 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char="×">200×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10.5 ± (2 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="×">40×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15a</b></td><td class="colsep0 rowsep0" align="left">12.7 ± 0.9 (10 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">3.2</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char="×">200×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10 ± 1 (3 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="×">60×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15b</b></td><td class="colsep0 rowsep0" align="left">17.5 ± 0.9 (10 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">0.05</td><td class="colsep0 rowsep0" align="char" char="×">200×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10 ± 1 (2 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="×">40×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16a</b></td><td class="colsep0 rowsep0" align="left">26 ± 1.0 (25 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char="×">50×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">     </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16b</b></td><td class="colsep0 rowsep0" align="left">24.3 ± 0.3 (25 mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char="×">40×</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn2"><div class="footnote" id="t4fn2"><sup><sup>a</sup></sup><p class="last">BAL = bronchoalveolar lavage.</p></div><div class="footnote" id="t4fn1"><sup><sup>b</sup></sup><p class="last">Compounds tested in Lewis rat (<i>n</i> = 3–4).</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Change in BAL protein levels of treated group relative to vehicle (PEG300) control.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Estimated ED<sub>50</sub> for lymphocyte reduction in rat at 24 h.</p></div></div></div><div class="NLM_p">The transient heart rate lowering reported with <b>1</b> (S1P<sub>1,3,4,5</sub> agonist) attributed to off-target activity on S1P<sub>3</sub> was later observed in clinical trials with S1P<sub>3</sub> sparing S1P<sub>1</sub> full agonists.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This was despite the fact that cardiovascular evaluations in nonclinical species did not predict for bradycardia with the S1P<sub>3</sub> sparing compounds.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Given this differential cardiovascular pharmacology between human and nonclinical species, a human cellular assay was utilized to guide our selection of molecules that would have reduced potential for heart rate effects in the clinic. The phosphates of isomers <b>14a</b>/<b>b</b>, <b>15a</b>/<b>b</b>, and <b>16a</b> were prepared and evaluated in cultured human cardiomyocytes derived from inducible pluripotent stem cells (iPSCs). Cardiomyocytes differentiated from iPSCs show a concentration-dependent response to cardioactive drugs that is consistent with observed clinical effects.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The rate of beating in these cells have been shown to be reduced by exposure to S1P<sub>1</sub> agonists independent of S1P<sub>3</sub> activity, with more limited reduction in beat rate being demonstrated by biased agonists of S1P<sub>1</sub>, such as <b>2</b>.<a onclick="showRef(event, 'cit15a cit15b'); return false;" href="javascript:void(0);" class="ref cit15a cit15b">(15a,b)</a></div><div class="NLM_p">Compounds <b>14a-P</b>, <b>14b-P</b>, <b>15a-P</b>, <b>15b-P</b>, and <b>16a-P</b> were evaluated at 1 and 10 nM (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) and compared to both <b>1-P</b>, an S1P<sub>1</sub>/S1P<sub>3</sub> full agonist, as well as <b>BMS-824</b>, an S1P<sub>1</sub> full agonist that is S1P<sub>3</sub> sparing. We considered the maximum desirable beating rate reduction at these concentrations to be 15% and 30%, respectively. All the methoxy phenethyl analogues were significantly improved over <b>1-P</b> and <b>BMS-824</b> in this assay at both concentrations. Compounds <b>14a-P</b> and <b>15a-P</b> were the only compounds with less than 15% rate reduction at 1 nM. At 10 nM, the compounds that exhibited an acceptable rate reduction of lower than 30% were <b>14a-P</b>, <b>14b-P</b>, and <b>15b-P</b>. While <b>14b-P</b> and <b>15b-P</b> both showed impressive results at 10 nM, neither compound gave a desirable active phosphate metabolite to parent ratio (see <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Compound <b>14a-P</b>, with 11% and 27% rate reduction at 1 and 10 nM, respectively, was the only compound to show the desired profile at both concentrations. This improvement of <b>14a-P</b> over <b>1-P</b> in the cardiomyocyte assay is notable given that <b>14a-P</b> exhibits a 2-fold potency increase over <b>1-P</b> in a human lymphocyte chemotaxis assay (see <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>).</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Reduction in beating rate of human iPSC derived cardiomyocytes in the presence of full S1P<sub>1</sub> agonists with varying S1P<sub>3</sub> agonist profiles versus partial S1P<sub>1</sub> agonists sparing of S1P<sub>3</sub> (average of two experiments).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <b>14a-P</b> in Vitro Pharmacology<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center"><b>1-P</b></th><th class="colsep0 rowsep0" align="center"><b>2-P</b></th><th class="colsep0 rowsep0" align="center"><b>14a-P</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-1 binding (IC<sub>50</sub>, nM), <i>Y</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">0.008 ± 0.0014 (<i>n</i> = 6), 101%</td><td class="colsep0 rowsep0" align="left">0.010 ± 0.004 (<i>n</i> = 7), 100%</td><td class="colsep0 rowsep0" align="left">0.014 ± 0.003 (<i>n</i> = 6), 101%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-1 cAMP (EC<sub>50</sub>, nM), <i>Y</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">0.007 ± 0.003 (<i>n</i> = 3), 100%</td><td class="colsep0 rowsep0" align="left">0.006 ± 0.002 (<i>n</i> = 3), 98%</td><td class="colsep0 rowsep0" align="left">0.008 ± 0.004 (<i>n</i> = 6), 101%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-1 GTPγS (EC<sub>50</sub>, nM), <i>Y</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">0.70 ± 0.28 (<i>n</i> = 6), 96%</td><td class="colsep0 rowsep0" align="left">0.90 ± 0.36 (<i>n</i> = 7), 81%</td><td class="colsep0 rowsep0" align="left">0.60 ± 0.08 (<i>n</i> = 6), 79%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-1 internalization (EC<sub>50</sub>, nM), <i>Y</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">0.070 ± 0.02 (<i>n</i> = 6), 102%</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.02 (<i>n</i> = 5), 68%</td><td class="colsep0 rowsep0" align="left">0.11 ± 0.06 (<i>n</i> = 5), 72%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-1 ERK-P (EC<sub>50</sub>, nM), <i>Y</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">0.02 ± 0.006 (<i>n</i> = 6), 100%</td><td class="colsep0 rowsep0" align="left">8.2 ± 3.6 (<i>n</i> = 4), 101%</td><td class="colsep0 rowsep0" align="left">3.5 ± 1.7 (<i>n</i> = 6), 99%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-3 GTPγS (EC<sub>50</sub>, nM)</td><td class="colsep0 rowsep0" align="left">3.6 ± 2.80 (<i>n</i> = 7)</td><td class="colsep0 rowsep0" align="left">>1000 (<i>n</i> = 7)</td><td class="colsep0 rowsep0" align="left">>1000 (<i>n</i> = 7)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-4 GTPγS (EC<sub>50</sub>, nM)</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.43 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">10.5 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">3.4 ± 2.2 (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hS1P-5 GTPγS (EC<sub>50</sub>, nM)</td><td class="colsep0 rowsep0" align="left">0.67 ± 0.24 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">10.7 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">3.5 ± 0.98 (<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">lymphocyte chemotaxis<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (IC<sub>50</sub>, nM)</td><td class="colsep0 rowsep0" align="left">1.2 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">2.5 (<i>n</i> = 2)</td><td class="colsep0 rowsep0" align="left">0.6 (<i>n</i> = 2)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">hS1<i>P</i> = human sphingosine 1-phosphate; <i>Y</i><sub>max</sub> = normalized maximal response.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Antagonist mode.</p></div></div></div><div class="NLM_p">Upon the basis of the assessments for lymphopenia, projected <i>T</i><sub>1/2</sub>, phosphorylation potential as well as pulmonary and cardiovascular safety, <b>14a</b> was chosen for further evaluation as it had the best overall profile from this series. The phosphate of <b>14a</b> was then extensively characterized in a variety of in vitro assays, and its profile was compared to <b>1-P</b> as well as to the phosphate of our previous clinical candidate, <b>2-P</b>. As is clear from <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, all three compounds have equivalent potency in the S1P<sub>1</sub> binding assay and act as full agonists in the cyclic AMP functional assay; however, as we found with <b>2-P</b>,<a onclick="showRef(event, 'cit15a'); return false;" href="javascript:void(0);" class="ref cit15a">(15a)</a><b>14a-P</b> is differentiated from <b>1-P</b> in the S1P<sub>1</sub> GTPγS, ERK-P, and S1P<sub>1</sub> internalization assays. The GTPγS assay shows <b>14a-P</b> to have a maximum efficacy that reaches ∼80% of the endogenous ligand while <b>1-P</b> reaches close to 100%. In the ERK-P assay, while all three exhibit full agonism, the potencies of <b>14a-P</b> and <b>2-P</b> are 100–500-fold weaker than <b>1-P</b>, and finally, in the S1P<sub>1</sub> internalization assay, <b>14a-P</b> and <b>2-P</b> are partial agonists whereas <b>1-P</b> exhibits full agonist activity in this assay. This partial agonist profile of <b>14a</b> and <b>2</b> in the internalization assay may be related to the improved pulmonary safety observed in preclinical studies (lower BAL protein elevation) because maintaining some level of S1P/S1P<sub>1</sub> signaling has been postulated to be crucial for controlling vascular tone.<a onclick="showRef(event, 'cit26d ref28'); return false;" href="javascript:void(0);" class="ref cit26d ref28">(26d,28)</a> It has also been postulated that transient activation of S1P<sub>1</sub> by fingolimod and other S1P<sub>1</sub>/S1P<sub>3</sub> selective compounds in atrial myocytes before functional antagonism of S1P<sub>1</sub>R underlies the first-dose bradycardia observed in some patients.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> This bradycardia effect is linked to S1P<sub>1</sub>R-dependent activation of G protein-coupled inwardly rectifying potassium (GIRK) channels on atrial myocytes. We hypothesize the weaker potency in ERK phosphorylation for <b>14a-P</b> and <b>2-P</b> may contribute to the their weaker potency in the cardiomyocyte beating rate assay. Compound <b>14a</b> also maintains excellent selectivity over S1P<sub>3</sub> while showing a full potent agonism of S1P<sub>4</sub> and S1P<sub>5</sub>. Finally, the compounds were assessed in a lymphocyte chemotaxis assay, a functional primary cell assay that correlates closely with in vivo lymphopenia. Compound <b>1-P</b> does not induce T-cell chemotaxis on its own but completely blocks the S1P induced T-cell migration with an IC<sub>50</sub> of 1.2 nM. Compound <b>14a-P</b> also completely blocks this S1P induced T-cell migration with an IC<sub>50</sub> of 0.6 nM.</div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a> shows the pharmacokinetic parameters for <b>14a</b> derived from whole blood concentrations via dried blood spot (DBS) analysis. The average absolute oral bioavailability (<i>F</i>%) was 53% across all species (range = 23–76%). The time to maximum concentration (<i>T</i><sub>max</sub>) occurred at 6–7 h for <b>14a</b> and for the active phosphate metabolite (<b>14a-P</b>), likely reflecting a slow rate of absorption. Compound <b>14a</b> has large volume of distribution, with an average blood steady-state volume of distribution (<i>V</i><sub>ss</sub>) of 16 L/kg (range = 10–21 L/kg) in nonclinical species. The terminal <i>T</i><sub>1/2</sub> of <b>14a</b> after IV dosing ranged from 38 to 165 h, which was much shorter than that for <b>2</b> (131–210 h). Low clearance from blood (CLTb) was observed in all the species tested, correlating well with the predicted CLTb values from liver microsomes of the respective species. The phosphate metabolite to parent blood AUC ratios in rats, dogs, monkeys, and humans after oral dosing for <b>1</b>, <b>2</b>, and <b>14a</b> are shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. As the phosphate is the active species for the mechanism of action, a higher phosphate to parent ratio can reduce the magnitude of dose and parent exposure, leading to reduced risk for off-target effects and a smaller dose that may be readily formulated. On the basis of the available data of <b>1</b> and <b>2</b>, it appears that although the extent of phosphorylation in human was reduced in comparison to nonclinical species, an improved phosphorylation in nonclinical species translated to improved phosphorylation in human. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>, the phosphate ratios of <b>14a</b> were superior to those of <b>2</b> in all three nonclinical species and were similar to those of <b>1</b> particularly in rat and dog.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetic Parameters for Compound <b>14a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char="±">IV CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">IV <i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i>% (PO)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sprague–Dawley rat</td><td class="colsep0 rowsep0" align="center">IV: 1 (<i>n</i> = 3); PO: 1 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="char" char="±">9.7 ± 0.57</td><td class="colsep0 rowsep0" align="center">16 ± 0.92</td><td class="colsep0 rowsep0" align="center">38 ± 2.7</td><td class="colsep0 rowsep0" align="char" char=".">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">beagle dog</td><td class="colsep0 rowsep0" align="center">IV: 1 (<i>n</i> =  6); PO: 0.3 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="char" char="±">1.9 ± 1.1</td><td class="colsep0 rowsep0" align="center">21 ± 7.5</td><td class="colsep0 rowsep0" align="center">165 ± 34</td><td class="colsep0 rowsep0" align="char" char=".">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus monkey</td><td class="colsep0 rowsep0" align="center">IV: 1 (<i>n</i> = 3); PO: 1 (<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="char" char="±">3.8 ± 0.95</td><td class="colsep0 rowsep0" align="center">10 ± 1.9</td><td class="colsep0 rowsep0" align="center">46 ± 1.4</td><td class="colsep0 rowsep0" align="char" char=".">76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">animal average</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="±"> </td><td class="colsep0 rowsep0" align="center">16</td><td class="colsep0 rowsep0" align="center">83</td><td class="colsep0 rowsep0" align="char" char=".">53</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">18.4% hydroxypropyl-β-cyclodextrin in 13.8 mM citric acid as vehicle. <i>F</i> = bioavailability; Cl = clearance, <i>V</i><sub>ss</sub> = volume of distribution at steady state; AUC = area under curve.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Phosphate/Parent Ratio for <b>1</b>, <b>2</b>, and <b>14a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">AUC ratio of phosphate to parent</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center" char="."><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th><th class="colsep0 rowsep0" align="center" char="."><b>14a</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Sprague–Dawley rat</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">beagle dog</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="center">2.4</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cynomolgus monkey</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="center">0.3</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="center">n/a<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Because of phosphate <b>2-P</b> levels being < LLOQ at most time points, an AUC ratio was not able to be generated.</p></div></div></div><div class="NLM_p">Compound <b>14a</b> was also profiled for off-target and genotoxic potential, CYP inhibition, protein binding, and liver microsomal half-life (<i>T</i><sub>1/2</sub>) determination (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Compound <b>14a</b> was negative in the Ames and in vitro micronucleus (IVtMN) assays. The CYP450 inhibition IC<sub>50</sub> profile of <b>14a</b> was in the micromolar range, therefore at clinically relevant concentrations, drug interactions involving the inhibition of the major drug-metabolizing CYPs are not anticipated. The half-lives of <b>14a</b> upon incubation with human, rat, cyno, and dog liver microsomes were long (all <i>T</i><sub>1/2</sub> > 97 min), and <b>14a</b> was found to be highly protein bound in all tested species (>99.9% bound in human, rat, mouse, cyno, and dog).</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. In Vitro Profiling Data for Compound <b>14a</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mutagenicity</td><td class="colsep0 rowsep0" align="left">Ames negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IVtMN negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> inhibition (IC<sub>50</sub>)</td><td class="colsep0 rowsep0" align="left">1A2, >20 μM; 2B6, 17 μM; 2C9, 14 μM; 2C19, 6.9 μM; 2D6,18 μM; 3A4, 5.5 μM; 2C8 8.6 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein Binding (% bound)</td><td class="colsep0 rowsep0" align="left">all >99.9% (h, r, m, c, d)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LM<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a><i>T</i><sub>1/2</sub> (min)</td><td class="colsep0 rowsep0" align="left">242/97/372/110 (h, r, d, c)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub></td><td class="colsep0 rowsep0" align="left">9.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">log <i>D</i> (pH 6.5)</td><td class="colsep0 rowsep0" align="left">5.05</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">CYP = cytochrome P450.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">LM = liver microsomes; h = human; r = rat; m = mouse; c = cynomolgus monkey; d = dog.</p></div></div></div><div class="NLM_p">We next evaluated the suppressive effect of <b>14a</b> on experimental autoimmune encephalomyelitis (EAE), a preclinical animal model for multiple sclerosis (MS) therapy. The graphs in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a> demonstrate the effects of orally administered <b>14a</b> as well as <b>1</b> in this EAE study. Compound <b>14a</b> was administered as once daily doses of 0.1 and 0.5 mg/kg, with PO dosing initiated at the time of immunization. Compound <b>14a</b> showed a dose-dependent reduction in clinical scores for inflammation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), and both doses were efficacious lowering the EAE clinical scores taken from day 12 until the completion of the study when compared to the vehicle treated group. To investigate the effects of <b>14a</b> on the formation of inflammatory lesions in the CNS, a histological evaluation of the spinal cord was performed on day 21 of the EAE study (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). Again, a dose-dependent reduction in the histological score was noted. On the basis of clinical scores and spinal cord histology, a dose of 0.5 mg/kg/day of <b>14a</b> demonstrates maximal efficacy and its clinical score was comparable to the 1.0 mg/kg/day dose of <b>1</b>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Efficacy of <b>14a</b> (BMS-986166: 0.1 and 0.5 mg/kg) and <b>1</b> (FTY: 1.0 mg/kg) vs vehicle in a mouse experimental autoimmune encephalomyelitis model (EAE), clinical score (A), and histological evaluation (B). Mice (<i>n</i> = 10/group) were administered <b>14a</b> PO/QD starting on day 0 at the time of immunization with MOG-peptide (myelin oligodendrocyte glycoprotein). Vehicle: PEG300. *<i>p</i> value <0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further understand the effect of <b>14a</b> on EAE and its potential as a treatment for MS, the active metabolite, <b>14a-P</b>, was assessed in an organotypic cerebellar slice culture assay to examine the effect on demyelinated axons (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> During the development of MS, myelin is attacked and destroyed by autoimmune responses, resulting in demyelination and subsequent axonal degeneration.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Compound <b>1-P</b> has been shown to promote remyelination by acting directly on demyelinated neuronal axons in the central nervous system, an effect that is believed to contribute to its clinical efficacy in MS.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a><a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> illustrates the effects of <b>14a-P</b> and <b>1-P</b> on lysophosphatidylcholine (LPC)-induced demyelination in the organotypic cerebellar slice. Most of axonal fibers in the slice treated with LPC lost their myelin sheaths as compared to those treated with vehicle (part A vs part B of <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>); however, treatment with <b>14a-P</b> or <b>1-P</b> reversed LPC-induced demyelination (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D). Similar results were reported with <b>2-P</b>.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> To quantify the remyelination effect of <b>14a-P</b> and <b>1-P</b>, myelination index values were generated (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>E). The myelination index value of LPC-treated slices was ∼50% of vehicle; treatment with either <b>14a-P</b> or <b>1-P</b> in the LPC-treated slices lifted the myelination index up to ∼100% (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C,D), suggesting that both <b>14a-P</b> or <b>1-P</b> promoted remyelination of demyelinated neuronal axons in the brain.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compounds in lysophosphatidylcholine (LPC)-induced demyelination model. Immunohistochemical staining showing myelination of organotypic cerebellar slices in vehicle (A), in slices incubated overnight with LPC (B), and in slices incubated overnight with LPC followed by treatment with <b>1-P</b> (C) or <b>14a-P</b> (D) for 7 days. Remyelination is induced by subsequent treatment. Myelination index of <b>1-P</b> and <b>14a-P</b> after overnight incubation with LPC followed by 7 days of treatment (E). <sup>a</sup>Incubated with 0.5 mg/mL LPC overnight; *<i>p</i> value 0.05 vs LPS; ANOVA followed by Dunnett test, <i>n</i> = 3–5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The in vivo efficacy of <b>14a</b> was further demonstrated in a collagen-induced arthritis (CIA) model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). DBA/1 mice received a primary collagen immunization to initiate disease development and were concurrently dosed orally with <b>14a</b> at single once-daily doses of 0.1 or 0.5 mg/kg or injected intraperitoneally (ip) with mCTLA-4Ig twice per week at 1 mg/kg. CTLA-4Ig is a soluble receptor-IgG fusion protein that interferes with T-cell costimulation and has been shown to be clinically efficacious in the treatment of rheumatoid arthritis.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Compound <b>14a</b> dose dependently reduced both the clinical score as well as the paw histology score following the dosing regimens. On the basis of these evaluations, a dose of 0.5 mg/kg/day of <b>14a</b> demonstrated maximal efficacy and its clinical score was comparable to the 1.0 mg/kg dose of mCTLA4Ig.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy of <b>14a</b> (0.1 and 0.5 mg/kg) and mCTLA4Ig (1.0 mg/kg) vs vehicle in a collagen induced arthritis model (CIA), clinical score (A), and histological evaluation (B). ***<i>p</i> < 0.001 vs vehicle; One-Way ANOVA with Dunnett’s test. <i>N</i> = 10 in each group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, our efforts to discover a highly potent and biased agonist of S1P<sub>1</sub> with a reduced <i>T</i><sub>1/2</sub> and increased in vivo phosphate metabolite formation resulted in the discovery of <b>14a</b>. In comparison to our first clinical candidate (<b>2</b>), <b>14a</b> exhibited both a shorter in vivo <i>T</i><sub>1/2</sub> and improved formation of the active phosphate metabolite. This compound efficiently reduced blood lymphocyte counts in rats, had an acceptable liability profile, and showed excellent pharmacokinetic properties across species. Furthermore, studies in preclinical models of arthritis and multiple sclerosis (mouse CIA and mouse EAE) demonstrated robust efficacy with <b>14a</b> treatment. This compound also demonstrated improved projected safety in preclinical evaluation of undesired cardiovascular effects as compared to <b>1</b>, a full agonist of S1P<sub>1</sub> currently marketed for the treatment of relapse remitting multiple sclerosis (RRMS), and had acceptable safety multiples in preclinical evaluations against undesired pulmonary effects. On the basis of these results, and additional evaluations, compound <b>14a</b> was advanced into phase I clinical trials where it was found to be well tolerated across the doses examined and provided the desired PD effect in a dose-dependent manner. Additionally, the conversion of <b>14a</b> to the active phosphate metabolite was found to be greater than observed with our first clinical compound, <b>2</b>. Further clinical details of <b>14a</b> will be disclosed in a forthcoming publication.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17852" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17852" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Chemical Methods</h3><div class="NLM_p">All commercially available chemicals and solvents were used without further purification. Reactions were performed under an atmosphere of nitrogen. All flash column chromatography was performed on EM Science silica gel 60 (particle size of 40–60 μm). All new compounds gave satisfactory <sup>1</sup>H NMR, LC/MS, and mass spectrometry results. <sup>1</sup>H NMR spectra were obtained on a Bruker 400 MHz or a JEOL 500 MHz NMR spectrometer using the residual signal of deuterated NMR solvent as internal reference. Electrospray ionization (ESI) mass spectra were obtained on a Waters ZQ single quadrupole mass spectrometer. High-resolution mass spectral analysis was performed on an LTQ-FT mass spectrometer interfaced to a Waters Acquity ultraperformance liquid chromatography.</div><div class="NLM_p">HPLC analyses were performed using the following conditions. All final compounds had an HPLC purity of ≥95% unless otherwise stated.</div><div class="NLM_p">Method A: (analytical) Waters Acquity UPLC, BEH C18 2.1 mm × 50 mm, 1.7 μm particles. Mobile phase A: 98:2 water:ACN with 0.05%TFA. Mobile phase B: acetonitrile with 0.05% TFA. Column temp 50 °C. Gradient 2–98%B over 1 min then 0.5 min hold at 100% B. Flow 0.8 mL/min. Detection: UV 200 nm.</div><div class="NLM_p">Method B: (preparative) Shimadzu prep HPLC, Luna C18 30 mm × 100 mm, 5 μm (Phenomenex Inc.); 2 mL injection. Mobile phase A: 0.1% TFA in water. Mobile phase B: 0.1% TFA in MeCN. Temperature: 25 °C. Gradient: 20–100% B over 5 min, then a 10 min hold at 100% B. Flow: 30 mL/min. Detection: UV at 220 nm.</div><div class="NLM_p">Method C: (analytical) Waters Acquity UPLC BEH C18 (2.1 mm × 50 mm), 1.7 μm particles. Mobile phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate. Mobile phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate. Temperature: 50 °C. Gradient: 0–100% B over 2 min, then a 0.5 min hold at 100% B. Flow: 1.0 mL/min. Detection: UV at 220 nm.</div><div class="NLM_p">Method D: (analytical purity long run) Shimadzu HPLC, Sunfire C18 (3.0 mm × 150 mm), 3.5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 0.05% TFA. Mobile phase B: 95:5 acetonitrile:water with 0.05 TFA. Temperature: 25 °C. Gradient: 0–100% B over 12 min, then a 3 min hold at 100% B. Flow: 1.0 mL/min; Detection: UV at 254 nm.</div><div class="NLM_p">Method E: (analytical purity long run) Shimadzu HPLC, Xbridge phenyl (3.0 mm × 150 mm), 3.5 μm particles. Mobile phase A: 5:95 acetonitrile:water with 0.05% TFA. Mobile phase B: 95:5 acetonitrile:water with 0.05 TFA. Temperature: 25 °C. Gradient: 0–100% B over 12 min, then a 3 min hold at 100% B. Flow: 1.0 mL/min; Detection: UV at 254 nm.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (5<i>R</i>,7<i>S</i>)-7-(4-Bromophenyl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>4</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of (1<i>R</i>,3<i>S</i>)-methyl 1-amino-3-(4-bromophenyl)cyclopentanecarboxylate (<b>3</b>)<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (15 g, 44.8 mmol) in MeOH (100 mL) at 0 °C was added sodium borohydride (4 g, 106 mmol) portionwise. The reaction mixture was warmed to room temperature and stirred for 1 h, then more sodium borohydride was added portionwise (500 mg at a time) at 30 min intervals until reaction was complete by LCMS. The reaction mixture was then cooled to 0 °C and quenched with water. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-(4-bromophenyl)cyclopentyl)methanol (11 g, 91% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.51–7.40 (m, 2H), 7.27 (d, <i>J</i> = 8.4 Hz, 2H), 3.32–3.20 (m, 2H), 3.09–2.92 (m, 1H), 2.11 (dd, <i>J</i> = 12.9, 8.7 Hz, 1H), 1.98–1.87 (m, 1H), 1.80 (qd, <i>J</i> = 11.1, 7.9 Hz, 1H), 1.69–1.58 (m, 1H), 1.48 (ddd, <i>J</i> = 12.4, 7.9, 2.2 Hz, 1H), 1.32 (dd, <i>J</i> = 12.8, 10.1 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 272. HPLC <i>t</i><sub><i>r</i></sub> = 0.65 min (method A).</div><div class="NLM_p last">To a mixture of ((1<i>R</i>,3<i>S</i>)-1-amino-3-(4-bromophenyl)cyclopentyl)methanol (11 g, 40.7 mmol) and pyridine (3.29 mL, 40.7 mmol) in dioxane (300 mL) was added 1,1′-carbonyldiimidazole (19.81 g, 122 mmol). The reaction was stirred for 4 h. The reaction mixture was diluted with ethyl acetate and washed with 1 M HCl, brine and satd NaHCO<sub>3</sub>. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford (5<i>R</i>,7<i>S</i>)-7-(4-bromophenyl)-3-oxa-1-azaspiro[4.4]nonan-2-one (10.5 g, 87% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.45 (d, <i>J</i> = 8.6 Hz, 2H), 7.12 (d, <i>J</i> = 8.4 Hz, 2H), 6.42 (br s, 1H), 4.41–4.21 (m, 2H), 3.17–2.91 (m, 1H), 2.34 (dd, <i>J</i> = 13.3, 7.4 Hz, 1H), 2.23–2.11 (m, 2H), 2.01–1.90 (m, 2H), 1.88–1.74 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 297.9. HPLC <i>t</i><sub><i>r</i></sub> = 0.87 min (method A).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl 2-(4-((5<i>R</i>,7<i>S</i>)-2-Oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)phenyl)acetate (<b>5</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(4-bromophenyl)-3-oxa-1-azaspiro[4.4]nonan-2-one (1.0 g, 3.38 mmol) in dioxane (10 mL) at room temperature was added 1 M lithium bis(trimethylsilyl)amide in THF (3.71 mL, 3.71 mmol). The reaction mixture was stirred for 30 min, then 1,2,3,4,5-pentaphenyl-1′-(di-<i>t</i>-butylphosphino)ferrocene (0.12 g, 0.17 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (0.155 g, 0.17 mmol), and (2-(<i>tert</i>-butoxy)-2-oxoethyl)zinc(II) chloride (8.1 mL, 4.05 mmol) were added. Then the reaction mixture was heated at 80 °C for 2 h. The reaction mixture was cooled then diluted with ethyl acetate and washed with 1 M HCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (0–100% EtOAc over 20 min) to afford <i>tert</i>-butyl 2-(4-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)phenyl)acetate (950 mg, 85% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.27–7.21 (m, 2H), 7.20–7.15 (m, 2H), 5.25–5.13 (m, 1H), 4.41–4.24 (m, 2H), 3.53 (s, 2H), 3.19–3.00 (m, 1H), 2.36 (dd, <i>J</i> = 13.3, 7.2 Hz, 1H), 2.22–2.10 (m, 2H), 2.04–1.91 (m, 2H), 1.90–1.74 (m, 1H), 1.47 (s, 9H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 332. HPLC <i>t</i><sub><i>r</i></sub> = 0.93 min (method A).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (5<i>R</i>,7<i>S</i>)-7-(6-Oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>6</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of <i>tert</i>-butyl 2-(4-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)phenyl)acetate (1 g, 3.0 mmol) in DCM (20 mL) was added TFA (10 mL). After 2 h, the mixture was concentrated in vacuo and dried. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 276. HPLC <i>t</i><sub><i>r</i></sub> = 0.65 min (method A).</div><div class="NLM_p last">To a mixture of 2-(4-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)phenyl)acetic acid (800 mg, 2.9 mmol) in DCM (20 mL) was added oxalyl chloride (1 mL, 11.4 mmol) along with a few drops of DMF. After 1 h, the reaction mixture was concentrated in vacuo and dried. Then the residue was redissolved in DCM (20 mL) in a glass pressure vessel. Aluminum chloride (1.55 g, 11.6 mmol) was added, and the reaction was cooled to −78 °C. Ethylene was bubbled through for 5 min then the reaction was sealed. The reaction mixture was allowed to slowly warm to room temperature and stirred for 4 h. The reaction mixture was poured onto ice then diluted with dichloromethane and washed with 1 M HCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an MeOH/DCM gradient (0–10% MeOH over 13 column volumes) to afford (5<i>R</i>,7<i>S</i>)-7-(6-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (770 mg, 92% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.20–7.00 (m, 3H), 5.49 (br s, 1H), 4.45–4.25 (m, 2H), 3.59 (s, 2H), 3.08 (t, <i>J</i> = 6.8 Hz, 3H), 2.58 (t, <i>J</i> = 6.7 Hz, 2H), 2.38 (dd, <i>J</i> = 13.2, 7.3 Hz, 1H), 2.27–2.11 (m, 2H), 2.05–1.92 (m, 2H), 1.92–1.74 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 286.. HPLC <i>t</i><sub><i>r</i></sub> = 0.74 min (method A).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 6-((5<i>R</i>,7<i>S</i>)-2-Oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-3,4-dihydronaphthalen-2-yl Trifluoromethanesulfonate (<b>7</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(6-oxo-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (340 mg, 1.2 mmol) and DMPU (0.43 mL, 3.6 mmol) in THF (10 mL) at −78 °C was added 2 M LDA in THF (1.5 mL, 2.6 mmol). The reaction mixture was stirred for 30 min then 1,1,1-trifluoro-<i>N</i>-phenyl-<i>N</i>-(trifluoromethyl)sulfonyl methanesulfonamide (640 mg, 1.8 mmol) in THF (10 mL) was added. The reaction mixture was warmed to 0 °C. After 1 h, the reaction was quenched with water. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (0–100% EtOAc over 20 min) to afford 6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-3,4-dihydronaphthalen-2-yl trifluoromethanesulfonate (400 mg, 60% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.07–7.05 (m, 1H), 7.04–7.00 (m, 1H), 6.79–6.70 (m, 1H), 6.52–6.40 (m, 1H), 4.43–4.24 (m, 2H), 3.09–3.04 (m, 3H), 2.77–2.65 (m, 2H), 2.37–2.28 (m, 1H), 2.23–2.09 (m, 2H), 2.04–1.93 (m, 2H), 1.92–1.78 (m, 2H). MS (M+H)<sup>+</sup> at <i>m</i>/<i>z</i> 418. HPLC <i>t</i><sub><i>r</i></sub> = 1.01 min (method A).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>8a</b>,<b>8b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of 6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-3,4-dihydronaphthalen-2-yl trifluoromethanesulfonate (75 mg, 0.18 mmol), triphenylphosphine (10 mg, 0.038 mmol), and acetylacetone cobalt(III) salt (4 mg, 0.011 mmol) in THF (5 mL) at 0 °C was added 1 M phenylmagnesium bromide in THF (0.54 mL, 0.54 mmol). The reaction was stirred for 3 h and during this time was allowed to warm to room temperature. The reaction was quenched with water, and the mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (0–100% EtOAc over 13 column volumes) to afford (5<i>R</i>,7<i>S</i>)-7-(6-phenyl-7,8-dihydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (55 mg, 88% yield) as an oil. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 346. HPLC <i>t</i><sub><i>r</i></sub> = 1.06 min (method A).</div><div class="NLM_p">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(6-phenyl-7,8-dihydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (55 mg, 0.159 mmol) in MeOH (10 mL) was added Pearlman’s catalyst (22 mg, 0.16 mmol). The mixture was hydrogenated under a balloon of H<sub>2</sub> for 1 h, then the catalyst was filtered away. The filtrate was concentrated to afford 38 mg of (5<i>R</i>,7<i>S</i>)-7-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one. The individual isomers were separated using a Chiralpak AD-H column under SFC conditions (50% MeOH in CO<sub>2</sub>).</div><div class="NLM_p">Peak 1 (12 mg, 22% yield), retention time on chiral HPLC <i>t</i><sub><i>r</i></sub> = 10.3 min. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 348.</div><div class="NLM_p">Peak 2 (12 mg, 22% yield), retention time on chiral HPLC <i>t</i><sub><i>r</i></sub> = 13.3 min.. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 348.</div><div class="NLM_p">The absolute stereochemistry of the isomers was not determined. The first eluting isomer was designated as isomer a and the second eluting isomer as isomer b.</div><div class="NLM_p">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (12 mg, 0.035 mmol, isomer a) in dioxane (2 mL) was added 2N NaOH (2 mL). The reaction mixture was heated at 100 °C overnight, then cooled and acidified with TFA. The solvents were removed in vacuo, and MeOH (1.8 mL) was added to the crude material. Solids were then filtered away, and the crude product was purified by HPLC (method B) to afford 8 mg (70% yield) of ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (<b>8a,</b> isomer a) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.40–7.25 (m, 4H), 7.25–7.15 (m, 1H), 7.11–6.97 (m, 3H), 3.81–3.55 (m, 2H), 3.24–3.06 (m, 1H), 3.03–2.79 (m, 5H), 2.45 (ddd, <i>J</i> = 13.4, 7.1, 1.1 Hz, 1H), 2.23–2.06 (m, 2H), 2.04–1.86 (m, 4H), 1.75 (t, <i>J</i> = 12.7 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 322. HPLC <i>t</i><sub><i>r</i></sub> = 8.22 min (method D). HPLC purity: 96.2%.</div><div class="NLM_p">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (12 mg, 0.035 mmol, isomer b) in dioxane (2 mL) was added 2N NaOH (2 mL). The reaction mixture was heated at 100 °C overnight, then cooled and acidified with TFA. The solvents were removed in vacuo, and MeOH (1.8 mL) was added to the crude material. Solids were then filtered away, and the crude product was purified by HPLC (method B) to afford 4.5 mg (40% yield) of ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (<b>8b,</b> isomer b) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.36–7.27 (m, 4H), 7.24–7.17 (m, 1H), 7.05 (s, 3H), 3.73–3.58 (m, 2H), 3.21–3.08 (m, 1H), 3.05–2.82 (m, 5H), 2.44 (ddd, <i>J</i> = 13.4, 7.1, 1.1 Hz, 1H), 2.21–2.07 (m, 2H), 2.04–1.88 (m, 4H), 1.75 (t, <i>J</i> = 12.7 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 322. HPLC <i>t</i><sub><i>r</i></sub> = 8.24 min (method D). HPLC purity: 99.7%.</div><div class="NLM_p last">The following compounds were prepared through the route described for <b>8a</b>/<b>8b</b>:</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>9a</b>) and ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>9b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">Separation conditions: Chiralpak AS-H column under SFC conditions (45% MeOH in CO<sub>2</sub>).</div><div class="NLM_p">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as an off-white solid (6 mg, 36%). Isomer a, <b>9a</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.35–7.26 (m, 2H), 7.25–7.16 (m, 3H), 7.04–6.91 (m, 3H), 3.73–3.54 (m, 2H), 3.14–3.02 (m, 1H), 2.89–2.71 (m, 3H), 2.68 (d, <i>J</i> = 7.3 Hz, 2H), 2.50–2.35 (m, 2H), 2.19–1.86 (m, 6H), 1.72 (t, <i>J</i> = 12.8 Hz, 1H), 1.44 (dtd, <i>J</i> = 12.8, 10.8, 5.9 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 336. HPLC <i>t</i><sub><i>r</i></sub> = 8.78 min (method D). HPLC purity: 98.8%.</div><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-benzyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as an off-white solid (7 mg, 37% yield). Isomer b, <b>9b</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.36–7.25 (m, 2H), 7.24–7.13 (m, 3H), 7.04–6.89 (m, 3H), 3.73–3.54 (m, 2H), 3.19–3.02 (m, 1H), 2.90–2.70 (m, 3H), 2.67 (d, <i>J</i> = 7.3 Hz, 2H), 2.51–2.33 (m, 2H), 2.18–1.86 (m, 6H), 1.72 (t, <i>J</i> = 12.7 Hz, 1H), 1.43 (dtd, <i>J</i> = 12.8, 10.8, 5.8 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 336. HPLC <i>t</i><sub><i>r</i></sub> = 8.72 min (method D). HPLC purity: 98.1%.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>10a</b>) and ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>10b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">Separation conditions: Chiralpak AS-H column under SFC conditions (37% MeOH in CO<sub>2</sub>).</div><div class="NLM_p">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as a white solid (9 mg, 50% yield). Isomer a, <b>10a</b>: <sup>1</sup>H NMR (500 MHz, MeOD) δ 7.29–7.24 (m, 2H), 7.23–7.19 (m, 2H), 7.18–7.12 (m, 1H), 7.03–7.00 (m, 2H), 6.99–6.97 (m, 1H), 3.72–3.57 (m, 2H), 3.15–2.99 (m, 1H), 2.89 (dd, <i>J</i> = 16.1, 3.6 Hz, 1H), 2.83–2.70 (m, 4H), 2.52–2.33 (m, 2H), 2.20–2.05 (m, 1H), 2.05–1.86 (m, 4H), 1.78–1.60 (m, 4H), 1.44 (dtd, <i>J</i> = 12.8, 10.6, 5.8 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 350. HPLC <i>t</i><sub><i>r</i></sub> = 7.2 min (method E). HPLC purity: 98.4%.</div><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-phenethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as a white solid (6 mg, 31% yield). Isomer b, <b>10b</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.31–7.19 (m, 4H), 7.19–7.11 (m, 1H), 7.05–6.94 (m, 3H), 3.73–3.56 (m, 2H), 3.20–3.03 (m, 1H), 2.89 (dd, <i>J</i> = 16.2, 3.4 Hz, 1H), 2.84–2.69 (m, 4H), 2.51–2.36 (m, 2H), 2.20–2.07 (m, 1H), 2.07–1.87 (m, 4H), 1.82–1.64 (m, 4H), 1.44 (dtd, <i>J</i> = 12.7, 10.4, 6.1 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 350. HPLC <i>t</i><sub><i>r</i></sub> = 8.97 min (method D). HPLC purity: 94.5%.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-(6-(2-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>11</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">Separation conditions: Chiralpak OJ-H column under SFC conditions (65% MeOH in CO<sub>2</sub>).</div><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(2-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol as a white solid (22 mg, 72% yield). Isomer b, <b>11</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.25–7.16 (m, 1H), 7.12 (dd, <i>J</i> = 7.5, 1.5 Hz, 1H), 7.02–6.83 (m, 5H), 3.83 (s, 3H), 3.66–3.50 (m, 2H), 3.05 (td, <i>J</i> = 11.3, 6.6 Hz, 1H), 2.88–2.62 (m, 5H), 2.43 (dd, <i>J</i> = 16.4, 10.5 Hz, 1H), 2.34 (dd, <i>J</i> = 13.3, 7.4 Hz, 1H), 2.14–1.98 (m, 2H), 1.98–1.80 (m, 4H), 1.65 (t, <i>J</i> = 12.5 Hz, 1H), 1.51–1.35 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 366. HPLC <i>t</i><sub><i>r</i></sub> = 0.88 min (method A). HPLC purity: 95%.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-(6-(3-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>12a</b>,<b>12b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">Separation conditions: Chiralpak OJ-H column under SFC conditions (70% MeOH in CO<sub>2</sub>).</div><div class="NLM_p">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(3-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol as a white solid (25 mg, 76% yield). Isomer a, <b>12a</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.21 (dd, <i>J</i> = 9.0, 7.5 Hz, 1H), 7.01–6.96 (m, 2H), 6.95–6.89 (m, 1H), 6.83–6.73 (m, 3H), 3.80 (s, 3H), 3.65–3.46 (m, 2H), 3.12–2.99 (m, 1H), 2.89–2.69 (m, 3H), 2.64 (d, <i>J</i> = 7.3 Hz, 2H), 2.42 (dd, <i>J</i> = 16.3, 10.3 Hz, 1H), 2.31 (ddd, <i>J</i> = 13.3, 7.3, 1.2 Hz, 1H), 2.11–1.77 (m, 6H), 1.63 (t, <i>J</i> = 12.5 Hz, 1H), 1.43 (dtd, <i>J</i> = 12.8, 10.7, 5.8 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 366. HPLC <i>t</i><sub><i>r</i></sub> = 7.26 min (method D). HPLC purity: 99.8%.</div><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(3-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol as a white solid (24 mg, 76% yield). Isomer b, <b>12b</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.21 (dd, <i>J</i> = 9.0, 7.5 Hz, 1H), 7.03–6.96 (m, 2H), 6.95–6.89 (m, 1H), 6.83–6.73 (m, 3H), 3.80 (s, 3H), 3.61–3.46 (m, 2H), 3.12–2.97 (m, 1H), 2.90–2.69 (m, 3H), 2.64 (d, <i>J</i> = 7.3 Hz, 2H), 2.42 (dd, <i>J</i> = 16.4, 10.2 Hz, 1H), 2.29 (dd, <i>J</i> = 13.2, 7.3 Hz, 1H), 2.11–1.74 (m, 6H), 1.61 (t, <i>J</i> = 12.5 Hz, 1H), 1.51–1.35 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 366. HPLC <i>t</i><sub><i>r</i></sub> = 7.25 min (method D). HPLC purity: 95%.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-(6-(4-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>13a</b>,<b>13b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">Separation conditions: Chiralpak OJ-H column under SFC conditions (65% MeOH in CO<sub>2</sub>).</div><div class="NLM_p">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(4-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol as a white solid (21 mg, 65% yield). Isomer a, <b>13a</b>: <sup>1</sup>H NMR (400 MHz MeOD) δ 7.12 (d, <i>J</i> = 8.6 Hz, 2H), 7.03–6.96 (m, 2H), 6.95–6.90 (m, 1H), 6.89–6.82 (m, 2H), 3.79 (s, 3H), 3.66–3.44 (m, 2H), 3.13–2.98 (m, 1H), 2.90–2.66 (m, 3H), 2.60 (d, <i>J</i> = 7.0 Hz, 2H), 2.48–2.27 (m, 2H), 2.12–2.04 (m, 1H), 2.00–1.81 (m, 5H), 1.66 (t, <i>J</i> = 12.7 Hz, 1H), 1.50–1.35 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 366. HPLC <i>t</i><sub><i>r</i></sub> = 7.31 min (method D). HPLC purity: 98.3%.</div><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(4-methoxybenzyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol as a white solid (28 mg, 84% yield). Isomer b, <b>13b</b>: <sup>1</sup>H NMR (400 MHz MeOD) δ 7.12 (d, <i>J</i> = 8.6 Hz, 2H), 7.02–6.96 (m, 2H), 6.95–6.90 (m, 1H), 6.86 (d, <i>J</i> = 8.6 Hz, 2H), 3.79 (s, 3H), 3.64–3.49 (m, 2H), 3.12–2.98 (m, 1H), 2.89–2.67 (m, 3H), 2.61 (d, <i>J</i> = 7.0 Hz, 2H), 2.48–2.27 (m, 2H), 2.16–2.02 (m, 1H), 2.02–1.78 (m, 5H), 1.64 (t, <i>J</i> = 12.5 Hz, 1H), 1.41 (dtd, <i>J</i> = 13.0, 11.0, 5.8 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 366. HPLC <i>t</i><sub><i>r</i></sub> = 7.24 min (method D). HPLC purity: 98.5%.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>14a</b>) and ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>14b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of 6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-3,4-dihydronaphthalen-2-yl trifluoromethanesulfonate (100 mg, 0.24 mmol), CuI (4.5 mg, 0.024 mmol), and bis(triphenylphosphine)palladium(II) chloride (17 mg, 0.024 mmol) in TEA (3 mL) was added 1-ethynyl-2-methoxybenzene (0.093 mL, 0.72 mmol). The reaction mixture was heated at 60 °C for 1 h then diluted with ethyl acetate and washed with 1 M HCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (0–100% EtOAc over 12 column volumes) to afford (5<i>R</i>,7<i>S</i>)-7-(6-((2-methoxyphenyl)ethynyl)-7,8-dihydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (55 mg, 0.113 mmol, 55% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.49–7.43 (m, 1H), 7.34–7.29 (m, 1H), 7.05–7.02 (m, 2H), 7.01–6.98 (m, 1H), 6.97–6.87 (m, 3H), 6.01–5.93 (m, 1H), 4.32 (d, <i>J</i> = 12.8 Hz, 2H), 3.96–3.91 (m, 3H), 3.12–2.99 (m, 1H), 2.94–2.81 (m, 2H), 2.64–2.54 (m, 2H), 2.41–2.28 (m, 1H), 2.22–2.10 (m, 2H), 2.04–1.76 (m, 3H).</div><div class="NLM_p">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(6-((2-methoxyphenyl)ethynyl)-7,8-dihydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (55 mg, 0.113 mmol) in MeOH (5 mL) was added Pearlman’s catalyst (15.8 mg, 0.11 mmol), and the reaction mixture was hydrogenated under a balloon of H<sub>2</sub> overnight. The catalyst was filtered away and the solvents were removed in vacuo to afford the desired reduced product. The individual isomers were separated using a Chiralpak OJ column under SFC conditions (35% MeOH in CO<sub>2</sub>)</div><div class="NLM_p">Isomer a: Recovered (5<i>R</i>,7<i>S</i>)-7-(6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (25 mg, 45% yield).</div><div class="NLM_p">Isomer b: Recovered (5<i>R</i>,7<i>S</i>)-7-(6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (26 mg, 46% yield).</div><div class="NLM_p">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(6-(5-methoxypentyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (isomer a, 25 mg, 0.062 mmol) in DMSO (0.5 mL) and MeOH (1 mL) was added 1N NaOH (0.5 mL, 0.5 mmol). The reaction mixture was heated at 95 °C for 4 h then cooled and acidified with TFA. The solids were filtered away and the filtrate was purified by HPLC (method B) to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(5-methoxypentyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (<b>14a</b>, isomer a, 14 mg, 0.048 mmol, 77% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.21–7.10 (m, 2H), 7.05–6.96 (m, 3H), 6.91 (d, <i>J</i> = 7.9 Hz, 1H), 6.86 (td, <i>J</i> = 7.4, 1.0 Hz, 1H), 3.83 (s, 3H), 3.72–3.54 (m, 2H), 3.20–3.03 (m, 1H), 2.97–2.69 (m, 5H), 2.48–2.35 (m, 2H), 2.21–1.86 (m, 5H), 1.80–1.57 (m, 4H), 1.52–1.36 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380. HPLC <i>t</i><sub><i>r</i></sub> = 8.87 min (method D). HPLC purity: 96.9%.</div><div class="NLM_p last">To a mixture of (5<i>R</i>,7<i>S</i>)-7-(6-(5-methoxypentyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (isomer b, 26 mg, 0.062 mmol) in DMSO (0.5 mL) and MeOH (1 mL) was added 1N NaOH (0.5 mL, 0.5 mmol). The reaction mixture was heated at 95 °C for 4 h then cooled and acidified with TFA. The solids were filtered away and the filtrate was purified by HPLC (method B) to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol as a TFA salt (<b>14b</b>, isomer b, 10 mg, 0.034 mmol, 55% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.21–7.10 (m, 2H), 7.04–6.97 (m, 3H), 6.91 (d, <i>J</i> = 7.9 Hz, 1H), 6.86 (td, <i>J</i> = 7.4, 1.1 Hz, 1H), 3.83 (s, 3H), 3.72–3.54 (m, 2H), 3.19–3.03 (m, 1H), 2.96–2.70 (m, 5H), 2.49–2.35 (m, 2H), 2.20–1.87 (m, 5H), 1.82–1.57 (m, 4H), 1.43 (dtd, <i>J</i> = 12.8, 10.5, 6.1 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380. HPLC <i>t</i><sub><i>r</i></sub> = 9.0 min (method D). HPLC purity: 97%.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Alternate Route for ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>14a</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a solution of ((<i>R</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate (<b>18a</b>, 700 mg, 1.54 mmol) and CuBr–DMS complex (948 mg, 4.6 mmol) in Et<sub>2</sub>O(50 mL) was added (2-methoxybenzyl)magnesium chloride (58 mL, 14.5 mmol) at room temperature, and the reaction mixture was stirred for 16 h. The reaction mixture was diluted with satd NH<sub>4</sub>Cl and water then extracted with EtOAc. The organic layer was collected, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to give 580 mg of desired product (93% yield). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 406.</div><div class="NLM_p">This material was dissolved in dioxane (10 mL), and 1N NaOH was added (10 mL). The reaction mixture was heated at 100 °C overnight. The reaction mixture was then cooled, diluted with water, and extracted with EtOAc (twice). The organic layers were combined, washed with satd NaCl, dried over MgSO<sub>4</sub>, and concentrated in vacuo. The resulting solid was triturated in MeCN (10 mL) then stirred for several hours. The solid was then collected by filtration and dried in vacuo to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (350 mg, 0.88 mmol, 57% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.20–7.09 (m, 2H), 7.03–6.93 (m, 3H), 6.91 (d, <i>J</i> = 7.7 Hz, 1H), 6.85 (td, <i>J</i> = 7.4, 1.0 Hz, 1H), 3.83 (s, 3H), 3.57–3.41 (m, 2H), 3.08–2.95 (m, 1H), 2.88 (br dd, <i>J</i> = 16.5, 4.4 Hz, 1H), 2.82–2.77 (m, 1H), 2.77–2.67 (m, 3H), 2.40 (dd, <i>J</i> = 16.3, 9.9 Hz, 1H), 2.21 (dd, <i>J</i> = 13.0, 7.5 Hz, 1H), 2.08–1.86 (m, 3H), 1.84–1.60 (m, 5H), 1.54 (t, <i>J</i> = 12.3 Hz, 1H), 1.42 (dtd, <i>J</i> = 12.7, 10.6, 5.9 Hz, 1H). <sup>13</sup>C NMR (126 MHz, MeOD) δ 157.5, 142.11–141.89 (m, 1C), 141.7, 136.3, 134.1, 130.8, 128.6, 126.8, 126.6, 123.8, 120.0, 110.0, 69.1, 61.5, 54.3, 48.1, 48.0, 47.3, 47.1, 44.9 (d, <i>J</i> = 10.1 Hz, 1C), 36.7, 36.4, 35.6, 34.3, 32.9. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380. HRMS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380.25829. HPLC <i>t</i><sub><i>r</i></sub> = 9.0 min (method D). HPLC purity: 97.3% with >99% de. <i>t</i><sub><i>r</i></sub> = 22.6 min (method: ChiralCel AD-H (25 cm × 0.46 cm, 5 μm). Flow rate: 2 mL/min. Mobile phase: CO<sub>2</sub>/(MeOH + 0.1%DEA) in 85:15 ratio isocratic); [α]<sub>D</sub><sup>20</sup> +53.77 (<i>c</i> 0.315, MeOH).</div><div class="NLM_p last">The following compounds were prepared using the procedures described for <b>14a</b>/<b>14b</b>:</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>15a</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as a white solid (14 mg, 67% yield). Isomer a, <b>15a</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.18 (t, <i>J</i> = 7.8 Hz, 1H), 7.04–6.97 (m, 3H), 6.85–6.77 (m, 2H), 6.74 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 3.79 (s, 3H), 3.71–3.57 (m, 2H), 3.20–3.02 (m, 1H), 2.89 (dd, <i>J</i> = 16.5, 3.3 Hz, 1H), 2.83–2.75 (m, 2H), 2.75–2.69 (m, 2H), 2.50–2.36 (m, 2H), 2.19–2.06 (m, 1H), 2.06–1.88 (m, 4H), 1.81–1.64 (m, 4H), 1.44 (dtd, <i>J</i> = 12.8, 10.4, 5.9 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380. HPLC <i>t</i><sub><i>r</i></sub> = 8.89 min (method D). HPLC purity = 95%.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-(6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>15b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as a white solid (14 mg, 67% yield). Isomer b, <b>15b</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.18 (t, <i>J</i> = 7.8 Hz, 1H), 7.05–6.96 (m, 3H), 6.85–6.76 (m, 2H), 6.74 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 3.79 (s, 3H), 3.71–3.56 (m, 2H), 3.19–3.02 (m, 1H), 2.89 (dd, <i>J</i> = 16.4, 3.6 Hz, 1H), 2.83–2.75 (m, 2H), 2.75–2.68 (m, 2H), 2.50–2.35 (m, 2H), 2.20–2.06 (m, 1H), 2.06–1.87 (m, 4H), 1.82–1.61 (m, 4H), 1.53–1.36 (m, 1H)). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380. HPLC <i>t</i><sub><i>r</i></sub> = 8.91 min (method D). HPLC purity = 99%.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>16a</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as a white solid (53 mg, 72% yield). Isomer a, <b>16a</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.13 (d, <i>J</i> = 8.6 Hz, 2H), 7.05–6.96 (m, 3H), 6.84 (d, <i>J</i> = 8.6 Hz, 2H), 3.77 (s, 3H), 3.71–3.56 (m, 2H), 3.20–3.01 (m, 1H), 2.97–2.74 (m, 3H), 2.75–2.61 (m, 2H), 2.42 (dd, <i>J</i> = 14.2, 7.8 Hz, 2H), 2.21–2.07 (m, 1H), 2.05–1.86 (m, 4H), 1.80–1.57 (m, 4H), 1.43 (dtd, <i>J</i> = 12.9, 10.4, 5.9 Hz, 1H)). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380. HPLC <i>t</i><sub><i>r</i></sub> = 8.88 min (method D). HPLC purity = 99.3%</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>16b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as a white solid (55 mg, 73% yield). Isomer b, <b>16b</b>: <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.13 (d, <i>J</i> = 8.8 Hz, 2H), 7.03–6.96 (m, 3H), 6.84 (d, <i>J</i> = 8.8 Hz, 2H), 3.77 (s, 3H), 3.70–3.57 (m, 2H), 3.19–3.03 (m, 1H), 2.96–2.74 (m, 3H), 2.73–2.63 (m, 2H), 2.42 (dd, <i>J</i> = 14.1, 7.9 Hz, 2H), 2.20–2.07 (m, 1H), 2.06–1.87 (m, 4H), 1.79–1.60 (m, 4H), 1.43 (dtd, <i>J</i> = 12.7, 10.6, 5.9 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 380. HPLC <i>t</i><sub><i>r</i></sub> = 8.90 min (method D). HPLC purity = 98%.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Methyl 6-((5<i>R</i>,7<i>S</i>)-2-Oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate (<b>17</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of potassium carbonate (523 mg, 3.8 mmol), (5<i>R</i>,7<i>S</i>)-7-(4-bromophenyl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>4</b>, 800 mg, 2.7 mmol), itaconic acid (456 mg, 3.5 mmol), and acetonitrile (8 mL) was added water (2.4 mL). The mixture was stirred until the evolution of carbon dioxide stopped and then was sparged with nitrogen for 3 min. After palladium(II) acetate (30 mg, 0.14 mmol) and tri-<i>o</i>-tolylphosphine (82 mg, 0.27 mmol) were added, the mixture was sparged with nitrogen for an additional 3 min. The mixture was stirred at 80 °C for 20 h and then concentrated in vacuo. The residue was mixed with water (40 mL), basified with potassium carbonate, and filtered. The filtrate was washed with diethyl ether (2 × 15 mL), then the aqueous layer was acidified to pH ∼2 with 6 N aqueous hydrochloric acid. The resulting solid was separated, and the aqueous solution was extracted with a mixture of THF/EtOAc (3:1; 4 × 10 mL). The solid and the extracts were combined and concentrated. MS (M + H – H<sub>2</sub>O)<sup>+</sup> at <i>m</i>/<i>z</i> 328.</div><div class="NLM_p">The residue was mixed with THF (5 mL), ethyl acetate (5 mL), methanol (20 mL), and 10% Pd-C (400 mg, 0.376 mmol) then hydrogenated under a balloon of H<sub>2</sub> overnight. The catalyst was filtered away and the filtrate was concentrated and lyophilized to give a white solid. MS (M + H – H<sub>2</sub>O)<sup>+</sup> at <i>m</i>/<i>z</i> 330.</div><div class="NLM_p">The solid was mixed with 98% sulfuric acid (15 mL, 281 mmol), and the clear solution was stirred at room temperature for 4 h. MeOH (8 mL, 198 mmol) was added slowly with water-bath cooling. The mixture was stirred at room temperature for 1 h before being poured onto ice (150 g). The mixture was extracted with ethyl acetate (4 × 40 mL). The combined ethyl acetate extracts were washed with satd aqueous sodium bicarbonate solution (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. Flash chromatography purification (24 g silica gel column, gradient elution from 10 to 100% ethyl acetate in hexanes) afforded methyl 4-oxo-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate (440 mg. MS (M + H – H<sub>2</sub>O)<sup>+</sup> at <i>m</i>/<i>z</i> 344.</div><div class="NLM_p last">A mixture of methyl 4-oxo-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate (440 mg, 1.281 mmol), MeOH (15 mL), acetic acid (1.5 mL), and 10% Pd-C (200 mg, 0.188 mmol) was hydrogenated under a balloon of H<sub>2</sub> over 3 days. The mixture was filtered through a membrane filter. The filtrate was concentrated in vacuo to give methyl 6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate (337 mg, 55% for 4 steps) as a white solid. MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 330. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.06 (s, 1H), 7.02–6.92 (m, 2H), 6.39–6.26 (m, 1H), 4.37–4.25 (m, 2H), 3.75 (s, 3H), 3.02–2.97 (m, 2H), 2.91–2.81 (m, 2H), 2.80–2.67 (m, 1H), 2.35–2.27 (m, 1H), 2.26–2.06 (m, 3H), 2.03–1.91 (m, 2H), 1.91–1.75 (m, 3H).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-(Hydroxymethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>18a</b>) and (5<i>R</i>,7<i>S</i>)-7-((<i>S</i>)-6-(Hydroxymethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>18b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">A mixture of methyl 6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carboxylate (337 mg, 1.023 mmol), anhydrous THF (3 mL), and a 2M solution of lithium borohydride (2.56 mL, 5.12 mmol) in THF was stirred at 70 °C for 4 h. Saturated aqueous ammonium chloride solution was added slowly at 0 °C to quench the reaction then water and ethyl acetate were added. The aqueous solution was extracted with ethyl acetate. The combined ethyl acetate solutions were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to afford (5<i>R</i>,7<i>S</i>)-7-(6-(hydroxymethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (300 mg, 0.995 mmol, 97% yield). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 302.</div><div class="NLM_p">Chiral SFC separation (AD-H (46 cm × 25 cm), 45% MeOH in CO<sub>2</sub>, 3 mL/min, 220 nm, 35 °C) gave isomers 1 and 2 as white solids.</div><div class="NLM_p">(5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-(hydroxymethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (isomer 2, 690 mg, 2.289 mmol) was dissolved in dry pyridine (5 mL), and <i>p</i>-toluenesulfonyl chloride (1.3 g, 6.9 mmol) was added in one portion. The resulting mixture was stirred at room temperature for 4 h. The solvent was removed in vacuo, and the crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (20–100% EtOAc over 12 column volumes) to afford ((<i>R</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate (<b>18a</b>, 860 mg, 1.89 mmol, 82% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.89–7.79 (m, 2H), 7.40 (s, 2H), 6.99 (br s, 3H), 6.45–6.32 (m, 1H), 4.42–4.23 (m, 2H), 4.07–3.96 (m, 2H), 3.08–2.93 (m, 1H), 2.90–2.70 (m, 3H), 2.51–2.48 (m, 3H), 2.46–2.38 (m, 1H), 2.36–2.25 (m, 1H), 2.21–2.07 (m, 3H), 2.03–1.89 (m, 3H), 1.87–1.74 (m, 1H), 1.52–1.37 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 456. HPLC <i>t</i><sub><i>r</i></sub> = 2.01 min (method A).</div><div class="NLM_p last">The above procedure was repeated using isomer 1 to afford ((<i>S</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate (<b>18b</b>, 800 mg, 95% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.84–7.79 (m, 2H), 7.39–7.33 (m, 2H), 7.00–6.90 (m, 3H), 6.48–6.41 (m, 1H), 4.34–4.24 (m, 2H), 4.06–3.94 (m, 2H), 3.04–2.91 (m, 1H), 2.87–2.72 (m, 3H), 2.46 (s, 3H), 2.44–2.35 (m, 1H), 2.33–2.21 (m, 1H), 2.20–2.03 (m, 3H), 2.00–1.88 (m, 3H), 1.84–1.78 (m, 1H), 1.48–1.37 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 456. HPLC <i>t</i><sub><i>r</i></sub> = 2.05 min (method A).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 6-((5<i>R</i>,7<i>S</i>)-2-Oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carbaldehyde (<b>19</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">A solution of oxalyl chloride (260 μL, 3 mmol) in DCM (5 mL) was stirred under N<sub>2</sub> and cooled to −78 °C. DMSO (425 μL, 6 mmol) was then added dropwise, and the reaction mixture was stirred for 1 h at −78 °C. A solution of (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-(hydroxymethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (600 mg, 2 mmol) in DCM/DMSO (3:1, 4 mL) was added dropwise. After 30 min, TEA (1.1 mL, 8 mmol) was added dropwise and the reaction mixture was stirred for 15 min at −78 °C then warmed to room temperature and stirred for another 15 min. The mixture was quenched with water (1 mL) at 0 °C, then diluted with EtOAc (50 mL) and washed with satd NH<sub>4</sub>Cl (2 × 30 mL). The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The residue was purified on a silica gel cartridge using an EtOAc/hex gradient (0–100% EtOAc over 15 min) to afford 6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carbaldehyde (500 mg, 84% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.89–9.71 (m, 1H), 7.15–7.10 (m, 1H), 7.03–6.98 (m, 1H), 6.97–6.93 (m, 1H), 5.16–5.02 (m, 1H), 4.38–4.27 (m, 2H), 3.11–3.01 (m, 1H), 3.01–2.95 (m, 2H), 2.91–2.84 (m, 2H), 2.78–2.66 (m, 1H), 2.39–2.30 (m, 1H), 2.29–2.21 (m, 1H), 2.16–2.09 (m, 2H), 2.05–1.91 (m, 2H), 1.89–1.76 (m, 2H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 300.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (5<i>R</i>,7<i>S</i>)-7-6-Ethynyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>20a</b>, <b>20b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of 6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalene-2-carbaldehyde (718 mg, 2.4 mmol) and potassium carbonate (995 mg, 7.20 mmol) in MeOH (3 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (0.540 mL, 3.60 mmol). The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (20–100% EtOAc over 12 column volumes) to afford 580 mg of (5<i>R</i>,7<i>S</i>)-7-6-ethynyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (82% yield). This diastereomeric mixture was separated by SFC using a Chiralpak OJ-H, 25 cm × 3 cm ID, 5 μm column, and eluting with 80/20 CO<sub>2</sub>/MeOH at 280 mL/min and each isomer was obtained with >98% d.e.</div><div class="NLM_p">Peak 1 was isolated to afford (5<i>R</i>,7<i>S</i>)-7-((<i>S</i>)-6-ethynyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-azaspiro[4.4]nonan-2-one (isomer a, <b>20a</b>, 225 mg, 32% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.09–7.02 (m, 1H), 7.01–6.93 (m, 2H), 5.90–5.72 (m, 1H), 4.32 (d, <i>J</i> = 12.3 Hz, 2H), 3.11–2.74 (m, 6H), 2.37–2.27 (m, 1H), 2.10 (d, <i>J</i> = 2.4 Hz, 4H), 2.04–1.76 (m, 4H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 296. HPLC <i>t</i><sub><i>r</i></sub> = 0.94 min (method A).</div><div class="NLM_p">Peak 2 was isolated and recovered to afford (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-ethynyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (isomer b, <b>20b</b>, 245 mg, 35% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.09–6.90 (m, 3H), 6.77–6.59 (m, 1H), 4.40–4.20 (m, 2H), 3.20–2.70 (m, 6H), 2.36–2.24 (m, 1H), 2.11 (br d, <i>J</i> = 1.8 Hz, 4H), 2.04–1.76 (m, 4H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 296. HPLC <i>t</i><sub><i>r</i></sub> = 0.94 min (method A).</div><div class="NLM_p last">Stereochemistry was assigned by converting one of the isomers to the precursor of <b>15a</b> and performing a chiral analysis to match the isomers.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-(pyridin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>22a</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">An oven-dried flask was charged with cesium carbonate (66.2 mg, 0.203 mmol), bis(di-<i>tert</i>-butyl(4- dimethylaminophenyl)phosphine)dichloropalladium(II) (3 mg, 4.24 μmol), and MeCN (1 mL) under nitrogen. It was then degassed 3× under vacuum, followed by stepwise addition of 2-bromopyridine (10 μL, 0.095 mmol) and (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-ethynyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>20a</b>, 20 mg, 0.068 mmol). The reaction mixture was heated at 80 °C overnight. The solvents were removed in vacuo, and the residue was dissolved in MeOH (2 mL). Pearlman’s catalyst (5 mg, 0.036 mmol) was added, and the reaction mixture was hydrogenated under a balloon of H<sub>2</sub> for 1 h. The catalyst was filtered away, and 1N NaOH (2 mL) was added to the filtrate. The reaction mixture was heated at 95 °C for 6 h then neutralized with TFA and filtered. The filtrate was purified by HPLC (method B) to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-(pyridin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (13 mg, 0.033 mmol, 49% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.44 (dd, <i>J</i> = 5.1, 0.9 Hz, 1H), 7.77 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H), 7.26 (ddd, <i>J</i> = 7.5, 5.1, 1.1 Hz, 1H), 6.99 (s, 3H), 3.62–3.46 (m, 2H), 3.14–2.98 (m, 1H), 2.93 (t, <i>J</i> = 7.8 Hz, 2H), 2.89–2.69 (m, 2H), 2.45 (dd, <i>J</i> = 16.3, 9.7 Hz, 1H), 2.31 (dd, <i>J</i> = 13.2, 6.4 Hz, 1H), 2.12–1.98 (m, 2H), 1.97–1.87 (m, 3H), 1.87–1.72 (m, 4H), 1.63 (t, <i>J</i> = 12.5 Hz, 1H), 1.46 (dtd, <i>J</i> = 12.8, 10.4, 5.9 Hz, 1H)). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 351. HPLC <i>t</i><sub><i>r</i></sub> = 3.66 min (method D). HPLC purity = 95%.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(2-(pyridin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>22b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">An oven-dried flask was charged with cesium carbonate (66 mg, 0.20 mmol), bis(di-<i>tert</i>-butyl(4- dimethylaminophenyl)phosphine)dichloropalladium(II) (3 mg, 4.24 μmol), and MeCN (1 mL) under nitrogen. It was degassed 3× under vacuum, followed by stepwise addition of (5<i>R</i>,7<i>S</i>)-7-((<i>S</i>)-6-ethynyl-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>20b</b>, 20 mg, 0.068 mmol) and 2-bromopyridine (10 μL, 0.095 mmol). The reaction mixture was heated at 80 °C for 1 h, then cooled and quenched with water. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was dissolved in MeOH (2 mL), and Pearlman’s catalyst (5 mg, 0.036 mmol) was added. The reaction mixture was hydrogenated under a balloon of H<sub>2</sub> for 1 h. The catalyst was filtered away, and 1N NaOH (2 mL) was added to the filtrate. The reaction mixture was heated at 95 °C for 6 h then neutralized with TFA and filtered. The filtrate was purified by HPLC (method B) to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(2-(pyridin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (14 mg, 0.036 mmol, 54% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.44 (d, <i>J</i> = 4.2 Hz, 1H), 7.78 (td, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H), 7.26 (ddd, <i>J</i> = 6.9, 5.7, 0.9 Hz, 1H), 7.08–6.90 (m, 3H), 3.70–3.53 (m, 2H), 3.21–3.01 (m, 1H), 2.98–2.84 (m, 3H), 2.84–2.72 (m, 2H), 2.53–2.33 (m, 2H), 2.05 (s, 4H), 1.83–1.62 (m, 5H), 1.55–1.39 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 351. HPLC <i>t</i><sub><i>r</i></sub> = 3.62 min (method D). HPLC purity = 95.1%.</div><div class="NLM_p last">The following compounds were prepared using the procedures described for <b>22a</b>/<b>22b</b>:</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-(pyridin-3-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>23a</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-(pyridin-3-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (35 mg, 0.096 mmol, 71% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.43 (d, <i>J</i> = 1.8 Hz, 1H), 8.37 (dd, <i>J</i> = 4.8, 1.3 Hz, 1H), 7.81–7.71 (m, 1H), 7.38 (dd, <i>J</i> = 7.5, 5.3 Hz, 1H), 7.06–6.94 (m, 3H), 3.69–3.54 (m, 2H), 3.15–3.02 (m, 1H), 2.99–2.74 (m, 5H), 2.55–2.32 (m, 2H), 1.95–1.85 (m, 5H), 1.79–1.63 (m, 4H), 1.57–1.39 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 351. HPLC <i>t</i><sub><i>r</i></sub> = 3.86 min (method D). HPLC purity = 95.5%.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(2-(pyridin-3-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>23b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(2-(pyridin-3-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (4.5 mg, 0.012 mmol, 36% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.47–8.42 (m, 1H), 8.39–8.33 (m, 1H), 7.78–7.73 (m, 1H), 7.40–7.35 (m, 1H), 7.02–7.00 (m, 2H), 7.00–6.98 (m, 1H), 3.19–3.04 (m, 1H), 2.88–2.75 (m, 4H), 2.55–2.34 (m, 2H), 2.20–1.99 (m, 3H), 1.83–1.67 (m, 4H), 1.54–1.40 (m, 2H), 1.33–1.25 (m, 4H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 351. HPLC <i>t</i><sub><i>r</i></sub> = 3.82 min (method D). HPLC purity = 96.5%.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(2-(pyridin-4-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>24</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(2-(pyridin-4-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (4 mg, 10.7 μmol, 32% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.42 (d, <i>J</i> = 5.1 Hz, 2H), 7.34 (d, <i>J</i> = 5.9 Hz, 2H), 7.06–6.95 (m, 3H), 3.77–3.47 (m, 2H), 3.20–3.04 (m, 1H), 2.99–2.73 (m, 4H), 2.57–2.33 (m, 2H), 1.82–1.62 (m, 4H), 1.39–1.20 (m, 7H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 351. HPLC <i>t</i><sub><i>r</i></sub> = 3.77 min (method D). HPLC purity = 94.2%.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-(pyrimidin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>25a</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-(pyrimidin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (8 mg, 0.022 mmol, 16% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.74 (d, <i>J</i> = 4.8 Hz, 2H), 7.35 (t, <i>J</i> = 5.0 Hz, 1H), 7.07–6.94 (m, 3H), 3.75–3.53 (m, 2H), 3.13–3.01 (m, 2H), 2.95–2.63 (m, 3H), 2.52–2.34 (m, 2H), 2.16–1.99 (m, 2H), 1.94–1.84 (m, 6H), 1.79–1.62 (m, 2H), 1.55–1.39 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 352. HPLC <i>t</i><sub><i>r</i></sub> = 5.48 min (method E). HPLC purity = 95.4%.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(2-(pyrimidin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>25b</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(2-(pyrimidin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (3 mg, 5.80 μmol, 27% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.72 (d, <i>J</i> = 5.1 Hz, 2H), 7.34 (t, <i>J</i> = 5.1 Hz, 1H), 7.03–6.93 (m, 3H), 3.71–3.51 (m, 2H), 3.15–3.00 (m, 3H), 2.96–2.70 (m, 3H), 2.52–2.34 (m, 2H), 2.16–1.81 (m, 7H), 1.77–1.62 (m, 2H), 1.44 (dtd, <i>J</i> = 12.8, 10.6, 5.9 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 352. HPLC <i>t</i><sub><i>r</i></sub> = 4.94 min (method D). HPLC purity = 96.8%.</div><div class="NLM_p last">The following compounds were prepared using the procedures described for <b>14a</b>/<b>14b</b>:</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-(6-(2-(1-methyl-1<i>H</i>-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>26</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(2-(1-methyl-1<i>H</i>-imidazol-5-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (isomer b, 12 mg, 0.023 mmol, 49% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.53 (s, 1H), 7.10–6.92 (m, 3H), 6.73 (d, <i>J</i> = 0.9 Hz, 1H), 3.71–3.55 (m, 5H), 3.18–3.03 (m, 1H), 2.98–2.77 (m, 3H), 2.76–2.66 (m, 2H), 2.55–2.32 (m, 2H), 2.20–1.98 (m, 2H), 1.99–1.85 (m, 4H), 1.85–1.64 (m, 3H), 1.47 (dtd, <i>J</i> = 12.8, 10.4, 6.4 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 354. HPLC <i>t</i><sub><i>r</i></sub> = 4.46 min (method E). HPLC purity = 95.3%.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>27</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of ((<i>R</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate (1 g, 2.2 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.910 g, 6.6 mmol) in DMF (10) was added 1-phenyl-1<i>H</i>-tetrazole-5-thiol (0.782 g, 4.39 mmol). The reaction mixture was heated at 80 °C overnight. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (0–100% EtOAc over 13 column volumes) to afford (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-(((1-phenyl-1<i>H</i>-tetrazol-5-yl)thio)methyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (0.94 g, 2.04 mmol, 93% yield). HPLC retention time = 1.02 min (method A). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 462.</div><div class="NLM_p">To H<sub>2</sub>O<sub>2</sub> (8.3 mL, 81 mmol) at 0 °C was added ammonium molybdate tetrahydrate (0.50 g, 0.40 mmol). The resulting solution was then added to a mixture of (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-(((1-phenyl-1<i>H</i>-tetrazol-5-yl)thio)methyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (0.94 g, 2.04 mmol) in THF (15 mL) at 0 °C. The reaction mixture was stirred overnight. The reaction mixture was diluted with ethyl acetate and washed with satd NaCl. The organic layer was dried with MgSO<sub>4</sub>, filtered, and concentrated to afford (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-(((1-phenyl-1<i>H</i>-tetrazol-5-yl)sulfonyl)methyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (1 g, 2.03 mmol, 99% yield), which was used without further purification. HPLC retention time = 0.96 min (method A). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 494.</div><div class="NLM_p">KHMDS in THF (1 M, 425 μL, 0.425 mmol) was added dropwise to a solution of (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-(((1-phenyl-1<i>H</i>-tetrazol-5-yl)sulfonyl)methyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (35 mg, 0.071 mmol) and 1-methyl-1<i>H</i>-pyrazole-3-carbaldehyde (39 mg, 0.36 mmol) in DMF (1 mL) and THF (1 mL) at −78 °C. The resultant solution was stirred at that temperature for 2 h then allowed to warm to room temperature and stirred for 16 h,. The reaction mixture was diluted with ethyl acetate and washed with satd NaHCO<sub>3</sub> (2 × 15 mL) and satd NaCl (20 mL). The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The crude material was purified on a silica gel cartridge using an EtOAc/hex gradient (0–65% EtOAc over 13 column volumes) to afford (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-((<i>E</i>)-2-(1-methyl-1<i>H</i>-pyrazol-3-yl)vinyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (<b>21</b>, 10 mg, 0.026 mmol, 37% yield). HPLC retention time = 1.14 min (method A). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 378.3.</div><div class="NLM_p">To a mixture of (5<i>R</i>,7<i>S</i>)-7-((<i>R</i>)-6-((<i>E</i>)-2-(1-methyl-1<i>H</i>-pyrazol-3-yl)vinyl)-5,6,7,8-tetrahydronaphthalen-2-yl)-3-oxa-1-azaspiro[4.4]nonan-2-one (10 mg, 0.026 mmol) in MeOH (5 mL) was added Pd-C (14 mg, 0.013 mmol). The reaction mixture was then hydrogenated under a balloon of H<sub>2</sub>. The mixture was stirred for 2 h. The catalyst was then filtered away, and the filtrate was concentrated in vacuo. The crude product was treated with 1,4-dioxane (2 mL) and 0.5 mL of water with lithium hydroxide hydrate (17 mg, 0.4 mmol). The mixture was stirred at 100 °C overnight, and then the solvent was removed under a stream of N<sub>2</sub>. The residue was purified by HPLC (method B) to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-(1-methyl-1<i>H</i>-pyrazol-3-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as an off-white solid (2 mg, 15% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.48 (d, <i>J</i> = 2.2 Hz, 1H), 7.02–7.00 (m, 2H), 7.00–6.97 (m, 1H), 6.12 (d, <i>J</i> = 2.2 Hz, 1H), 3.84 (s, 3H), 3.75–3.52 (m, 2H), 3.17–3.01 (m, 1H), 2.96–2.64 (m, 5H), 2.50–2.32 (m, 2H), 2.20–1.86 (m, 5H), 1.82–1.62 (m, 4H), 1.53–1.35 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 354. HPLC <i>t</i><sub><i>r</i></sub> = 5.26 min (method D). HPLC purity = 97.6%.</div><div class="NLM_p last">The following compound was prepared using the procedures described for <b>27</b>:</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>28</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-(1-methyl-1<i>H</i>-pyrazol-4-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA as an off-white solid (3 mg, 23% yield). <sup>1</sup>H NMR (400 MHz, MeOD) δ 7.42 (s, 1H), 7.34 (s, 1H), 7.01 (s, 2H), 6.99 (d, <i>J</i> = 1.1 Hz, 1H), 3.85 (s, 3H), 3.71–3.57 (m, 2H), 3.21–3.03 (m, 1H), 3.00–2.71 (m, 3H), 2.69–2.56 (m, 2H), 2.50–2.34 (m, 2H), 2.19–2.07 (m, 1H), 2.05–1.85 (m, 4H), 1.80–1.57 (m, 4H), 1.43 (dtd, <i>J</i> = 12.8, 10.5, 5.9 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 354. HPLC <i>t</i><sub><i>r</i></sub> = 5.56 min (method D). HPLC purity = 96.4%.</div><div class="NLM_p last">The following compound was prepared using the procedures described for <b>22a</b>/<b>22b</b>:</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(2-(4-methoxypyridin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (<b>29</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Obtained ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(2-(4-methoxypyridin-2-yl)ethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (6 mg, 0.012 mmol, 34% yield) as a clear oil. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.51 (d, <i>J</i> = 7.0 Hz, 1H), 7.47 (d, <i>J</i> = 2.9 Hz, 1H), 7.39 (dd, <i>J</i> = 7.0, 2.6 Hz, 1H), 7.08–6.96 (m, 3H), 4.15 (s, 3H), 3.74–3.55 (m, 2H), 3.21–3.04 (m, 3H), 2.99–2.76 (m, 3H), 2.61–2.36 (m, 2H), 2.17–2.02 (m, 2H), 2.00–1.89 (m, 3H), 1.89–1.80 (m, 3H), 1.74 (t, <i>J</i> = 12.8 Hz, 1H), 1.58–1.42 (m, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 352. HPLC <i>t</i><sub><i>r</i></sub> = 4.94 min (method D). HPLC purity = 97.1%.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Preparation of Phosphates</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl Dihydrogen phosphate (<b>14a-P</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p">To a mixture of ((1<i>R</i>,3<i>S</i>)-1-amino-3-(6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol, TFA (2 mg, 4.05 μmol) in acetonitrile (0.5 mL) was added pyrophosphoryl chloride (30 μL, 0.217 mmol). Stirred for 1 h then quenched with water and purified by HPLC (method B) to afford ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl dihydrogen phosphate (1.5 mg, 82% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + CF<sub>3</sub>OD (2 drops)) δ 7.22–7.15 (m, 2H), 7.06 (d, <i>J</i> = 7.9 Hz, 1H), 6.99–6.87 (m, 4H), 4.18 (br d, <i>J</i> = 7.3 Hz, 2H), 3.86 (s, 3H), 3.21–3.08 (m, 1H), 2.93 (br dd, <i>J</i> = 16.6, 4.4 Hz, 1H), 2.85–2.69 (m, 4H), 2.56–2.39 (m, 2H), 2.27–2.10 (m, 2H), 2.10–1.88 (m, 4H), 1.84–1.72 (m, 1H), 1.66 (qd, <i>J</i> = 7.5, 2.6 Hz, 2H), 1.44 (dtd, <i>J</i> = 12.8, 10.7, 6.1 Hz, 1H). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 460. HPLC <i>t</i><sub><i>r</i></sub> = 6.94 min (method D). HPLC purity = 98.4%.</div><div class="NLM_p last">The following phosphates were prepared using the procedure for <b>14a-P</b>:</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl Dihydrogen Phosphate (<b>14b-P</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Recovered ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl dihydrogen phosphate (1.4 mg, 77% yield). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 460. HPLC <i>t</i><sub><i>r</i></sub> = 0.88 min (method A). HPLC purity = 95%.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol Dihydrogen Phosphate (<b>15a-P</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Recovered ((1<i>R</i>,3<i>S</i>)-1-amino-((<i>R</i>)-6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl dihydrogen phosphate (1 mg, 55% yield). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 460. HPLC <i>t</i><sub><i>r</i></sub> = 0.86 min (method A). HPLC purity = 95%.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol Dihydrogen Phosphate (<b>15b-P</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Recovered ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(3-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl dihydrogen phosphate (1.4 mg, 77% yield). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 460. HPLC <i>t</i><sub><i>r</i></sub> = 0.86 min (method A). HPLC purity = 95%.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>R</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol Dihydrogen Phosphate (<b>16a-P</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Recovered ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol dihydrogen phosphate (1.5 mg, 83% yield). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 460. HPLC <i>t</i><sub><i>r</i></sub> = 0.86 min (method A). HPLC purity = 95%.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> ((1<i>R</i>,3<i>S</i>)-1-Amino-3-((<i>S</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol Dihydrogen Phosphate (<b>16b-P</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></h4><div class="NLM_p last">Recovered ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(4-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methyl dihydrogen phosphate (1.5 mg, 83% yield). MS (M + H)<sup>+</sup> at <i>m</i>/<i>z</i> 460. HPLC <i>t</i><sub><i>r</i></sub> = 0.86 min (method A). HPLC purity = 95%.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Biological Methods</h3><div class="NLM_p">All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee and conformed to the “Guide for the Care and Use of Laboratory Animals” published by the National Institutes of Health (NIH Publication no. 85-23, revised 2011). Phosphates were dissolved in 0.3 M NaOH as a 3 mM stock prior to being assayed.</div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> SIP<sub>1</sub> Binding Assay</h4><div class="NLM_p last">Membranes were prepared from CHO cells expressing human S1P<sub>1</sub>. Cell pellets (l × 109 cells/pellet) were suspended in buffer containing 20 mM HEPES (4-(2- hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5, 50 mM NaCl, 2 mM EDTA (ethylenediaminetetraacetic acid) and protease inhibitor cocktail (Roche), and disrupted on ice using the Polytron homogenizer. The homogenate was centrifuged at 20000 rpm (48000<i>g</i>), and the supernatant was discarded. The membrane pellets were resuspended in buffer containing 50 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM MgCl<sub>2</sub>, 2 mM EDTA and stored in aliquots at −80 °C after protein concentration determination. Membranes (2 μg/well) and 0.03 nM final concentration of <sup>33</sup>P-S1P ligand (1 mCi/mL, Perkin Elmer or American Radiolabeled Chemicals) diluted in assay buffer (50 mM HEPES, pH 7.4, 5 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 0.5% fatty acid free BSA (bovine serum albumin), 1 mM NaF) were added to the compound plates (384 Falcon v-bottom plate (0.5 μL/well in a 11 point, 3-fold dilution). Binding was performed for 45 min at room temperature, terminated by collecting the membranes onto 384-well Millipore FB filter plates, and radioactivity was measured by TOPCOUNT. The competition data of the test compounds over a range of concentrations was plotted as percentage inhibition of radioligand specific binding.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> Receptor [<sup>35</sup>S] GTPγS Binding Assays (S1P<sub>1</sub> GTPγS/S1P<sub>3</sub> GTPγS)</h4><div class="NLM_p last">Compounds were loaded in a 384 Falcon v-bottom plate (0.5 μL/well in a 11 point, 3-fold dilution). Membranes prepared from S1P<sub>1</sub>/CHO cells or EDG3-Ga15-bla HEK293T cells (EDG3 equiv S1P<sub>3</sub>) were added to the compound plate (40 μL/well, final protein 3 μg/well) with MULTIDROP. [<sup>35</sup>S]GTP (1250 Ci/mmol, Perkin-3-Elmer) was diluted in assay buffer: 20 mM HEPES, pH7.5, 10 mM MgCl<sub>2</sub>, 150 mM NaCl, 1 mM EGTA (ethylene glycol tetraacetic acid), 1 mM dithiothreitol, 10 μM GDP, 0.1% fatty acid free BSA, and 10 μg/mL Saponin to 0.4 nM. Then 40 μL of the [<sup>35</sup>S]GTP solution was added to the compound plate with a final concentration of 0.2 nM. The reaction was kept at room temperature for 45 min. At the end of incubation, all the mixtures in the compound plate were transferred to Millipore 384-well FB filter plates via the VELOCITY l  Vprep liquid handler. The filter plate was washed with water 4 times by using the manifold Embla plate washer and dried at 60 °C for 45 min. MicroScint 20 scintillation fluid (30 μL) was added to each well for counting on the Packard TOPCOUNT. EC<sub>50</sub> is defined as the agonist concentration that corresponds to 50% of the <i>Y</i><sub>max</sub> (maximal response) obtained for each individual compound tested.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> hS1P<sub>1</sub> cAMP Assay</h4><div class="NLM_p last">Test compounds were prediluted in 1 μM forskolin (Sigma-Aldrich, MO, USA) and 100 μM isobutyl methyl xanthine (IBMX; Sigma-Aldrich, MO, USA) in PBS buffer on 384-well Proxi-plates (PerkinElmer, MA, USA). hS1P-1/CHO cells were plated in F12 medium (Gibco, NY, USA) and incubated with test compound for 30 min at room temperature. cAMP was measured using cAMP homogeneous time-resolved fluorescence (HTRF) reagents (CISBIO, MA, USA) per manufacturer’s instructions. Briefly, cells were lysed using HTRF lysis buffer, incubated with anti-cAMP cryptate for 1 h at room temperature, and then read on PerkinElmer Envision. A standard curve was run on each plate to obtain the absolute concentration of cAMP. The IC<sub>50</sub> was defined as the concentration of test compound which produces 50% of the maximal response (defined by 1 μM S1P) and was quantified using the four-parameter logistic equation to fit the data.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> hS1P<sub>1</sub> ERK Phosphorylation</h4><div class="NLM_p last">hS1P<sub>1</sub>/CHO cells were plated in BD Amine 384-well plates the day before the assay. On the day of the assay, growth medium was removed and replaced with serum-free medium (Ham’s F-12; Invitrogen) and incubated for 2 h. Test compounds prediluted in HBSS/20 mM HEPES (Gibco, NY, USA) were transferred to the cell plates and incubated for 7 min at 37 °C. Cells were lysed in a lysis buffer (PerkinElmer, MA, USA), and phospho-ERK was measured using the SureFire pERK kit (PerkinElmer, MA, USA) per manufacturer’s instructions. Data were plotted as percentage activation of the test compound relative to the efficacy of 10 μM S1P. The EC<sub>50</sub> was defined as the concentration of test compound which produces 50% of the maximal response and was quantified using the four-parameter logistic equation to fit the data.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> S1P<sub>1</sub> Internalization Assay</h4><div class="NLM_p last">For quantification of S1P<sub>1</sub> expression using a high content system, GFP was fused to hS1P<sub>1</sub> at its C-terminus and a stable CHO cell line expressing hS1P<sub>1</sub>/GFP was established. Cells were suspended in assay medium (F12 medium with 5% charcoal-dextran treated FBS, 20 mM HEPES, and 1× Pen/Strep) at 7.5 × 104 cells/mL and plated into 384-well plates (in 20 μL, 1500 cells/well final) with a Multidrop liquid handler (Thermo Scientific, Waltham, MA). Cell plates were incubated at 37 °C for 48 h. Titrated S1P and test compounds were dispensed into the cell plates (concentration range from 100 to 0.005 μM), and the plates were further incubated at 37 °C for 50 min. Cells were fixed by adding 10 μL of fixation buffer (7.4% v/v formaldehyde containing 15 μM Draq5 in DPBS) directly onto the assay medium and incubated for 15 min at room temperature followed by two washes with DPBS. This was followed by the addition of 50 μL of DPBS to the cell layer and the plates were sealed with a transparent plate seal (PerkinElmer no. 6005185). Imaging was carried out using the Evotec Opera High Content Confocal System (PerkinElmer, Boston, MA) equipped with three diode lasers, Peltier cooled CCD camera detector and a Nipkow spinning disk. Cell images were quantified using a membrane fluorescent scoring algorithm. Data was analyzed using a customized HTS data analysis software package. EC<sub>50</sub> values were determined using XL-Fit software program.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Chemotaxis Assay</h4><div class="NLM_p last">Human T cells were isolated from peripheral blood mononuclear cells by rosetting with sheep red blood cells for 1 h at 4 °C. The sheep red blood cells were removed by lysis using ACK lysing buffer (Gibco). Human T cells from two donors were cultured for 72 h in RPMI-1640 containing 0.5% fatty-acid free BSA (Calbiochem) and then labeled with the fluorescent dye Calcein-AM (10 μg/mL; Molecular Probes) in chemotaxis buffer (phenol red-free RPMI-1640, containing 0.5% fatty-acid free BSA) at room temperature for 45 min. The labeled cells were then washed and resuspended in chemotaxis buffer at 1.2 × 10<sup>7</sup>/mL. Chemotaxis was measured using a chemotaxis plate with 5 μm pores (Neuroprobe). Labeled cells (3 × 10<sup>5</sup> in 25 μL of chemotaxis buffer) were preincubated with test compound (final assay concentrations ranged from 0.01 to 50 nM) for 10 min at room temperature before being loaded to each of the upper wells of a plate. The bottom wells of the plate were loaded with S1P at concentration that is known to give 90% maximal chemotaxis without presence of test compounds. The membrane was placed over the lower wells, and the plate was covered and incubated at 37 °C for 120 min. Following incubation the upper wells were washed twice with PBS to remove unmigrated cells and fluorescence in the lower wells was read at 485 nm/530 nm excitation/emission on a Cytofluor 4000 (Perceptive Biosystems). The inhibition of chemotaxis achieved by titrated concentrations of compounds was calculated as a percentage of the compound-free S1P control signal after plate background and buffer background signal subtraction. The IC<sub>50</sub> is defined as the concentration of compound required to reach 50% inhibition of chemotaxis and was calculated by the XLFit software program.</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Blood Lymphocyte Reduction (BLR) Assay in Rodent</h4><div class="NLM_p last">Balb/c mice or Lewis rats were dosed orally with vehicle alone (polyethylene glycol 300) or with test compounds. Compounds were dosed as a solution or suspension in the vehicle, adjusted to reflect the free amount of test article in the event that salt forms are utilized. Blood was drawn at different time points, and blood lymphocyte counts were determined on an ADVIA 120 hematology analyzer (Siemens Healthcare Diagnostics). The results were measured as a reduction in the percentage of circulating lymphocytes as compared to the vehicle treated group at the time of measurement. The results represent the average results of all animals within each treatment group (<i>n</i> = 2–4).</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> In Vivo Phosphate Ester Formation</h4><div class="NLM_p last">BALB/c mice or Lewis rats were dosed orally with compounds. Blood was drawn at 24 h and spotted onto Dried Blood Spot (DBS) cards. DBS cards were stored at ambient temperature in sealed plastic bags with desiccant added. When ready for analysis, a 6 mm punch (equivalent to 12.5 μL of wet blood) was taken at <i>n</i> = 1 and placed in a shallow 96-well filter plate. Next, 105 μL of a mixture of 75% acetonitrile and 25% water containing internal standard was added and gently vortexed for 30 min and then centrifuged. Supernatant was separated from the protein pellet, and 5 μL was injected. The parent (alcohol) and active phosphate ester compounds were quantitatively analyzed, using a DBS calibration curve, by LC/MS/MS on a triple quadrapole instrument. The area ratios of the phosphorylated compound to the parent (alcohol) compound were determined. A larger value for the ratio of the phosphorylated compound to the parent (alcohol) compound indicated greater phosphate ester compound formation from the parent (alcohol) compound. Reference material (parent alcohol and phosphate ester) was analyzed to optimize the LC-MS/MS assay and enable data reporting in concentrations. DBS standard curves containing both parent alcohol and phosphate ester compounds were prepared and analyzed in the same manner as the study samples and analyzed by the optimized LC-MS/MS to quantify the amount of phosphate ester compound formed. The results represent the average results of all animals within each treatment group (<i>n</i> = 2–4).</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>T</i><sub>1/2</sub> Microsome Assay</h4><div class="NLM_p">S1P<sub>1</sub> compounds were added to 0.1 M Tris-HCl buffer (pH 7.4, 37 °C) containing 1 mg/mL liver microsomal protein and 1 mM MgCl<sub>2</sub> in a shaking water bath, to yield a final compound concentration of 0.5 μM. The reaction was initiated by adding an NADPH-regenerating system. The samples were taken at 0, 60, and 120 min, and the reaction was stopped by the addition of acetonitrile to precipitate proteins. The samples were then centrifuged and prepared for analysis via ultraperformance liquid chromatography (UPLC) with tandem mass spectrometry (LC/MS/MS). %remaining (%Rem) was quantified by peak ratio of analyte to internal standard at time <i>t</i> to time 0. In vitro <i>T</i><sub>1/2</sub> was estimated by<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_m001.gif" alt="" id="_i67" /></img></span><span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_m002.gif" alt="" id="_i68" /></img></span>where <i>k</i> denotes the rate constant of compound elimination from in vitro microsomal incubation. In vivo <i>T</i><sub>1/2</sub> was estimated by<span class="NLM_disp-formula" id="ueq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_m003.gif" alt="" id="_i69" /></img></span></div><div class="NLM_p last"><i>V</i> denotes the volume of distribution and was rendered a value of 13 L/kg based on the similar volume of distribution of the compounds in this series. CL (clearance) is scaled up from in vitro <i>T</i><sub>1/2</sub> based on an established method.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> In Vitro Phosphate Ester Formation</h4><div class="NLM_p last">The rates of ATP-dependent phosphorylation were determined using recombinant sphingosine kinase 1 and 2 (SK1 and SK2). Test compounds (30 mM stock in DMSO) were diluted to 0.3 mM in 0.2% fatty acid-free BSA in 1 mM Tris-HCl (pH 7.4). The phosphorylation reaction consisted of 80 μL of assay buffer (100 mM Tris-HCl (pH 7.4), 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 1 mM sodium vanadate, 10 mM sodium fluoride, and 0.5 mM 4-deoxypyridoxine-HCl), 10 μL of 0.3 mM substrate/BSA, 5 μL of kinase enzyme (SK1, human recombinant, no. 10348, 0.44 mg/mL (0.22 μg/assay) Cayman Chemical Company, Ann Arbor, MI; SK2, human recombinant, no. E-K069, 0.5 mg/mL (0.25 μg/assay) Echelon Biosciences, Inc., Salt Lake City, UT), and 5 μL of 20 mM Mg-ATP (containing 1 μCi [<sup>33</sup>P]ATP, pH 7.4). The reaction was incubated for 30 min in a 37 °C shaking water bath and stopped by addition of cold 350 μL of methanol-HCl (150:1), 250 μL 2 M KCl, and 350 μL chloroform. The tubes were vigorously mixed and placed on ice for 15 min. The chloroform phase was separated from the aqueous phase by centrifugation at 10000<i>g</i> for 10 min. The upper aqueous phase was discarded, and the remaining lipid/chloroform phase was evaporated over a nitrogen stream. The remaining pellet was resuspended in 40 μL of 1-butanol, and completely spotted at the origin of a thin-layer chromatography (TLC) plate. The product was resolved in 1-butanol:glacial acetic acid:water (3:1:1) for 2.5 h in a chromatography tank. Standards were prepared from the [<sup>33</sup>P]ATP assay stock (200 nCi/μL), and diluted 1:10 (20 nCi/μL), 1:100 (2.0 nCi/μL), 1:1000 (0.2 nCi/μL), and 1:10,000 (0.02 nCi/μL) in PBS. Each dilution standard was spotted at the top of the TLC plate at 0.2, 0.4, 0.6, 0.8, and 1.0 μL and produced a linear standard curve on each plate. The TLC plate, including the resolved lipid products and spotted standards, were enclosed in plastic wrap, and exposed for 18 h to a phosphor-imaging storage screen. The captured area-volume of radiation was determined with an imaging scanner (Storm, GE Healthcare, Sunnyvale, CA). Quantitation of the standards and resolved product were determined by ImageQuant software</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Pulmonary Toxicity Assay</h4><div class="NLM_p last">The analysis of protein levels in bronchoalveolar lavage (BAL) fluid obtained from an animal were used to gauge pulmonary side effects. Post study rats were euthanized with intraperitoneal barbiturate overdose. The animals were placed in a supine position, a skin incision was made, and blunt dissection followed to expose the trachea. The trachea was incised, and a catheter was inserted 4–6 mm into the trachea. Phosphate-buffered saline (PBS; 1 mL/mouse) was infused into the lungs and then aspirated. The concentration of the protein in the recovered BAL fluid was determined on an Advia 1800 chemistry analyzer (Siemens Healthcare Diagnostics). The results represent the average results of all animals within each treatment group (<i>n</i> = 2–4).</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Multi-Electrode Array (MEA) Electrophysiology Studies in Human-Inducible Pluripotent Stem Cell-Derived Cardiomyocytes</h4><div class="NLM_p last">Human-inducible pluripotent stem cell-derived cardiomyocytes (hiPSC CMs) were purchased from Cellular Dynamics International (Madison, WI). qPCR analysis showed similar RNA expression levels of S1P<sub>1</sub>, S1P<sub>2</sub>, and S1P<sub>3</sub> in hiPSC CMs as in adult human heart tissue (results not shown). hiPSC CMs were cultured with 7% CO<sub>2</sub> on 0.1% gelatin treated 6-well culture plates for 7 days, then trypsinized and diluted with cardiac fibroblasts (10%). Suspensions of hiPSC CMs and fibroblasts were then cocultured on laminin-coated 9-well multielectrode arrays (MEA) plates (256-259 well MEA300/30iRITO-mq; Multichannel Systems; Atlanta, GA). After 7 days culture on MEA plates, cells formed a spontaneously beating monolayer over recording electrodes embedded in each well. Spontaneous extracellular field potentials (FPs) were recorded from 28 electrodes/well at a sampling frequency of 10 kHz using an USB-MEA256 system and MC Rack acquisition software (Multi Channel Systems). Following a 20–60 min equilibration period in a humidified environment at 37 °C with constant 5% CO<sub>2</sub> and 95% O<sub>2</sub> supply, compounds were added to each well in 300 μL of maintenance medium with final DMSO or NaOH vehicle concentration less than 0.1% or 30 μM. Dilute NaOH (30 μM was used as control in these studies and had no significant effect on beating rate of hiPSC CMs. Effects of test agents on field potentials were evaluated for at least 2 h. Data were analyzed with MC_DataTool and custom software written in MatLab (Mathworks; Natick, MA).</div></div><div id="sec5_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Mouse Experimental Autoimmune Encephalomyelitis Assay (EAE)</h4><div class="NLM_p last">Mice (C57BL/6 female, 6–8 weeks of age, Charles River, <i>n</i> = 10–12 treatment group) were immunized subcutaneously with 150 μg of MOG35-55 emulsified 1:1 with incomplete Freund’s adjuvant (sigma) supplemented with 150 μg of <i>Mycobacterium tuberculosis</i> H37RA (Difco Laboratories). Then 400 ng of pertussis toxin (CalBiochem) was injected intraperitoneally on the day of immunization and 2 days later. Animals were dosed once daily with the test article (as a solution or suspension in the vehicle) or vehicle alone (polyethylene glycol 300, “PEG300”) starting from 1 day after immunization. Clinical scoring and body weight were taken 3 times per week until the end of the study on day 24. Clinical scoring system: 0.5, partial tail weakness; 1, limp tail or waddling gait with tail tonicity; 1.5, waddling gait with partial tail weakness; 2, waddling gait with limp tail (ataxia); 2.5, ataxia with partial limb paralysis; 3, full paralysis of one limb; 3.5, full paralysis of one limbs with partial paralysis of a second limb; 4, full paralysis of two limbs; 4.5, moribund; 5, death. Upon termination of the study, spinal columns were excised and submersion fixed in 10% neutral buffered formalin. Three transverse sections of lumbar spinal cord were routinely processed, paraffin embedded (RPPE), and were sectioned at 3 μm and 6um, stained with hematoxylin and eosin, and the myelin-specific stain Luxol Fast Blue, respectively. Slides were analyzed in a blinded fashion for severity of inflammation, tissue damage, and demyelination. Lesion activity was scored on a semiquantitative 0–5 scale, and overall mean histological score of inflammation, damage, and demyelination from each group was calculated.</div></div><div id="sec5_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Organotypic Cerebellar Slice Culture Assay</h4><div class="NLM_p">Newborn (P1-2) wild-type CD1 mouse pups were obtained from Charles River. After decapitation, the cerebellum was isolated and cut into 350 μm parasagittal slices. Slices were then transferred to culture inserts (Millipore Millicell-CM organotypic culture inserts) in a 6-well plate with 1 mL of culture medium and incubated at 36–37 °C with 5% CO<sub>2</sub>. Culture medium was composed of 50% minimal essential media, 25% heat-inactivated horse serum, 25% Earle’s balanced salt solution, 6.5 mg/mL glucose (Sigma-Aldrich, St. Louis, MO), and penicillin and glutamine supplements (all from Invitrogen, Carlsbad, CA) and was replaced every 2–3 days. Slices were cultured for 13 days in vitro (DIV13) to allow clearance of debris and myelination to occur. For remyelination studies, slices were incubated with 0.5 mg/mL LPC overnight and then transferred to the culture medium for 24 h. Afterward, slices were treated with <b>1-P</b> or <b>14a-P</b> for 7 days before being processed for immunohistochemistry.</div><div class="NLM_p last">Cerebellar slices were fixed with 4% paraformaldehyde and incubated with rat antimyelin basic protein (MBP, 1:1000, Abcam) and rabbit anticalbindin D-28K (CBD, 1:4000, Swant, Switzerland) at 4 °C overnight. MBP and CBD were used for visualizing myelin protein and Purkinje cell bodies and axonal processes, respectively. The slices were incubated with 1:500 goat antirat IgG Alexa Fluor 594 and goat antirabbit IgG Alexa Fluor 488 (Life Technologies) and then mounted and coverslipped. A SP8 confocal microscopy was used for immunofluorescence image acquisition. MBP and CBD immunostaining was imaged at ×40 magnification, and multiple images were captured from each slice. The areas covered by axonal processes singly stained for CBD or doubly stained for CBD and MBP immunoreactivity were analyzed using a macro with Image-J (NIH). The myelination index was calculated by dividing CBD + MBP double immunoreactivity/area unit with CBD single immunoreactivity/area unit as a measure of the amount of myelination per axon area. Quantitative data were analyzed statistically using ANOVA, followed by the Dunnett’s multiple comparison test.</div></div><div id="sec5_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Collagen-Induced Arthritis in Mice</h4><div class="NLM_p">DBA/1 male mice (8–10 week of age; Harlan) were immunized subcutaneously at the base of the tail on day 0 and again on day 21 with 200 μg of bovine type II collagen admixed with reconstituted Sigma Adjuvant System (SAS; Sigma-Aldrich). For “preventative” dosing, mice were dosed daily (beginning on day 0) by oral gavage with vehicle (EtOH:TPGS:PEG300; 5:5:90) or with <b>14a</b>. mCTLA4Ig was injected intraperitoneally twice per week at 1 mg/kg. Following the booster immunization, disease activity was monitored and scored twice per week using standard criteria (0, normal; 1, mild but definite redness and swelling of the ankle or wrist or apparent redness and swelling limited to individual digits regardless of number of affected digits; 2, moderate redness and swelling of ankle or wrist; 3, severe redness and swelling of the entire paw including digits; 4, maximally inflamed limb with involvement of multiple joints). Clinical paw scores for all four paws were summed for each mouse, and mean ± SEM was calculated for each treatment group.</div><div class="NLM_p last">For histological evaluation, right hind paws were fixed, decalcified, and embedded in paraffin. Sections were cut in the sagittal plane, stained in H&E, and evaluated microscopically without knowledge of treatment group. Lesions were scored on a severity scale of 0 (normal) to 4 in two separate categories, inflammation (cellular infiltration, pannus formation, and edema) and bone resorption. For inflammation/edema, the scoring was as follows: grade 0, unremarkable; grade 1, minimal change; grade 2, mild change; grade 3, moderate change; grade 4, marked change. For bone resorption, the grading was as follows: grade 0, unremarkable; grade 1, minimal focal to multifocal cortical or trabecular bone resorption; grade 2, mild focal to multifocal cortical or trabecular bone resorption; grade 3, moderate resorption of cortical or trabecular bone with rare full-thickness resorption; grade 4, full-thickness resorption with distortion of bone architecture. Statistical analysis for all the parameters were compared by one-way analysis of variance and Dunnett’s multiple comparison test.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01695" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34155" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34155" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01695" class="ext-link">10.1021/acs.jmedchem.8b01695</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">X-ray crystallographic structures of <b>18b</b> and <b>14a</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_001.pdf">jm8b01695_si_001.pdf (3.31 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_002.csv">jm8b01695_si_002.csv (1.78 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01695" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10775" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10775" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John L. Gilmore</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0520-8746" title="Orcid link">http://orcid.org/0000-0002-0520-8746</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7d17121513531a141110120f183d1f100e531e1210"><span class="__cf_email__" data-cfemail="4a20252224642d23262725382f0a28273964292527">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hai-Yun Xiao</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">T. G. Murali Dhar</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0738-1021" title="Orcid link">http://orcid.org/0000-0003-0738-1021</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael G. Yang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2908-4060" title="Orcid link">http://orcid.org/0000-0003-2908-4060</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zili Xiao</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jenny Xie</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lois D. Lehman-McKeeman</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Gong</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huadong Sun</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lloyd Lecureux</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cliff Chen</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dauh-Rurng Wu</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marta Dabros</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoxia Yang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tracy L. Taylor</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xia D. Zhou</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth M. Heimrich</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rochelle Thomas</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kim W. McIntyre</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Virna Borowski</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bethanne M. Warrack</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuwen Li</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shi</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul C. Levesque</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Yang</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony M. Marino</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Georgia Cornelius</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Celia J. D’Arienzo</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Mathur</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard Rampulla</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anuradha Gupta</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4211-1441" title="Orcid link">http://orcid.org/0000-0002-4211-1441</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bala Pragalathan</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ding Ren Shen</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ellen Cvijic</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luisa M. Salter-Cid</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Percy H. Carter</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5880-1164" title="Orcid link">http://orcid.org/0000-0002-5880-1164</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alaric J. Dyckman</span> - <span class="hlFld-Affiliation affiliation">Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1050-2077" title="Orcid link">http://orcid.org/0000-0002-1050-2077</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">S1P</td><td class="NLM_def"><p class="first last">sphingosine-1-phosphate</p></td></tr><tr><td class="NLM_term">S1P<sub>1–5</sub></td><td class="NLM_def"><p class="first last">sphingosine-1-phosphate receptors 1–5</p></td></tr><tr><td class="NLM_term">RRMS</td><td class="NLM_def"><p class="first last">relapsing-remitting multiple sclerosis</p></td></tr><tr><td class="NLM_term">BLR</td><td class="NLM_def"><p class="first last">blood lymphocyte reduction</p></td></tr><tr><td class="NLM_term">BAL</td><td class="NLM_def"><p class="first last">bronchoalveolar lavage</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen induced arthritis</p></td></tr><tr><td class="NLM_term">EAE</td><td class="NLM_def"><p class="first last">experimental autoimmune encephalomyelitis</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40781" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40781" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 37 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornancin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechtcheriakova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumruker, T.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">47408</span>– <span class="NLM_lpage">47415</span>, <span class="refDoi"> DOI: 10.1074/jbc.M307687200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1074%2Fjbc.M307687200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=13129923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47408-47415&author=A.+Billichauthor=F.+Bornancinauthor=P.+Devayauthor=D.+Mechtcheriakovaauthor=N.+Urtzauthor=T.+Baumruker&title=Phosphorylation+of+the+immunomodulatory+drug+FTY720+by+sphingosine+kinases&doi=10.1074%2Fjbc.M307687200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span></div><div class="casAuthors">Billich, Andreas; Bornancin, Frederic; Devay, Piroska; Mechtcheriakova, Diana; Urtz, Nicole; Baumruker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">47408-47415</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biol. effects of the compd.  So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented.  We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower Km of FTY720 for SPHK2.  Similarly, murine SPHK2 was more efficient than SPHK1a.  Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself.  Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720.  Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720.  Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured.  While activity of SPHK2 toward sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2.  In human endothelial cells, while activity of SPHK1 toward sphingosine was 2-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions.  Finally, FTY720 was poorly phosphorylated in human blood as compared with rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood.  To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quant. more important than SPHK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR5e-dVWnBT7Vg90H21EOLACvtfcHk0lhoQJ44iRj_Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D&md5=26820503680682863dc76a69ea02fc7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307687200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307687200%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBornancin%26aufirst%3DF.%26aulast%3DDevay%26aufirst%3DP.%26aulast%3DMechtcheriakova%26aufirst%3DD.%26aulast%3DUrtz%26aufirst%3DN.%26aulast%3DBaumruker%26aufirst%3DT.%26atitle%3DPhosphorylation%2520of%2520the%2520immunomodulatory%2520drug%2520FTY720%2520by%2520sphingosine%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47408%26epage%3D47415%26doi%3D10.1074%2Fjbc.M307687200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hartwieg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welzenbach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zécri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span></span> <span> </span><span class="NLM_article-title">Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5373</span>– <span class="NLM_lpage">5377</span>, <span class="refDoi"> DOI: 10.1021/jm050242f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050242f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5373-5377&author=R.+Albertauthor=K.+Hinterdingauthor=V.+Brinkmannauthor=D.+Gueriniauthor=C.+Muller-Hartwiegauthor=H.+Knechtauthor=C.+Simeonauthor=M.+Streiffauthor=T.+Wagnerauthor=K.+Welzenbachauthor=F.+Z%C3%A9criauthor=M.+Zollingerauthor=N.+Cookeauthor=E.+Francotte&title=Novel+immunomodulator+FTY720+is+phosphorylated+in+rats+and+humans+to+form+a+single+stereoisomer.+Identification%2C+chemical+proof%2C+and+biological+characterization+of+the+biologically+active+species+and+its+enantiomer&doi=10.1021%2Fjm050242f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer</span></div><div class="casAuthors">Albert, Rainer; Hinterding, Klaus; Brinkmann, Volker; Guerini, Danilo; Mueller-Hartwieg, Constanze; Knecht, Helmut; Simeon, Corinne; Streiff, Markus; Wagner, Trixie; Welzenbach, Karl; Zecri, Frederic; Zollinger, Markus; Cooke, Nigel; Francotte, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5373-5377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vivo phosphorylation of FTY720 (1) in rats and humans resulted exclusively in the biol. active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol esp. elaborated for phosphates of 1.  Starting from the prochiral amino alc. 1, racemic and enantiomerically pure phosphates of 1 were synthesized.  Pure enantiomers were obtained after purifn. of a partially protected key intermediate on an enantioselective support.  The abs. stereochem. was detd. by x-ray diffraction.  Data on human and rat studies are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh0U1_F0bQtLVg90H21EOLACvtfcHk0lhoQJ44iRj_Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D&md5=34b956ad7d7e60c2013e66320a88560e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm050242f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050242f%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DMuller-Hartwieg%26aufirst%3DC.%26aulast%3DKnecht%26aufirst%3DH.%26aulast%3DSimeon%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWelzenbach%26aufirst%3DK.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DFrancotte%26aufirst%3DE.%26atitle%3DNovel%2520immunomodulator%2520FTY720%2520is%2520phosphorylated%2520in%2520rats%2520and%2520humans%2520to%2520form%2520a%2520single%2520stereoisomer.%2520Identification%252C%2520chemical%2520proof%252C%2520and%2520biological%2520characterization%2520of%2520the%2520biologically%2520active%2520species%2520and%2520its%2520enantiomer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5373%26epage%3D5377%26doi%3D10.1021%2Fjm050242f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, H.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis</span>. <i>Clin. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1097/WNF.0b013e3181cbf825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1097%2FWNF.0b013e3181cbf825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=91-101&author=J.+Chunauthor=H.+Hartung&title=Mechanism+of+action+of+oral+fingolimod+%28FTY720%29+in+multiple+sclerosis&doi=10.1097%2FWNF.0b013e3181cbf825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FWNF.0b013e3181cbf825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWNF.0b013e3181cbf825%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DH.%26atitle%3DMechanism%2520of%2520action%2520of%2520oral%2520fingolimod%2520%2528FTY720%2529%2520in%2520multiple%2520sclerosis%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2010%26volume%3D33%26spage%3D91%26epage%3D101%26doi%3D10.1097%2FWNF.0b013e3181cbf825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quackenbush, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shei, G.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupprecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.-J.+Sheiauthor=D.+Cardauthor=C.+A.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+lymphocyte+trafficking+by+sphingosine-1-phosphate+receptor+agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0liQZGzoqCiGOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520lymphocyte%2520trafficking%2520by%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieschl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumruker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiestand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span> <span> </span><span class="NLM_article-title">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">21453</span>– <span class="NLM_lpage">21457</span>, <span class="refDoi"> DOI: 10.1074/jbc.C200176200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1074%2Fjbc.C200176200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=11967257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=21453-21457&author=V.+Brinkmannauthor=M.+D.+Davisauthor=C.+E.+Heiseauthor=R.+Albertauthor=S.+Cottensauthor=R.+Hofauthor=C.+Brunsauthor=E.+Prieschlauthor=T.+Baumrukerauthor=P.+Hiestandauthor=C.+A.+Fosterauthor=M.+Zollingerauthor=K.+R.+Lynch&title=The+immune+modulator+FTY720+targets+sphingosine+1-phosphate+receptors&doi=10.1074%2Fjbc.C200176200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Brinkmann, Volker; Davis, Michael D.; Heise, Christopher E.; Albert, Rainer; Cottens, Sylvain; Hof, Robert; Bruns, Christian; Prieschl, Eva; Baumruker, Thomas; Hiestand, Peter; Foster, Carolyn A.; Zollinger, Markus; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">21453-21457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis.  In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation.  FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms.  Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compd. is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis.  Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6zyZnHOYNbVg90H21EOLACvtfcHk0liQZGzoqCiGOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D&md5=b59856fffa9ebae7fb8182d18daa025f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C200176200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C200176200%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DCottens%26aufirst%3DS.%26aulast%3DHof%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPrieschl%26aufirst%3DE.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHiestand%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DC.%2BA.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DThe%2520immune%2520modulator%2520FTY720%2520targets%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D21453%26epage%3D21457%26doi%3D10.1074%2Fjbc.C200176200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1146/annurev-immunol-020711-075011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1146%2Fannurev-immunol-020711-075011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22149932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=69-94&author=J.+G.+Cysterauthor=S.+R.+Schwab&title=Sphingosine-1-phosphate+and+lymphocyte+egress+from+lymphoid+organs&doi=10.1146%2Fannurev-immunol-020711-075011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Cyster, Jason G.; Schwab, Susan R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-94</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Much has been learned about how cells enter lymphoid tissues.  But how do they leave.  Sphingosine-1-phosphate (S1P) has emerged over the past decade as a central mediator of lymphocyte egress.  In this review, we summarize the current understanding of how S1P promotes exit from the secondary lymphoid organs and thymus.  We review what is known about addnl. requirements for emigration and summarize the mostly distinct requirements for exit from the bone marrow.  Egress from lymphoid organs is limited during immune responses, and we examine how this regulation works.  There is accumulating evidence for roles of S1P in directing immune cell behavior within lymphoid tissues.  How such actions can fit together with the egress-promoting role of S1P is discussed.  Finally, we examine current understanding of how FTY720, a drug that targets S1P receptors and is approved for the treatment of multiple sclerosis, causes immune suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvMroRvgkZrVg90H21EOLACvtfcHk0liQZGzoqCiGOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D&md5=c9f9ef63f2248594b0f9ce4d06024bba</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev-immunol-020711-075011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-immunol-020711-075011%26sid%3Dliteratum%253Aachs%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26atitle%3DSphingosine-1-phosphate%2520and%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D30%26spage%3D69%26epage%3D94%26doi%3D10.1146%2Fannurev-immunol-020711-075011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendataraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, J.</span></span> <span> </span><span class="NLM_article-title">The vascular S1P gradient: cellular sources and biological significance</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1781</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2008.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.bbalip.2008.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=18674637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1781&publication_year=2008&pages=477-482&author=T.+Hlaauthor=K.+Vendataramanauthor=J.+Michaud&title=The+vascular+S1P+gradient%3A+cellular+sources+and+biological+significance&doi=10.1016%2Fj.bbalip.2008.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The vascular S1P gradient-Cellular sources and biological significance</span></div><div class="casAuthors">Hla, Timothy; Venkataraman, Krishnan; Michaud, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1781</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P), a product of sphingomyelin metab., is enriched in the circulatory system whereas it is estd. to be much lower in interstitial fluids of tissues.  This concn. gradient, termed the vascular S1P gradient appears to form as a result of substrate availability and the action of metabolic enzymes.  S1P levels in blood and lymph are estd. to be in the μM range.  In the immune system, the S1P gradient is needed as a spatial cue for lymphocyte and hematopoietic cell trafficking.  During inflammatory reactions in which enhanced vascular permeability occurs, a burst of S1P becomes available to its receptors in the extravascular compartment, which likely contributes to the tissue reactions.  Thus, the presence of the vascular S1P gradient is thought to contribute to physiol. and pathol. conditions.  From an evolutionary perspective, S1P receptors may have co-evolved with the advent of a closed vascular system and the trafficking paradigms for hematopoietic cells to navigate in and out of the vascular system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosbyXvTWrRf7Vg90H21EOLACvtfcHk0lj3Zmt-YM7x-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF&md5=a9c4420dff6764f71060b18149669767</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2008.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2008.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DHla%26aufirst%3DT.%26aulast%3DVendataraman%26aufirst%3DK.%26aulast%3DMichaud%26aufirst%3DJ.%26atitle%3DThe%2520vascular%2520S1P%2520gradient%253A%2520cellular%2520sources%2520and%2520biological%2520significance%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2008%26volume%3D1781%26spage%3D477%26epage%3D482%26doi%3D10.1016%2Fj.bbalip.2008.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span> <span> </span><span class="NLM_article-title">Finding a way out: lymphocyte egress from lymphoid organs</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1301</span>, <span class="refDoi"> DOI: 10.1038/ni1545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fni1545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=18026082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1295-1301&author=S.+R.+Schwabauthor=J.+G.+Cyster&title=Finding+a+way+out%3A+lymphocyte+egress+from+lymphoid+organs&doi=10.1038%2Fni1545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Finding a way out: lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Schwab, Susan R.; Cyster, Jason G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1295-1301</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The egress of lymphocytes from the thymus and secondary lymphoid organs into circulatory fluids is essential for normal immune function.  The discovery that a small-mol. inhibitor of lymphocyte exit, FTY720, is a ligand for sphingosine 1-phosphate (S1P) receptors led to studies demonstrating that S1P receptor type 1 (S1P1) is needed in T cells and B cells for their egress from lymphoid organs.  S1P exists in higher concns. in blood and lymph than in lymphoid organs, and this differential is also required for lymphocyte exit.  Transcriptional and post-translational mechanisms regulate S1P1 and thus the egress of lymphocytes.  In this review we discuss the body of evidence supporting a model in which lymphocyte egress is promoted by encounter with S1P at exit sites.  We relate this model to work examg. the effects of S1P receptor agonists on endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWY-Rk111SmLVg90H21EOLACvtfcHk0lj3Zmt-YM7x-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J&md5=ccf7ef06130d3ebd218707ac92618f36</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fni1545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1545%26sid%3Dliteratum%253Aachs%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DFinding%2520a%2520way%2520out%253A%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DNat.%2520Immunol.%26date%3D2007%26volume%3D8%26spage%3D1295%26epage%3D1301%26doi%3D10.1038%2Fni1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetzl, E. J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1038/nri1650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fnri1650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=15999095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=560-570&author=H.+Rosenauthor=E.+J.+Goetzl&title=Sphingosine+1-phosphate+and+its+receptors%3A+an+autocrine+and+paracrine+network&doi=10.1038%2Fnri1650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span></div><div class="casAuthors">Rosen, Hugh; Goetzl, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">560-570</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a biol. active lysophospholipid that transmits signals through a family of G-protein-coupled receptors to control cellular differentiation and survival, as well as the vital functions of several types of immune cell.  In this Review article, the authors discuss recent results that indicate that S1P and its receptors are required for the emigration of thymocytes from the thymus, the trafficking of lymphocytes in secondary lymphoid organs and the migration of B cells into splenic follicles.  In an autocrine manner, through interactions with different G-protein-coupled receptors, S1P also enhances optimal mast-cell migration and release of pro-inflammatory mediators in allergic reactions.  S1P-S1P-receptor regulatory systems might therefore be novel targets for the therapy of diverse immunol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6-Zo0R14YILVg90H21EOLACvtfcHk0lj3Zmt-YM7x-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D&md5=b680f6c9e29d407579ab7f056209d853</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnri1650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1650%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DGoetzl%26aufirst%3DE.%2BJ.%26atitle%3DSphingosine%25201-phosphate%2520and%2520its%2520receptors%253A%2520an%2520autocrine%2520and%2520paracrine%2520network%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D560%26epage%3D570%26doi%3D10.1038%2Fnri1650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regard, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1126/science.1139221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1126%2Fscience.1139221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17363629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=295-298&author=R.+Pappuauthor=S.+R.+Schwabauthor=I.+Cornelissenauthor=J.+P.+Pereiraauthor=J.+B.+Regardauthor=Y.+Xuauthor=E.+Camererauthor=Y.-W.+Zhengauthor=Y.+Huangauthor=J.+G.+Cysterauthor=S.+R.+Coughlin&title=Promotion+of+lymphocyte+egress+into+blood+and+lymph+by+distinct+sources+of+sphingosine-1-phosphate&doi=10.1126%2Fscience.1139221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate</span></div><div class="casAuthors">Pappu, Rajita; Schwab, Susan R.; Cornelissen, Ivo; Pereira, Joao P.; Regard, Jean B.; Xu, Ying; Camerer, Eric; Zheng, Yao-Wu; Huang, Yong; Cyster, Jason G.; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5822</span>),
    <span class="NLM_cas:pages">295-298</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lymphocytes require sphingosine-1-phosphate (S1P) receptor-1 to exit lymphoid organs, but the source(s) of extracellular S1P and whether S1P directly promotes egress are unknown.  By using mice in which the two kinases that generate S1P were conditionally ablated, we find that plasma S1P is mainly hematopoietic in origin, with erythrocytes a major contributor, whereas lymph S1P is from a distinct radiation-resistant source.  Lymphocyte egress from thymus and secondary lymphoid organs was markedly reduced in kinase-deficient mice.  Restoration of S1P to plasma rescued egress to blood but not lymph, and the rescue required lymphocyte expression of S1P-receptor-1.  Thus, sep. sources provide S1P to plasma and lymph to help lymphocytes exit the low-S1P environment of lymphoid organs.  Disruption of compartmentalized S1P signaling is a plausible mechanism by which S1P-receptor-1 agonists function as immunosuppressives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH4WVYwTIX7Vg90H21EOLACvtfcHk0lj3Zmt-YM7x-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D&md5=6c658296c3b1d34543c193987092506b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1139221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1139221%26sid%3Dliteratum%253Aachs%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCornelissen%26aufirst%3DI.%26aulast%3DPereira%26aufirst%3DJ.%2BP.%26aulast%3DRegard%26aufirst%3DJ.%2BB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCamerer%26aufirst%3DE.%26aulast%3DZheng%26aufirst%3DY.-W.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DPromotion%2520of%2520lymphocyte%2520egress%2520into%2520blood%2520and%2520lymph%2520by%2520distinct%2520sources%2520of%2520sphingosine-1-phosphate%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D295%26epage%3D298%26doi%3D10.1126%2Fscience.1139221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobias, K.</span></span> <span> </span><span class="NLM_article-title">Oral fingolomid for the treatment of patients with relapsing forms of multiple sclerosis</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2011.02721.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fj.1742-1241.2011.02721.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=21679286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2011&pages=887-895&author=B.+Singerauthor=A.+P.+Rossauthor=K.+Tobias&title=Oral+fingolomid+for+the+treatment+of+patients+with+relapsing+forms+of+multiple+sclerosis&doi=10.1111%2Fj.1742-1241.2011.02721.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span></div><div class="casAuthors">Singer, B.; Ross, A. P.; Tobias, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-895</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine 1-phosphate receptor modulator, is the first oral treatment approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).  The aim of this review was to provide a concise, comprehensive overview of the clin. relevant mechanism of action, efficacy and safety information available for fingolimod.  Key data were derived from two international, Phase III, double-blind, randomised trials (TRANSFORMS and FREEDOMS) performed over 12 and 24 mo, resp., which evaluated fingolimod 0.5 and 1.25 mg daily in 1703 patients with relapsing forms of MS.  In TRANSFORMS, there was a 52% redn. in the annualised relapse rate (ARR) with fingolimod 0.5 mg vs. 30 μg i.m. interferon beta-1a (0.16 vs. 0.33; p < 0.001) at 1 yr.  In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001).  Risk of disability progression, confirmed at 3 mo, was also reduced by 30% over the 2-yr study period with fingolimod vs. placebo (p = 0.02).  Significantly fewer new or enlarged lesions on T2-weighted images were seen in both studies (TRANSFORMS, p = 0.002 vs. interferon beta-1a at 1 yr; FREEDOMS, p < 0.001 vs. placebo at 2 years).  Overall, fingolimod 0.5 mg was well tolerated by patients.  Transient, generally asymptomatic bradycardia and infrequent atrioventricular block were seen with the administration of the first dose.  Macular edema and serious infections occurred infrequently.  Reversible, asymptomatic elevations of liver enzymes could also occur.  As the first approved oral disease-modifying treatment, fingolimod offers patients a convenient alternative to regular self-injection for the treatment of relapsing forms of MS.  In addn. to high efficacy with a relatively acceptable safety profile, fingolimod provides a therapy with a new mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKs1Biiz177Vg90H21EOLACvtfcHk0li__MeZk6KhKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D&md5=8be8ad56fc253ddccb59597c041b9ff8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2011.02721.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2011.02721.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DA.%2BP.%26aulast%3DTobias%26aufirst%3DK.%26atitle%3DOral%2520fingolomid%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsing%2520forms%2520of%2520multiple%2520sclerosis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D65%26spage%3D887%26epage%3D895%26doi%3D10.1111%2Fj.1742-1241.2011.02721.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Hernandez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claffey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and action of the immunomodulatory FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">47281</span>– <span class="NLM_lpage">47290</span>, <span class="refDoi"> DOI: 10.1074/jbc.M306896200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1074%2Fjbc.M306896200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47281-47290&author=T.+Sanchezauthor=T.+Estrada-Hernandezauthor=J.-H.+Paikauthor=M.-T.+Wuauthor=K.+Venkataramanauthor=V.+Brinkmannauthor=K.+Claffeyauthor=T.+Hla&title=Phosphorylation+and+action+of+the+immunomodulatory+FTY720+inhibits+vascular+endothelial+cell+growth+factor-induced+vascular+permeability&doi=10.1074%2Fjbc.M306896200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M306896200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M306896200%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DEstrada-Hernandez%26aufirst%3DT.%26aulast%3DPaik%26aufirst%3DJ.-H.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DVenkataraman%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DClaffey%26aufirst%3DK.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DPhosphorylation%2520and%2520action%2520of%2520the%2520immunomodulatory%2520FTY720%2520inhibits%2520vascular%2520endothelial%2520cell%2520growth%2520factor-induced%2520vascular%2520permeability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47281%26epage%3D47290%26doi%3D10.1074%2Fjbc.M306896200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A.</span></span> <span> </span><span class="NLM_article-title">Modulators of sphingosine-1-phosphate pathway biology: recent advances in the discovery and development of sphingosine-1-phosphate-1 receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5267</span>– <span class="NLM_lpage">5289</span>, and references cited therein <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01575</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01575" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ohsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5267-5289&author=A.+Dyckman&title=Modulators+of+sphingosine-1-phosphate+pathway+biology%3A+recent+advances+in+the+discovery+and+development+of+sphingosine-1-phosphate-1+receptor+agonists&doi=10.1021%2Facs.jmedchem.6b01575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives</span></div><div class="casAuthors">Dyckman, Alaric J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5267-5289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sphingoid base derived class of lipids (sphingolipids) is a family of interconverting mols. that play key roles in numerous structural and signaling processes.  The biosynthetic pathway of the sphingolipids affords many opportunities for therapeutic intervention: targeting the ligands directly, targeting the various proteins involved in the interconversion of the ligands, or targeting the receptors that respond to the ligands.  The focus of this article is on the most advanced of the sphingosine-related therapeutics, agonists of sphingosine-1-phosphate receptor 1 (S1P1).  The diverse structural classes of S1P1 agonists will be discussed and the status of compds. of clin. relevance will be detailed.  An examn. of how potential safety concerns are being navigated with compds. currently under clin. evaluation is followed by a discussion of the novel methods being explored to identify next-generation S1P1 agonists with improved safety profiles.  Finally, therapeutic opportunities for sphingosine-related targets outside of S1P1 are touched upon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNydOixG1FbVg90H21EOLACvtfcHk0li__MeZk6KhKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ohsr4%253D&md5=254a3b0960cff5c3268df13a326b887e</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01575%26sid%3Dliteratum%253Aachs%26aulast%3DDyckman%26aufirst%3DA.%26atitle%3DModulators%2520of%2520sphingosine-1-phosphate%2520pathway%2520biology%253A%2520recent%2520advances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520sphingosine-1-phosphate-1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5267%26epage%3D5289%26doi%3D10.1021%2Facs.jmedchem.6b01575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptor agonists: a patent review (2010–2012)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">841</span>, and references cited therein <span class="refDoi"> DOI: 10.1517/13543776.2013.783022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1517%2F13543776.2013.783022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=23541049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=817-841&author=E.+Robertsauthor=M.+Guerreroauthor=M.+Urbanoauthor=H.+Rosen&title=Sphingosine+1-phosphate+receptor+agonists%3A+a+patent+review+%282010%E2%80%932012%29&doi=10.1517%2F13543776.2013.783022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor agonists: a patent review (2010 - 2012)</span></div><div class="casAuthors">Roberts, Edward; Guerrero, Miguel; Urbano, Mariangela; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">817-841</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The sphingosine-1-phosphate (S1P)-driven signaling regulates fundamental biol. functions, including cell proliferation, angiogenesis, endothelial cell chemotaxis, immune cell trafficking and mitogenesis.  A large body of research has been focusing on the development of immunosuppressive S1P1 receptor (S1P1-R) agonist mols.  The S1P1,3 - 5-R pan-agonist fingolimod (FTY720) has been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis.  However, FTY720 is now contraindicated in patients with compromised cardiac function.  Although the main adverse effect bradycardia has been linked to the S1P3-R activation, cardiovascular liabilities persist with more selective S1P1-R agonists that have entered clin. trials.  In contrast to the S1P1-R, the therapeutic application of the S1P2 - 5-Rs remains poorly explored.  Areas covered: This review provides the patent literature from 2010 to date on S1P-R agonist mols. and their relevant biol. properties.  Expert opinion: Limited progress has been made on agonists at S1P4,5-R subtypes, with some families of S1P5-R agonists showing promising results in animal models of age-related cognitive disorders.  A discrete no. of reviewed mols. are S1P1-R agonists with a promising clin. outlook in transplantation, inflammation, cancer and autoimmune settings.  Further preclin. and clin. studies will det. whether the new developed S1P1-R agonists do indeed improve the safety profile of FTY720.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrASpSMDS37Vg90H21EOLACvtfcHk0lj2evC09WtSQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D&md5=405b6350b777d3040e2be21adf85d440</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.783022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.783022%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DUrbano%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-phosphate%2520receptor%2520agonists%253A%2520a%2520patent%2520review%2520%25282010%25E2%2580%25932012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D817%26epage%3D841%26doi%3D10.1517%2F13543776.2013.783022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kappos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polman, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radue, E. W.</span></span> <span> </span><span class="NLM_article-title">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa052643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1056%2FNEJMoa052643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=16971719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1124-1140&author=L.+Kapposauthor=J.+Antelauthor=G.+Comiauthor=X.+Montalbanauthor=P.+O%E2%80%99Connorauthor=C.+H.+Polmanauthor=T.+Haasauthor=A.+A.+Kornauthor=G.+Karlssonauthor=E.+W.+Radue&title=Oral+fingolimod+%28FTY720%29+for+relapsing+multiple+sclerosis&doi=10.1056%2FNEJMoa052643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span></div><div class="casAuthors">Kappos, Ludwig; Antel, Jack; Comi, Giancarlo; Montalban, Xavier; O'Connor, Paul; Polman, Chris H.; Haas, Tomas; Korn, Alexander A.; Karlsson, Goeril; Radue, Ernst W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1124-1140</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.  We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 mo with magnetic resonance imaging (MRI) and clin. evaluations (core study, months 0 to 6).  The primary end point was the total no. of gadolinium-enhanced lesions recorded on T1-weighted MRI at monthly intervals for 6 mo.  In an extension study in which the investigators and patients remained unaware of the dose assignments (months 7 to 12), patients who received placebo underwent randomization again to one of the fingolimod doses.  A total of 255 patients completed the core study.  The median total no. of gadolinium-enhanced lesions on MRI was lower with 1.25 mg of fingolimod (1 lesion, P < 0.001) and 5.0 mg of fingolimod (3 lesions, P = 0.006) than with placebo (5 lesions).  The annualized relapse rate was 0.77 in the placebo group, as compared with 0.35 in the group given 1.25 mg of fingolimod (P = 0.009) and 0.36 in the group given 5.0 mg of fingolimod (P = 0.01).  For the 227 patients who completed the extension study, the no. of gadolinium-enhanced lesions and relapse rates remained low in the groups that received continuous fingolimod, and both measures decreased in patients who switched from placebo to fingolimod.  Adverse events included nasopharyngitis, dyspnea, headache, diarrhea, and nausea.  Clin. asymptomatic elevations of alanine aminotransferase levels were more frequent with fingolimod (10 to 12%, vs. 1% in the placebo group).  One case of the posterior reversible encephalopathy syndrome occurred in the 5.0-mg group.  Fingolimod was also assocd. with an initial redn. in the heart rate and a modest decrease in the forced expiratory vol. in 1 s.  In this proof-of-concept study, fingolimod reduced the no. of lesions detected on MRI and clin. disease activity in patients with multiple sclerosis.  Evaluation in larger, longer-term studies is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4MSvDIuvV7Vg90H21EOLACvtfcHk0lj2evC09WtSQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D&md5=2a84e8f5fb92091782406da9dcbc1453</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa052643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa052643%26sid%3Dliteratum%253Aachs%26aulast%3DKappos%26aufirst%3DL.%26aulast%3DAntel%26aufirst%3DJ.%26aulast%3DComi%26aufirst%3DG.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DPolman%26aufirst%3DC.%2BH.%26aulast%3DHaas%26aufirst%3DT.%26aulast%3DKorn%26aufirst%3DA.%2BA.%26aulast%3DKarlsson%26aufirst%3DG.%26aulast%3DRadue%26aufirst%3DE.%2BW.%26atitle%3DOral%2520fingolimod%2520%2528FTY720%2529%2520for%2520relapsing%2520multiple%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1124%26epage%3D1140%26doi%3D10.1056%2FNEJMoa052643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">David, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovarik, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmouder, R. L.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of fingolimod</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2165/11596550-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.2165%2F11596550-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22149256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=15-28&author=O.+J.+Davidauthor=J.+M.+Kovarikauthor=R.+L.+Schmouder&title=Clinical+pharmacokinetics+of+fingolimod&doi=10.2165%2F11596550-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of fingolimod</span></div><div class="casAuthors">David, Olivier J.; Kovarik, John M.; Schmouder, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review.  Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compds. and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).  Fingolimod is a structural analog of endogenous sphingosine and undergoes phosphorylation to produce fingolimod phosphate, the active moiety.  Fingolimod targets MS via effects on the immune system, and evidence from animal models indicates that it may also have actions in the central nervous system.  In phase III studies in patients with relapsing-remitting MS, fingolimod has demonstrated efficacy superior to that of an approved first-line therapy, i.m. interferon-β-1a, as well as placebo, with benefits extending across clin. and magnetic resonance imaging measures.  The pharmacokinetic profiles of fingolimod and fingolimod phosphate have been extensively investigated in studies in healthy volunteers, renal transplant recipients (the indication for which fingolimod was initially under clin. development, but the development was subsequently discontinued) and MS patients.  Results from these studies have demonstrated that fingolimod is efficiently absorbed, with an oral bioavailability of >90%, and its absorption is unaffected by dietary intake, therefore it can be taken without regard to meals.  Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 mo of daily dosing.  The long half-life of fingolimod, together with its slow absorption, means that fingolimod has a fiat concn. profile over time with once-daily dosing.  Fingolimod and fingolimod phosphate show dose-proportional exposure in single- and multiple-dose studies over a range of 0.125-5 mg; hence, there is a predictable relationship between dose and systemic exposure.  Furthermore, fingolimod and fingolimod phosphate exhibit low to moderate intersubject pharmacokinetic variability.  Fingolimod is extensively metabolized, with biotransformation occurring via three main pathways: (i) reversible phosphorylation to fingolimod phosphate; (ii) hydroxylation and oxidn. to yield a series of inactive carboxylic acid metabolites; and (iii) formation of non-polar ceramides.  Fingolimod is largely cleared through metab. by cytochrome P 450 (CYP) 4F2.  Since few drugs are metabolized by CYP4F2, fingolimod would be expected to have a relatively low potential for drug-drug interactions.  This is supported by data from in vitro studies indicating that fingolimod and fingolimod phosphate have little or no capacity to inhibit and no capacity to induce other major drug-metabolizing CYP enzymes at therapeutically relevant steady-state blood concns.  Population pharmacokinetic evaluations indicate that CYP3A inhibitors and CYP3A inducers have no effect or only a weak effect on the pharmacokinetics of fingolimod and fingolimod phosphate.  However, blood concns. of fingolimod and fingolimod phosphate are increased moderately when fingolimod is coadministered with ketoconazole, an inhibitor of CYP4F2.  The pharmacokinetics of fingolimod are unaffected by renal impairment or mild-to-moderate hepatic impairment.  However, exposure to fingolimod is increased in patients with severe hepatic impairment.  No clin. relevant effects of age, sex or ethnicity on the pharmacokinetics of fingolimod have been obsd.  Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoxIUshcr8m7Vg90H21EOLACvtfcHk0lgbiPYNJBHj4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D&md5=a1a6d271470f6c297892ef00f0fe6ec6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F11596550-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596550-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DKovarik%26aufirst%3DJ.%2BM.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520fingolimod%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D15%26epage%3D28%26doi%3D10.2165%2F11596550-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenewegen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaliti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttringer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumb, W. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallstrom, E.</span></span> <span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22646698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergelyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstrom&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span></div><div class="casAuthors">Gergely, P.; Nuesslein-Hildesheim, B.; Guerini, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J., Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1035-1047</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose BAF312 is a next-generation sphingosine 1-phosphate (S1P) receptor modulator, selective for S1P1 and S1P5 receptors.  S1P1 receptors are essential for lymphocyte egress from lymph nodes and a drug target in immune-mediated diseases.  Here, we have characterized the immunomodulatory potential of BAF312 and the S1P receptor-mediated effects on heart rate using preclin. and human data.  Exptl. Approach BAF312 was tested in a rat exptl. autoimmune encephalomyelitis (EAE) model.  Electrophysiol. recordings of G-protein-coupled inwardly rectifying potassium (GIRK) channels were carried out in human atrial myocytes.  A Phase I multiple-dose trial studied the pharmacokinetics, pharmacodynamics and safety of BAF312 in 48 healthy subjects.  Key Results BAF312 effectively suppressed EAE in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes.  In healthy volunteers, BAF312 caused preferential decreases in CD4+ T cells, Tnaive, Tcentral memory and B cells within 4-6 h.  Cell counts returned to normal ranges within a week after stopping treatment, in line with the elimination half-life of BAF312.  Despite sparing S1P3 receptors (assocd. with bradycardia in mice), BAF312 induced rapid, transient (day 1 only) bradycardia in humans.  BAF312-mediated activation of GIRK channels in human atrial myocytes can fully explain the bradycardia.  Conclusion and Implications This study illustrates species-specific differences in S1P receptor specificity for first-dose cardiac effects.  Based on its profound but rapidly reversible inhibition of lymphocyte trafficking, BAF312 may have potential as a treatment for immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42VfW58NMyLVg90H21EOLACvtfcHk0lgbiPYNJBHj4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE&md5=0034be62fb68b10abefff50f0220be2a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstrom%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical pharmacology of clinical candidate ((1<i>R</i>,3<i>S</i>)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) - a differentiated S1P<sub>1</sub> receptor modulator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=283-288&author=T.+G.%0AM.+Dharauthor=H.-Y.+Xiaoauthor=J.+Xieauthor=L.+D.+Lehman-McKeemanauthor=D.-R.+Wuauthor=M.+Dabrosauthor=X.+Yangauthor=T.+L.+Taylorauthor=X.+D.+Zhouauthor=E.+M.+Heimrichauthor=R.+Thomasauthor=K.+W.+McIntyreauthor=B.+Warrackauthor=H.+Shiauthor=P.+C.+Levesqueauthor=J.+L.+Zhuauthor=J.+Hennanauthor=P.+Balimaneauthor=Z.+Yangauthor=A.+Marinoauthor=G.+Corneliusauthor=C.+D%27Arienzoauthor=A.+Mathurauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+Salter-cidauthor=J.+C.+Barrishauthor=P.+C.+Carterauthor=A.+J.+Dyckman&title=Identification+and+preclinical+pharmacology+of+clinical+candidate+%28%281R%2C3S%29-1-amino-3-%28%28R%29-6-hexyl-5%2C6%2C7%2C8-tetrahydronaphthalen-2-yl%29cyclopentyl%29methanol+%28BMS-986104%29+-+a+differentiated+S1P1+receptor+modulator&doi=10.1021%2Facsmedchemlett.5b00448"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00448%26sid%3Dliteratum%253Aachs%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXiao%26aufirst%3DH.-Y.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DZhou%26aufirst%3DX.%2BD.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DHennan%26aufirst%3DJ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%2527Arienzo%26aufirst%3DC.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520and%2520preclinical%2520pharmacology%2520of%2520clinical%2520candidate%2520%2528%25281R%252C3S%2529-1-amino-3-%2528%2528R%2529-6-hexyl-5%252C6%252C7%252C8-tetrahydronaphthalen-2-yl%2529cyclopentyl%2529methanol%2520%2528BMS-986104%2529%2520-%2520a%2520differentiated%2520S1P1%2520receptor%2520modulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D283%26epage%3D288%26doi%3D10.1021%2Facsmedchemlett.5b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulators</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1039/C6MD00539J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1039%2FC6MD00539J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=725-729&author=D.+Marcouxauthor=H.-Y.+Xiaoauthor=T.+G.+M.+Murali+Dharauthor=J.+Xieauthor=L.+D.+Lehman-McKeemanauthor=D.-R.+Wuauthor=M.+Dabrosauthor=X.+Yangauthor=T.+L.+Taylorauthor=X.+D.+Zhouauthor=E.+M.+Heimrichauthor=R.+Thomasauthor=K.+W.+McIntyreauthor=H.+Shiauthor=P.+C.+Levesqueauthor=H.+Sunauthor=Z.+Yangauthor=A.+Marinoauthor=G.+Corneliusauthor=C.+D%27Arienzoauthor=A.+Guptaauthor=B.+Pragalathanauthor=R.+Rampullaauthor=A.+Mathurauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+Salter-cidauthor=L.+J.+Lombardoauthor=P.+C.+Carterauthor=A.+J.+Dyckman&title=Identification+of+potent+tricyclic+prodrug+S1P1+receptor+modulators&doi=10.1039%2FC6MD00539J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1039%2FC6MD00539J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00539J%26sid%3Dliteratum%253Aachs%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DXiao%26aufirst%3DH.-Y.%26aulast%3DMurali%2BDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DZhou%26aufirst%3DX.%2BD.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%2527Arienzo%26aufirst%3DC.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-cid%26aufirst%3DL.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520potent%2520tricyclic%2520prodrug%2520S1P1%2520receptor%2520modulators%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D725%26epage%3D729%26doi%3D10.1039%2FC6MD00539J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6428</span>– <span class="NLM_lpage">6435</span>, <span class="refDoi"> DOI: 10.1021/jm7010172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7010172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6428-6435&author=R.+Zhuauthor=A.+H.+Snyderauthor=Y.+Kharelauthor=L.+Schaffterauthor=Q.+Sunauthor=P.+C.+Kennedyauthor=K.+R.+Lynchauthor=T.+L.+Macdonald&title=Asymmetric+synthesis+of+conformationally+constrained+fingolimod+analogues%2D%2Ddiscovery+of+an+orally+active+sphingosine+1-phosphate+receptor+type-1+agonist+and+receptor+type-3+antagonist&doi=10.1021%2Fjm7010172"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fjm7010172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010172%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DSnyder%26aufirst%3DA.%2BH.%26aulast%3DKharel%26aufirst%3DY.%26aulast%3DSchaffter%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DKennedy%26aufirst%3DP.%2BC.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DAsymmetric%2520synthesis%2520of%2520conformationally%2520constrained%2520fingolimod%2520analogues--discovery%2520of%2520an%2520orally%2520active%2520sphingosine%25201-phosphate%2520receptor%2520type-1%2520agonist%2520and%2520receptor%2520type-3%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6428%26epage%3D6435%26doi%3D10.1021%2Fjm7010172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppeck, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure activity relationship (SAR) of a series of ethanolamine-based direct acting agonists of sphingosine-1-phosphate (S1P1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6248</span>– <span class="NLM_lpage">6264</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6248-6264&author=J.+L.+Gilmoreauthor=J.+E.+Sheppeckauthor=S.+H.+Wattersonauthor=L.+Haqueauthor=P.+Mukhopadhyayauthor=A.+J.+Tebbenauthor=M.+A.+Galellaauthor=D.+R.+Shenauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=V.+Borowskiauthor=K.+M.+Gilloolyauthor=T.+Taylorauthor=K.+W.+McIntyreauthor=B.+Warrackauthor=P.+C.+Levesqueauthor=J.+P.+Liauthor=G.+Corneliusauthor=C.+J.+D%E2%80%99Arienzoauthor=A.+M.+Marinoauthor=P.+V.+Balimaneauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=W.+J.+Pittsauthor=P.+H.+Carterauthor=J.+Xieauthor=A.+J.+Dyckman&title=Discovery+and+structure+activity+relationship+%28SAR%29+of+a+series+of+ethanolamine-based+direct+acting+agonists+of+sphingosine-1-phosphate+%28S1P1%29&doi=10.1021%2Facs.jmedchem.6b00373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00373%26sid%3Dliteratum%253Aachs%26aulast%3DGilmore%26aufirst%3DJ.%2BL.%26aulast%3DSheppeck%26aufirst%3DJ.%2BE.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DHaque%26aufirst%3DL.%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DJ.%2BP.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DMarino%26aufirst%3DA.%2BM.%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520and%2520structure%2520activity%2520relationship%2520%2528SAR%2529%2520of%2520a%2520series%2520of%2520ethanolamine-based%2520direct%2520acting%2520agonists%2520of%2520sphingosine-1-phosphate%2520%2528S1P1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6248%26epage%3D6264%26doi%3D10.1021%2Facs.jmedchem.6b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="note"><p class="first last">Protein sequence alignment shows sphinosine kinase (SK) and sphingosine-1-phosphate phosphatase (SGPP) share high homology between rat and human, with 77–79% for SK1, 79–80% for SK2, 81% for SGPP1, and 82–85% for SGPP2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopacki, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fix-Stenzel, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grongsaard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, R. H.</span></span> <span> </span><span class="NLM_article-title">Scalable synthesis and isolation of the four stereoisomers of methyl 1-amino-3-(4-bromophenyl)cyclopentanecarboxylate, useful intermediates for the synthesis of S1P1 receptor agonists</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4886</span>– <span class="NLM_lpage">4889</span>, <span class="refDoi"> DOI: 10.1021/jo900376b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo900376b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=4886-4889&author=G.+A.+Wallaceauthor=T.+D.+Gordonauthor=M.+E.+Hayesauthor=D.+B.+Konopackiauthor=S.+F.+Fix-Stenzelauthor=X.+Zhangauthor=P.+Grongsaardauthor=K.+P.+Cusackauthor=L.+M.+Schaffterauthor=R.+F.+Henryauthor=R.+H.+Stoffel&title=Scalable+synthesis+and+isolation+of+the+four+stereoisomers+of+methyl+1-amino-3-%284-bromophenyl%29cyclopentanecarboxylate%2C+useful+intermediates+for+the+synthesis+of+S1P1+receptor+agonists&doi=10.1021%2Fjo900376b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjo900376b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo900376b%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DG.%2BA.%26aulast%3DGordon%26aufirst%3DT.%2BD.%26aulast%3DHayes%26aufirst%3DM.%2BE.%26aulast%3DKonopacki%26aufirst%3DD.%2BB.%26aulast%3DFix-Stenzel%26aufirst%3DS.%2BF.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGrongsaard%26aufirst%3DP.%26aulast%3DCusack%26aufirst%3DK.%2BP.%26aulast%3DSchaffter%26aufirst%3DL.%2BM.%26aulast%3DHenry%26aufirst%3DR.%2BF.%26aulast%3DStoffel%26aufirst%3DR.%2BH.%26atitle%3DScalable%2520synthesis%2520and%2520isolation%2520of%2520the%2520four%2520stereoisomers%2520of%2520methyl%25201-amino-3-%25284-bromophenyl%2529cyclopentanecarboxylate%252C%2520useful%2520intermediates%2520for%2520the%2520synthesis%2520of%2520S1P1%2520receptor%2520agonists%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2009%26volume%3D74%26spage%3D4886%26epage%3D4889%26doi%3D10.1021%2Fjo900376b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silveira, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braga, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardao, E. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches to 2-tetralones</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8295</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.06.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.tet.2004.06.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvV2gsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=8295-8328&author=C.+C.+Silveiraauthor=A.+L.+Bragaauthor=T.+S.+Kaufmanauthor=E.+J.+Lenardao&title=Synthetic+approaches+to+2-tetralones&doi=10.1016%2Fj.tet.2004.06.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to 2-tetralones</span></div><div class="casAuthors">Silveira, Claudio C.; Braga, Antonio L.; Kaufman, Teodoro S.; Lenardao, Eder J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">8295-8328</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review discusses a variety of methods for the prepn. of substituted 2-tetralones; the review discusses methods of prepg. 2-tetralones either by construction of the tetralone ring system or by functionalization of a previously obtained naphthalene or tetralone ring system.  The assembly of 2-tetralones by reactions such as the cyclization of α-diazocarbonyl compds., the copper-mediated cyclization of iodonium ylides, Friedel-Crafts alkylation and acylation reactions, cyclizations of β-ketosulfoxides, nucleophilic substitution of ruthenium-complexed arenes, the oxidative cyclization of δ-aryl-β-dicarbonyl compds., cyclization of silyl enol ethers onto radical cations, α-arylation reactions, benzyne cycloaddns., carbopalladation of arom. nitriles and acetylenes, and Dieckmann condensations are discussed.  Methods of prepg. 2-tetralones from either 1-tetralones or naphthols by carbonyl transposition, hydroboration and oxidn., redn., or ionic hydrogenation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTfe2eaaFdhbVg90H21EOLACvtfcHk0ljSbInAL9X9kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvV2gsLw%253D&md5=47a6c66bc6d8c7c7ade29c344725ca09</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.06.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.06.080%26sid%3Dliteratum%253Aachs%26aulast%3DSilveira%26aufirst%3DC.%2BC.%26aulast%3DBraga%26aufirst%3DA.%2BL.%26aulast%3DKaufman%26aufirst%3DT.%2BS.%26aulast%3DLenardao%26aufirst%3DE.%2BJ.%26atitle%3DSynthetic%2520approaches%2520to%25202-tetralones%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26spage%3D8295%26epage%3D8328%26doi%3D10.1016%2Fj.tet.2004.06.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonogashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, N.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4467</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)91094-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2FS0040-4039%2800%2991094-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1975&pages=4467-4470&author=K.+Sonogashiraauthor=Y.+Tohdaauthor=N.+Hagihara&title=A+convenient+synthesis+of+acetylenes%3A+catalytic+substitutions+of+acetylenic+hydrogen+with+bromoalkenes%2C+iodoarenes+and+bromopyridines&doi=10.1016%2FS0040-4039%2800%2991094-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2991094-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252991094-3%26sid%3Dliteratum%253Aachs%26aulast%3DSonogashira%26aufirst%3DK.%26aulast%3DTohda%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DN.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520acetylenes%253A%2520catalytic%2520substitutions%2520of%2520acetylenic%2520hydrogen%2520with%2520bromoalkenes%252C%2520iodoarenes%2520and%2520bromopyridines%26jtitle%3DTetrahedron%2520Lett.%26date%3D1975%26volume%3D16%26spage%3D4467%26epage%3D4470%26doi%3D10.1016%2FS0040-4039%2800%2991094-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compound <b>18b</b> was unambiguously assigned ((<i>S</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate by X-ray crystal structure. Crystallographic data for the structures <b>18b</b> reported in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1876258. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-336-033; e-mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="107475607f63796450737374733e73717d3e71733e657b">[email protected]</a>). The absolute and relative stereochemistry of <b>18a</b> was assigned ((<i>R</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate based on the results for the crystal structure of <b>18b</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compound <b>14a</b> was unambiguously assigned ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol by X-ray crystal structure. Crystallographic data for the structures <b>14a</b> reported in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1876257. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-336-033; e-mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="335756435c405a4773505057501d50525e1d52501d4658">[email protected]</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compounds <b>9a</b>/<b>9b</b>, <b>10a</b>/<b>10b</b>, and <b>20a</b>/<b>20b</b> were assigned by chiral HPLC analysis using material with known stereochemistry synthesized using <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. This analysis indicated that <b>9a</b> has the <i>S</i> configuration and <b>9b</b> has the <i>R</i> configuration at the benzyl attachment point. This analysis indicated that <b>10a</b> has the R configuration and <b>10b</b> has the <i>S</i> configuration at the phenethyl attachment point. This analysis indicated that <b>20a</b> has the <i>R</i> configuration and <b>20b</b> has the <i>S</i> configuration at the alkyne attachment point.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocieński, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, A.</span></span> <span> </span><span class="NLM_article-title">A stereoselective synthesis of <i>trans</i>-1,2-disubstituted alkenes based on the condensation of aldehydes with metallated 1-phenyl-1<i>H</i>-tetrazol-5-yl sulfones</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1998</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1055/s-1998-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1055%2Fs-1998-1570" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=26-28&author=P.+R.+Blakemoreauthor=W.+J.+Coleauthor=P.+J.+Kocie%C5%84skiauthor=A.+Morley&title=A+stereoselective+synthesis+of+trans-1%2C2-disubstituted+alkenes+based+on+the+condensation+of+aldehydes+with+metallated+1-phenyl-1H-tetrazol-5-yl+sulfones&doi=10.1055%2Fs-1998-1570"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1055%2Fs-1998-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1998-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBlakemore%26aufirst%3DP.%2BR.%26aulast%3DCole%26aufirst%3DW.%2BJ.%26aulast%3DKocie%25C5%2584ski%26aufirst%3DP.%2BJ.%26aulast%3DMorley%26aufirst%3DA.%26atitle%3DA%2520stereoselective%2520synthesis%2520of%2520trans-1%252C2-disubstituted%2520alkenes%2520based%2520on%2520the%2520condensation%2520of%2520aldehydes%2520with%2520metallated%25201-phenyl-1H-tetrazol-5-yl%2520sulfones%26jtitle%3DSynlett%26date%3D1998%26volume%3D1998%26spage%3D26%26epage%3D28%26doi%3D10.1055%2Fs-1998-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siow, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattenberg, B. W.</span></span> <span> </span><span class="NLM_article-title">An assay system for measuring the acute production of sphingosine 1-phosphate in intact monolayers</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2007.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.ab.2007.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17884005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=184-193&author=D.+L.+Siowauthor=B.+W.+Wattenberg&title=An+assay+system+for+measuring+the+acute+production+of+sphingosine+1-phosphate+in+intact+monolayers&doi=10.1016%2Fj.ab.2007.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">An assay system for measuring the acute production of sphingosine 1-phosphate in intact monolayers</span></div><div class="casAuthors">Siow, Deanna L.; Wattenberg, Binks W.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-193</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sphingosine kinase (SK) is a signaling enzyme that phosphorylates sphingosine to produce sphingosine 1-phosphate.  Sphingosine and sphingosine 1-phosphate (S1P) belong to a class of bioactive sphingolipid metabolites that are crit. in a no. of cellular processes, yet often have opposing biol. functions.  The intracellular localization of sphingosine kinase has been demonstrated in multiple studies to be a crit. aspect of its signaling function.  To date, assays of sphingosine kinase activity have been developed for measuring activity in lysates, where the effects of localization are lost.  Here the authors outline a system in which the rate of prodn. of S1P can be measured in intact cells using exogenously added radiolabeled ATP instead of tritiated sphingosine.  The surprising ability of ATP to enter unpermeabilized monolayers is one aspect that makes this assay simple, efficient, and inexpensive, yet sensitive enough to measure endogenous enzyme activity.  The assay is well behaved in terms of kinetics and substrate dependence.  Overall, this assay is ideal for future studies to identify changes in S1P prodn. in intact cells such as those that result from the differential intracellular targeting of sphingosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8eyI_ZniaG7Vg90H21EOLACvtfcHk0li5OFjZaPFY3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjO&md5=475c29aeca26fb40069e565efef7b273</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2007.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2007.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DSiow%26aufirst%3DD.%2BL.%26aulast%3DWattenberg%26aufirst%3DB.%2BW.%26atitle%3DAn%2520assay%2520system%2520for%2520measuring%2520the%2520acute%2520production%2520of%2520sphingosine%25201-phosphate%2520in%2520intact%2520monolayers%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D371%26spage%3D184%26epage%3D193%26doi%3D10.1016%2Fj.ab.2007.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, L. B.</span></span> <span> </span><span class="NLM_article-title">Biomarkers in acute lung injury – marking forward progress</span>. <i>Crit. Care Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1016/j.ccc.2011.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.ccc.2011.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=21742222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslWrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=661-683&author=N.+Barnettauthor=L.+B.+Ware&title=Biomarkers+in+acute+lung+injury+%E2%80%93+marking+forward+progress&doi=10.1016%2Fj.ccc.2011.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers in Acute Lung Injury-Marking Forward Progress</span></div><div class="casAuthors">Barnett, Nicolas; Ware, Lorraine B.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Clinics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">661-683</span>CODEN:
                <span class="NLM_cas:coden">CCCLEH</span>;
        ISSN:<span class="NLM_cas:issn">0749-0704</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  This article reviews the state of the art regarding biomarkers for prediction, diagnosis, and prognosis in acute lung injury.  Biomarkers and the goals of biomarker research are defined.  Progress along 4 general routes is examd.  First, the results of wide-ranging existing protein biomarkers are reported.  Second, newer biomarkers awaiting or with strong potential for validation are described.  Third, progress in the fields of genomics and proteomics is reported.  Finally, given the complexity and no. of potential biomarkers, the results of combining clin. predictors with protein and other biomarkers to produce better prognostic and diagnostic indexes are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDQHoERr7RdrVg90H21EOLACvtfcHk0lhVN4_lsvjD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslWrs7w%253D&md5=bada458495b6ae9da2b57f1d72ee37d8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccc.2011.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccc.2011.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DBarnett%26aufirst%3DN.%26aulast%3DWare%26aufirst%3DL.%2BB.%26atitle%3DBiomarkers%2520in%2520acute%2520lung%2520injury%2520%25E2%2580%2593%2520marking%2520forward%2520progress%26jtitle%3DCrit.%2520Care%2520Clin.%26date%3D2011%26volume%3D27%26spage%3D661%26epage%3D683%26doi%3D10.1016%2Fj.ccc.2011.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tager, A.</span></span> <span> </span><span class="NLM_article-title">Prolonged exposure to sphingosine 1–phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung lnjury</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2009-0345OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1165%2Frcmb.2009-0345OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=20081052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=662-673&author=B.+S.+Sheaauthor=S.+F.+Brooksauthor=B.+A.+Fontaineauthor=J.+Chunauthor=A.+D.+Lusterauthor=A.+Tager&title=Prolonged+exposure+to+sphingosine+1%E2%80%93phosphate+receptor-1+agonists+exacerbates+vascular+leak%2C+fibrosis%2C+and+mortality+after+lung+lnjury&doi=10.1165%2Frcmb.2009-0345OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury</span></div><div class="casAuthors">Shea, Barry S.; Brooks, Sarah F.; Fontaine, Benjamin A.; Chun, Jerold; Luster, Andrew D.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a key endogenous regulator of the response to lung injury, maintaining endothelial barrier integrity through interaction with one of its receptors, S1P1.  The short-term administration of S1P or S1P1 receptor agonists enhances endothelial monolayer barrier function in vitro, and attenuates injury-induced vascular leak in the lung and other organ systems in vivo.  Although S1P1 agonists bind to and activate S1P1, several of these agents also induce receptor internalization and degrdn., and may therefore act as functional antagonists of S1P1 after extended exposure.  Here we report on the effects of prolonged exposure to these agents in bleomycin-induced lung injury.  We demonstrate that repeated administration of S1P1 agonists dramatically worsened lung injury after bleomycin challenge, as manifested by increased vascular leak and mortality.  Consistent with these results, prolonged exposure to S1P1 agonists in vitro eliminated the ability of endothelial cell monolayers to respond appropriately to the barrier-protective effects of S1P, indicating a loss of normal S1P-S1P1 signaling.  As bleomycin-induced lung injury progressed, continued exposure to S1P1 agonists also resulted in increased pulmonary fibrosis.  These data indicate that S1P1 agonists can act as functional antagonists of S1P1 on endothelial cells in vivo, which should be considered in developing these agents as therapies for vascular leak syndromes.  Our findings also support the hypothesis that vascular leak is an important component of the fibrogenic response to lung injury, and suggest that targeting the S1P-S1P1 pathway may also be an effective therapeutic strategy for fibrotic lung diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8d_yM8ZpErVg90H21EOLACvtfcHk0lhVN4_lsvjD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM&md5=1b0c0384272545d0ca4dfb3c4df0c8c9</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2009-0345OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2009-0345OC%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DBrooks%26aufirst%3DS.%2BF.%26aulast%3DFontaine%26aufirst%3DB.%2BA.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26aulast%3DTager%26aufirst%3DA.%26atitle%3DProlonged%2520exposure%2520to%2520sphingosine%25201%25E2%2580%2593phosphate%2520receptor-1%2520agonists%2520exacerbates%2520vascular%2520leak%252C%2520fibrosis%252C%2520and%2520mortality%2520after%2520lung%2520lnjury%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2010%26volume%3D43%26spage%3D662%26epage%3D673%26doi%3D10.1165%2Frcmb.2009-0345OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sammani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Vinasco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzapoiazova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evenoski, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. G. N.</span></span> <span> </span><span class="NLM_article-title">Differential effects of sphingosine 1-phosphate on airway and vascular barrier function in the murine lung</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2009-0223OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1165%2Frcmb.2009-0223OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=19749179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=394-402&author=S.+Sammaniauthor=L.+Moreno-Vinascoauthor=T.+Mirzapoiazovaauthor=P.+A.+Singletonauthor=E.+T.+Chiangauthor=C.+L.+Evenoskiauthor=T.+Wangauthor=B.+Mathewauthor=A.+Husainauthor=J.+Moitraauthor=X.+Sunauthor=L.+Nunezauthor=J.+R.+Jacobsonauthor=S.+M.+Dudekauthor=V.+Natarajanauthor=J.+G.+N.+Garcia&title=Differential+effects+of+sphingosine+1-phosphate+on+airway+and+vascular+barrier+function+in+the+murine+lung&doi=10.1165%2Frcmb.2009-0223OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung</span></div><div class="casAuthors">Sammani, Saad; Moreno-Vinasco, Liliana; Mirzapoiazova, Tamara; Singleton, Patrick A.; Chiang, Eddie T.; Evenoski, Carrie L.; Wang, Ting; Mathew, Biji; Husain, Aliya; Moitra, Jaideep; Sun, Xiaoguang; Nunez, Luis; Jacobson, Jeffrey R.; Dudek, Steven M.; Natarajan, Viswanathan; Garcia, Joe G. N.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">394-402</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The therapeutic options for ameliorating the profound vascular permeability, alveolar flooding, and organ dysfunction that accompanies acute inflammatory lung injury (ALI) remain limited.  Extending our previous finding that the i.v. administration of the sphingolipid angiogenic factor, sphingosine 1-phosphate (S1P), attenuates inflammatory lung injury and vascular permeability via ligation of S1PR1, we det. that a direct intratracheal or i.v. administration of S1P, or a selective S1P receptor (S1PR1) agonist (SEW-2871), produces highly concn.-dependent barrier-regulatory responses in the murine lung.  The intratracheal or i.v. administration of S1P or SEW-2871 at < 0.3 mg/kg was protective against LPS-induced murine lung inflammation and permeability.  However, intratracheal delivery of S1P at 0.5 mg/kg (for 2 h) resulted in significant alveolar-capillary barrier disruption (with a 42% increase in bronchoalveolar lavage protein), and produced rapid lethality when delivered at 2 mg/kg.  Despite the greater selectivity for S1PR1, intratracheally delivered SEW-2871 at 0.5 mg/kg also resulted in significant alveolar-capillary barrier disruption, but was not lethal at 2 mg/kg.  Consistent with the S1PR1 regulation of alveolar/vascular barrier function, wild-type mice pretreated with the S1PR1 inverse agonist, SB-649146, or S1PR1+/- mice exhibited reduced S1P/SEW-2871-mediated barrier protection after challenge with LPS.  In contrast, S1PR2-/- knockout mice as well as mice with reduced S1PR3 expression (via silencing S1PR3-contg. nanocarriers) were protected against LPS-induced barrier disruption compared with control mice.  These studies underscore the potential therapeutic effects of highly selective S1PR1 receptor agonists in reducing inflammatory lung injury, and highlight the crit. role of the S1P delivery route, S1PR1 agonist concn., and S1PR1 expression in target tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr268-TV7Sk97Vg90H21EOLACvtfcHk0lhVN4_lsvjD4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qsbzE&md5=b65a25010b114f0ddcec189d2c540e65</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2009-0223OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2009-0223OC%26sid%3Dliteratum%253Aachs%26aulast%3DSammani%26aufirst%3DS.%26aulast%3DMoreno-Vinasco%26aufirst%3DL.%26aulast%3DMirzapoiazova%26aufirst%3DT.%26aulast%3DSingleton%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DE.%2BT.%26aulast%3DEvenoski%26aufirst%3DC.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DMoitra%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DNunez%26aufirst%3DL.%26aulast%3DJacobson%26aufirst%3DJ.%2BR.%26aulast%3DDudek%26aufirst%3DS.%2BM.%26aulast%3DNatarajan%26aufirst%3DV.%26aulast%3DGarcia%26aufirst%3DJ.%2BG.%2BN.%26atitle%3DDifferential%2520effects%2520of%2520sphingosine%25201-phosphate%2520on%2520airway%2520and%2520vascular%2520barrier%2520function%2520in%2520the%2520murine%2520lung%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2010%26volume%3D43%26spage%3D394%26epage%3D402%26doi%3D10.1165%2Frcmb.2009-0223OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocke, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellwig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutbier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonrock, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippenstiel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">N’Guessan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosseau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttorp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witzenrath, M.</span></span> <span> </span><span class="NLM_article-title">The sphingosine-1–phosphate receptor agonist FTY720 dose dependently affected endothelial integrity <i>in vitro</i> and aggravated ventilator-induced lung injury in mice</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2011.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.pupt.2011.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=21419858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjvVGksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=377-385&author=H.+C.+Mullerauthor=A.+C.+Hockeauthor=K.+Hellwigauthor=B.+Gutbierauthor=H.+Petersauthor=S.+M.+Schonrockauthor=T.+Tschernigauthor=A.+Schmiedlauthor=S.+Hippenstielauthor=P.+D.+N%E2%80%99Guessanauthor=S.+Rosseauauthor=N.+Suttorpauthor=M.+Witzenrath&title=The+sphingosine-1%E2%80%93phosphate+receptor+agonist+FTY720+dose+dependently+affected+endothelial+integrity+in+vitro+and+aggravated+ventilator-induced+lung+injury+in+mice&doi=10.1016%2Fj.pupt.2011.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice</span></div><div class="casAuthors">Muller Holger Christian; Hocke Andreas Christian; Hellwig Katharina; Gutbier Birgitt; Peters Harm; Schonrock Stefanie Maria; Tschernig Thomas; Schmiedl Andreas; Hippenstiel Stefan; N'Guessan Philippe Dje; Rosseau Simone; Suttorp Norbert; Witzenrath Martin</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary pharmacology & therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung barrier protection by Sphingosine-1 Phosphate (S1P) has been demonstrated experimentally, but recent evidence suggests barrier disruptive properties of high systemic S1P concentrations.  The S1P analog FTY720 recently gained an FDA approval for treatment of multiple sclerosis.  In case of FTY720 treated patients experiencing multiple organ dysfunction syndrome the drug may accumulate due to liver failure, and the patients may receive ventilator therapy.  Whereas low doses of FTY720 enhanced endothelial barrier function, data on effects of increased FTY720 concentrations are lacking.  We measured transcellular electrical resistance (TER) of human umbilical vein endothelial cell (HUVEC) monolayers, performed morphologic analysis and measured apoptosis by TUNEL staining and procaspase-3 degradation in HUVECs stimulated with FTY720 (0.01-100 μM).  Healthy C57BL/6 mice and mice ventilated with 17 ml/kg tidal volume and 100% oxygen for 2 h were treated with 0.1 or 2 mg/kg FTY720 or solvent, and lung permeability, oxygenation and leukocyte counts in BAL and blood were quantified.  Further, electron microscopic analysis of lung tissue was performed.  We observed barrier protective effects of FTY720 on HUVEC cell layers at concentrations up to 1 μM while higher concentrations induced irreversible barrier breakdown accompanied by induction of apoptosis.  Low FTY720 concentrations (0.1 mg/kg) reduced lung permeability in mechanically ventilated mice, but 2 mg/kg FTY720 increased pulmonary vascular permeability in ventilated mice accompanied by endothelial apoptosis, while not affecting permeability in non-ventilated mice.  Moreover, hyperoxic mechanical ventilation sensitized the pulmonary vasculature to a barrier disrupting effect of FTY720, resulting in worsening of ventilator induced lung injury.  In conclusion, the current data suggest FTY720 induced endothelial barrier dysfunction, which was probably caused by proapoptotic effects and enhanced by mechanical ventilation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnm0D5Ux3vzbt7lRqEFUJVfW6udTcc2eb6dGWDXVGNJbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjvVGksw%253D%253D&md5=1389da129056ace3a9166de853e0a3e1</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DH.%2BC.%26aulast%3DHocke%26aufirst%3DA.%2BC.%26aulast%3DHellwig%26aufirst%3DK.%26aulast%3DGutbier%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DH.%26aulast%3DSchonrock%26aufirst%3DS.%2BM.%26aulast%3DTschernig%26aufirst%3DT.%26aulast%3DSchmiedl%26aufirst%3DA.%26aulast%3DHippenstiel%26aufirst%3DS.%26aulast%3DN%25E2%2580%2599Guessan%26aufirst%3DP.%2BD.%26aulast%3DRosseau%26aufirst%3DS.%26aulast%3DSuttorp%26aufirst%3DN.%26aulast%3DWitzenrath%26aufirst%3DM.%26atitle%3DThe%2520sphingosine-1%25E2%2580%2593phosphate%2520receptor%2520agonist%2520FTY720%2520dose%2520dependently%2520affected%2520endothelial%2520integrity%2520in%2520vitro%2520and%2520aggravated%2520ventilator-induced%2520lung%2520injury%2520in%2520mice%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D24%26spage%3D377%26epage%3D385%26doi%3D10.1016%2Fj.pupt.2011.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit26d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Oo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaul, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2290</span>– <span class="NLM_lpage">2300</span>, <span class="refDoi"> DOI: 10.1172/JCI45403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1172%2FJCI45403" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2290-2300&author=M.+L.+Ooauthor=S.-H.+Changauthor=S.+Thangadaauthor=M.-T.+Wuauthor=K.+Rezaulauthor=V.+Blahoauthor=S.-I.+Hwangauthor=D.+K.+Hanauthor=T.+Hla&title=Engagement+of+S1P%281%29-degradative+mechanisms+leads+to+vascular+leak+in+mice&doi=10.1172%2FJCI45403"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.1172%2FJCI45403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45403%26sid%3Dliteratum%253Aachs%26aulast%3DOo%26aufirst%3DM.%2BL.%26aulast%3DChang%26aufirst%3DS.-H.%26aulast%3DThangada%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DRezaul%26aufirst%3DK.%26aulast%3DBlaho%26aufirst%3DV.%26aulast%3DHwang%26aufirst%3DS.-I.%26aulast%3DHan%26aufirst%3DD.%2BK.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520S1P%25281%2529-degradative%2520mechanisms%2520leads%2520to%2520vascular%2520leak%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2290%26epage%3D2300%26doi%3D10.1172%2FJCI45403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span> <span> </span><span class="NLM_article-title">The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening</span>. <i>Br. J. Pharamacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02118.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fj.1476-5381.2012.02118.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22845396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=304-317&author=J.+M.+Khanauthor=A.+R.+Lyonauthor=S.+E.+Harding&title=The+case+for+induced+pluripotent+stem+cell-derived+cardiomyocytes+in+pharmacological+screening&doi=10.1111%2Fj.1476-5381.2012.02118.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening</span></div><div class="casAuthors">Khan, Jaffar M.; Lyon, Alexander R.; Harding, Sian E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-317</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The current drug screening models are deficient, particularly in detecting cardiac side effects.  Human stem cell-derived cardiomyocytes could aid both early cardiotoxicity detection and novel drug discovery.  Work over the last decade has generated human embryonic stem cells as potentially accurate sources of human cardiomyocytes, but ethical constraints and poor efficacy in establishing cell lines limit their use.  Induced pluripotent stem cells do not require the use of human embryos and have the added advantage of producing patient-specific cardiomyocytes, allowing both generic and disease- and patient-specific pharmacol. screening, as well as drug development through disease modeling.  A crit. question is whether sufficient stds. have been achieved in the reliable and reproducible generation of "adult-like" cardiomyocytes from human fibroblast tissue to progress from validation to safe use in practice and drug discovery.  This review will highlight the need for a new exptl. system, assess the validity of human induced pluripotent stem cell-derived cardiomyocytes and explore what the future may hold for their use in pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF1oDJmQ4dyLVg90H21EOLACvtfcHk0lj2ozHag_MEGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7w%253D&md5=86a904e75a13cdc3282b35f5e6a6b2d3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02118.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02118.x%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BM.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26atitle%3DThe%2520case%2520for%2520induced%2520pluripotent%2520stem%2520cell-derived%2520cardiomyocytes%2520in%2520pharmacological%2520screening%26jtitle%3DBr.%2520J.%2520Pharamacol.%26date%3D2013%26volume%3D169%26spage%3D304%26epage%3D317%26doi%3D10.1111%2Fj.1476-5381.2012.02118.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G. L.</span>; <span class="NLM_string-name">Bhaskaran, V.</span>; <span class="NLM_string-name">Lecureux, L.</span>; <span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-Phosphate Receptor 1 (S1PR1) Agonists Cause Proliferative and Pro-fibrotic Changes in Rat Lung</span>. Presented at <span class="NLM_publisher-name">Society of Toxicology Meeting</span>, <span class="NLM_publisher-loc">Baltimore, MD</span>, March 12–16, <span class="NLM_year">2017</span>; paper  <span class="NLM_fpage">1668</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=1668&author=G.+L.+Gong&author=V.+Bhaskaran&author=L.+Lecureux&author=L.+D.+Lehman-McKeeman&title=Sphingosine-1-Phosphate+Receptor+1+%28S1PR1%29+Agonists+Cause+Proliferative+and+Pro-fibrotic+Changes+in+Rat+Lung"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DG.%2BL.%26atitle%3DSphingosine-1-Phosphate%2520Receptor%25201%2520%2528S1PR1%2529%2520Agonists%2520Cause%2520Proliferative%2520and%2520Pro-fibrotic%2520Changes%2520in%2520Rat%2520Lung%26pub%3DSociety%2520of%2520Toxicology%2520Meeting%26date%3D2017%26spage%3D1668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span> <span> </span><span class="NLM_article-title">Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">632</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/j.ahj.2014.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.ahj.2014.06.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=25440790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFSjtbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2014&pages=632-644&author=J.+Cammauthor=T.+Hlaauthor=R.+Bakshiauthor=V.+Brinkmann&title=Cardiac+and+vascular+effects+of+fingolimod%3A+mechanistic+basis+and+clinical+implications&doi=10.1016%2Fj.ahj.2014.06.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications</span></div><div class="casAuthors">Camm, John; Hla, Timothy; Bakshi, Rajesh; Brinkmann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">American Heart Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">632-644</span>CODEN:
                <span class="NLM_cas:coden">AHJOA2</span>;
        ISSN:<span class="NLM_cas:issn">0002-8703</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine-1-phosphate receptor (S1PR) modulator, was the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis; it reduces autoreactive lymphocytes' egress from lymphoid tissues by down-regulating S1PRs.  Sphingosine-1-phosphate signaling is implicated in a range of physiol. functions, and S1PRs are expressed differentially in various tissues, including the cardiovascular system.  Modulation of S1PRs on cardiac cells provides an explanation for the transient effects of fingolimod on heart rate and atrioventricular conduction at initiation of fingolimod therapy, and for the mild but more persistent effects on blood pressure obsd. in some patients on long-term treatment.  This review describes the nontherapeutic actions of fingolimod in the context of sphingosine-1-phosphate signaling in the cardiovascular system, as well as providing a summary of the assocd. clin. implications useful to physicians considering initiation of fingolimod therapy in patients.  A transient redn. in heart rate (mean decrease of 8 beats per min) and, less commonly, a temporary delay in atrioventricular conduction obsd. in some patients when initiating fingolimod therapy are both due to activation of S1PR subtype 1 on cardiac myocytes.  These effects are a reflection of fingolimod first acting as a full S1PR agonist and thereafter functioning as an S1PR antagonist after down-regulation of S1PR subtype 1 at the cell surface.  For most individuals, first-dose effects of fingolimod are asymptomatic, but all patients need to be monitored for at least 6 h after the first dose, in accordance with the label recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovWJ_QWgnozbVg90H21EOLACvtfcHk0lj2ozHag_MEGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFSjtbvF&md5=1e9ea571e48690f02a8cc5310636fd66</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2014.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2014.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DBakshi%26aufirst%3DR.%26aulast%3DBrinkmann%26aufirst%3DV.%26atitle%3DCardiac%2520and%2520vascular%2520effects%2520of%2520fingolimod%253A%2520mechanistic%2520basis%2520and%2520clinical%2520implications%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2014%26volume%3D168%26spage%3D632%26epage%3D644%26doi%3D10.1016%2Fj.ahj.2014.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J. E.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological models to assess demyelination and remyelination</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1038/npp.2008.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fnpp.2008.145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=18800062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=55-73&author=J.+E.+Merrill&title=In+vitro+and+in+vivo+pharmacological+models+to+assess+demyelination+and+remyelination&doi=10.1038%2Fnpp.2008.145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination</span></div><div class="casAuthors">Merrill, Jean E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-73</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In making a selection of cellular tools and animal models for generating screening assays in the search for new drugs, one needs to take into consideration the practicality of their use in the drug discovery process.  Conducting high-throughput primary screens using libraries of small mols., close to 1 million members in size, requires the generation of large nos. of cells which are easily acquired, reliably enriched, and reproducibly responsive to std. pos. controls.  These cells need to be similar in form and function to their counterparts in human disease.  In vitro assays that can be mechanized by using robots can therefore save time and costs.  In selecting in vivo models, consideration must be given to the species and strain of animal chosen, the appropriateness of the model to human disease, the extent of animal husbandry required during the in-life pharmacol. assessment, the tech. aspects of generating the model and harvesting the tissues for analyses, the cost of research tools in terms of time and money (demyelinating and remyelinating agents, amt. of compd. to be generated), and the length of time required for drug testing in the model.  A consideration of the translational aspects of the in vivo model compared to those used in the clinic is also important.  These themes will be developed with examples for drug discovery in the field of CNS demyelination and repair, specifically as it pertains to multiple sclerosis.  Neuropsychopharmacol. (2009) 34, 55-73; doi:10.1038/npp.2008.145; published online 17 Sept. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjK7BPEmVTWLVg90H21EOLACvtfcHk0lhChE_QSi4CZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7vN&md5=fe9c0fc0d6d677612b081621bf32ea42</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.145%26sid%3Dliteratum%253Aachs%26aulast%3DMerrill%26aufirst%3DJ.%2BE.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520models%2520to%2520assess%2520demyelination%2520and%2520remyelination%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D55%26epage%3D73%26doi%3D10.1038%2Fnpp.2008.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dev, K. K.</span></span> <span> </span><span class="NLM_article-title">S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1002/glia.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1002%2Fglia.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22108845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A280%3ADC%252BC387mvFeltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=382-392&author=G.+K.+Sheridanauthor=K.+K.+Dev&title=S1P1+receptor+subtype+inhibits+demyelination+and+regulates+chemokine+release+in+cerebellar+slice+cultures&doi=10.1002%2Fglia.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures</span></div><div class="casAuthors">Sheridan Graham K; Dev Kumlesh K</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sphingosine-1-phosphate receptors (S1PRs) are drug targets for the compound FTY720, which is the first oral therapy developed for treatment of relapsing-remitting multiple sclerosis.  S1PRs play a variety of functional roles in the differentiation, proliferation, survival and/or migration of neurons and glia.  In this study, rat organotypic cerebellar slice cultures were used to assess whether S1PRs play a role in demyelination induced by lysolecithin (LPC).  The data demonstrated that FTY720 and SEW2871 (a S1P1R-specific agonist) inhibited LPC-induced demyelination as assessed by myelin basic protein (MBP) immunofluorescence.  Treatment with both drugs for 48 h also induced an increase in S1P1R expression in astrocytes.  Moreover, FTY720 and SEW2871 inhibited the release of several chemokines in conditions of LPC-induced demyelination, including LIX (CXCL5), MIP-1alpha, and MIP-3alpha.  Taken together, the data suggest that activation of S1P1Rs prevents LPC-induced demyelination via a mechanism involving a reduction of chemotactic chemokine release.  The study supports the concept that FTY720 attenuates demyelination by not only preventing S1PR-mediated T cell migration into the CNS but also by limiting cytokine communication between cells of the immune system and the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0i22J0AjP3DMsgLhIoICsfW6udTcc2eaFyd7OzHCFTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387mvFeltA%253D%253D&md5=17308ee161b253fb4a7ad341edbe6534</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fglia.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.22272%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DG.%2BK.%26aulast%3DDev%26aufirst%3DK.%2BK.%26atitle%3DS1P1%2520receptor%2520subtype%2520inhibits%2520demyelination%2520and%2520regulates%2520chemokine%2520release%2520in%2520cerebellar%2520slice%2520cultures%26jtitle%3DGlia%26date%3D2012%26volume%3D60%26spage%3D382%26epage%3D392%26doi%3D10.1002%2Fglia.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, S.</span></span> <span> </span><span class="NLM_article-title">Dissecting demyelination</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1354</span>, <span class="refDoi"> DOI: 10.1038/nn1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fnn1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17965654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ajsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=1351-1354&author=R.+H.+Millerauthor=S.+Mi&title=Dissecting+demyelination&doi=10.1038%2Fnn1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting demyelination</span></div><div class="casAuthors">Miller, Robert H.; Mi, Sha</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1351-1354</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The loss of central nervous system myelin and the failure of remyelination by oligodendrocytes contribute to the functional impairment that characterizes diseases such as multiple sclerosis.  Why myelin repair fails in multiple sclerosis is currently unclear; however, new understanding of the generation of oligodendrocytes and myelination during development, as well as an increasing understanding of the bases of successful remyelination, are providing new insights and therapeutic targets.  We propose that successful myelin repair of the adult CNS recapitulates a sequence of stages that generally correlate with those seen during development, whereas unsuccessful myelin repair results from the perturbation of a crit. process in any one of several sequential events.  Defining the rate-limiting steps and most vulnerable aspects at each stage of myelin repair will provide logical targets for therapeutic intervention in demyelinating diseases such as multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxyvKG-czMIrVg90H21EOLACvtfcHk0lhChE_QSi4CZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ajsbbJ&md5=2f95a264434d134c678dace5c77c1bc2</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1038%2Fnn1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1995%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BH.%26aulast%3DMi%26aufirst%3DS.%26atitle%3DDissecting%2520demyelination%26jtitle%3DNat.%2520Neurosci.%26date%3D2007%26volume%3D10%26spage%3D1351%26epage%3D1354%26doi%3D10.1038%2Fnn1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Slowik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, M.</span></span> <span> </span><span class="NLM_article-title">The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1111/bph.12938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fbph.12938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=25220526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=80-92&author=A.+Slowikauthor=T.+Schmidtauthor=C.+Beyerauthor=S.+Amorauthor=T.+Clarnerauthor=M.+Kipp&title=The+sphingosine+1-phosphate+receptor+agonist+FTY720+is+neuroprotective+after+cuprizone-induced+CNS+demyelination&doi=10.1111%2Fbph.12938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination</span></div><div class="casAuthors">Slowik, A.; Schmidt, T.; Beyer, C.; Amor, S.; Clarner, T.; Kipp, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-92</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes within the lymph nodes.  Here, we evaluated the potential of an agonist at this receptor, FTY720 (fingolimod), to activate the promyelinating pathways within the brain to encourage remyelination and neuroprotection.  Exptl. Approach : In this study, we used the cuprizone model in male C57BL/6 mice and tested the promyelinating and neuroprotective effects of FTY720 after acute and chronic toxin-induced exptl. demyelination.  We used histol., immunohistochem. and gene expression methods.  Key Results : The midline of the corpus callosum was severely demyelinated after acute and chronic cuprizone-induced demyelination.  Robust endogenous remyelination was evident after acute, but impaired after chronic, demyelination.  FTY720 treatment modestly accelerated myelin recovery after acute but not chronic cuprizone exposure.  Markers of gliosis (astrocyte and microglia activation) were not affected by FTY720 treatment.  Remarkably, the accumulation of amyloid precursor protein-pos. spheroids in axons was less distinct in FTY720-treated animals, indicating that this compd. alleviated ongoing axonal damage.  Conclusions and Implications : We show that even during endogenous remyelination, axonal degeneration continued at a low level, accumulating over time.  This continuous neurodegenerative process was ameliorated by FTY720 treatment.  FTY720 preserved CNS integrity by direct interaction with brain resident cells, the actions of which are still to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRi-heBO2_H7Vg90H21EOLACvtfcHk0liAkIFwHx56kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3J&md5=ee2c20b31e7a7e0766cc604621c070de</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1111%2Fbph.12938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12938%26sid%3Dliteratum%253Aachs%26aulast%3DSlowik%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DT.%26aulast%3DBeyer%26aufirst%3DC.%26aulast%3DAmor%26aufirst%3DS.%26aulast%3DClarner%26aufirst%3DT.%26aulast%3DKipp%26aufirst%3DM.%26atitle%3DThe%2520sphingosine%25201-phosphate%2520receptor%2520agonist%2520FTY720%2520is%2520neuroprotective%2520after%2520cuprizone-induced%2520CNS%2520demyelination%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D80%26epage%3D92%26doi%3D10.1111%2Fbph.12938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Assymetric hydroboration approach to the scalable synthesis of ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-hexyl-5,6,7,8-tetrahydronaphalen-2-yl)cyclopentyl)methanol (BMS-986104) as a potent S1P receptor modulator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">11138</span>– <span class="NLM_lpage">11147</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01433</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01433" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=11138-11147&author=M.+G.+Yangauthor=Z.+Xiaoauthor=T.+G.+M.+Dharauthor=H.-Y.+Xiaoauthor=J.+L.+Gilmoreauthor=D.+Marcouxauthor=J.+H.+Xieauthor=K.+W.+McIntyreauthor=T.+L.+Taylorauthor=V.+Borowskiauthor=E.+M.+Heimrichauthor=Y.-W.+Liauthor=J.+Fengauthor=A.+Fernandesauthor=Z.+Yangauthor=P.+Balimaneauthor=A.+Marinoauthor=G.+Corneliusauthor=B.+Warrackauthor=A.+Mathurauthor=D.-R.+Wuauthor=P.+Liauthor=A.+Guptaauthor=B.+Pragalathanauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+D.+Lehman-McKeemanauthor=L.+Salter-cidauthor=J.+C.+Barrishauthor=P.+C.+Carterauthor=A.+J.+Dyckman&title=Assymetric+hydroboration+approach+to+the+scalable+synthesis+of+%28%281R%2C3S%29-1-amino-3-%28%28R%29-6-hexyl-5%2C6%2C7%2C8-tetrahydronaphalen-2-yl%29cyclopentyl%29methanol+%28BMS-986104%29+as+a+potent+S1P+receptor+modulator&doi=10.1021%2Facs.jmedchem.6b01433"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01433%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%2BG.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXiao%26aufirst%3DH.-Y.%26aulast%3DGilmore%26aufirst%3DJ.%2BL.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.-W.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DSalter-cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DAssymetric%2520hydroboration%2520approach%2520to%2520the%2520scalable%2520synthesis%2520of%2520%2528%25281R%252C3S%2529-1-amino-3-%2528%2528R%2529-6-hexyl-5%252C6%252C7%252C8-tetrahydronaphalen-2-yl%2529cyclopentyl%2529methanol%2520%2528BMS-986104%2529%2520as%2520a%2520potent%2520S1P%2520receptor%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D11138%26epage%3D11147%26doi%3D10.1021%2Facs.jmedchem.6b01433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozelle, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy results from pivotal clinical trials with abatacept</span>. <i>Clin. Exp. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">S30</span>– <span class="NLM_lpage">S34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17977486" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=S30-S34&author=A.+L.+Rozelleauthor=M.+C.+Genovese&title=Efficacy+results+from+pivotal+clinical+trials+with+abatacept"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRozelle%26aufirst%3DA.%2BL.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DEfficacy%2520results%2520from%2520pivotal%2520clinical%2520trials%2520with%2520abatacept%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2007%26volume%3D25%26spage%3DS30%26epage%3DS34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bihorel, S.</span>; <span class="NLM_string-name">Singhal, S.</span>; <span class="NLM_string-name">Shevell, D.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Basdeo, S.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">Dutta, S.</span>; <span class="NLM_string-name">Huang, H.</span>; <span class="NLM_string-name">Lin, K.</span>; <span class="NLM_string-name">Throup, J.</span>; <span class="NLM_string-name">Girgis, I.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic analysis of BMS-986166, a novel selective sphingosine-1-phosphate 1 receptor modulator, and exposure-response assessment of its effects on lymphocyte counts and heart rate in healthy participants unpublished results</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bihorel%2C+S.%3B+Singhal%2C+S.%3B+Shevell%2C+D.%3B+Sun%2C+H.%3B+Xie%2C+J.%3B+Basdeo%2C+S.%3B+Liu%2C+A.%3B+Dutta%2C+S.%3B+Huang%2C+H.%3B+Lin%2C+K.%3B+Throup%2C+J.%3B+Girgis%2C+I.+Population+pharmacokinetic+analysis+of+BMS-986166%2C+a+novel+selective+sphingosine-1-phosphate+1+receptor+modulator%2C+and+exposure-response+assessment+of+its+effects+on+lymphocyte+counts+and+heart+rate+in+healthy+participants+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DBihorel%26aufirst%3DS.%26atitle%3DPopulation%2520pharmacokinetic%2520analysis%2520of%2520BMS-986166%252C%2520a%2520novel%2520selective%2520sphingosine-1-phosphate%25201%2520receptor%2520modulator%252C%2520and%2520exposure-response%2520assessment%2520of%2520its%2520effects%2520on%2520lymphocyte%2520counts%2520and%2520heart%2520rate%2520in%2520healthy%2520participants%2520unpublished%2520results" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span>; <span class="NLM_string-name">Dyckman, A. J.</span>; <span class="NLM_string-name">Xiao, Z.</span>; <span class="NLM_string-name">Yang, M. G.</span>; <span class="NLM_string-name">Dhar, T. G. M.</span>; <span class="NLM_string-name">Gilmore, J. L.</span>; <span class="NLM_string-name">Marcoux, D.</span></span>; <span> </span><span class="NLM_article-title">Substituted Bicyclic Compounds</span>. U.S. Pat. Appl. <span class="NLM_patent">0052888</span>, World Patent <span class="NLM_patent">WO201628959</span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.-Y.+Xiao&author=A.+J.+Dyckman&author=Z.+Xiao&author=M.+G.+Yang&author=T.+G.+M.+Dhar&author=J.+L.+Gilmore&author=D.+Marcoux&title=Substituted+Bicyclic+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DH.-Y.%26atitle%3DSubstituted%2520Bicyclic%2520Compounds%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+Obachauthor=J.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0ljTJN2ypEZVog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%26aulast%3DBaxter%26aufirst%3DJ.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c','cit15d'],'ref16':[],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':[],'ref21':[],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26a','cit26b','cit26c','cit26d'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">John L. Gilmore, Hai-Yun Xiao, T. G. Murali Dhar, Michael Yang, Zili Xiao, Xiaoxia Yang, Tracy L. Taylor, Kim W. McIntyre, Bethanne M. Warrack, Hong Shi, Paul C. Levesque, Anthony M. Marino, Georgia Cornelius, Arvind Mathur, Ding Ren Shen, Jian Pang, Mary Ellen Cvijic, Lois D. Lehman-McKeeman, Huadong Sun, Jenny Xie, Luisa Salter-Cid, Percy H. Carter, <span class="NLM_string-name hlFld-ContribAuthor">Alaric J. Dyckman</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic Ligand-Biased Agonists of S1P1: Exploring Side Chain Modifications to Modulate the PK, PD, and Safety Profiles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1454-1480. <a href="https://doi.org/10.1021/acs.jmedchem.0c01109" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01109%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBicyclic%252BLigand-Biased%252BAgonists%252Bof%252BS1P1%25253A%252BExploring%252BSide%252BChain%252BModifications%252Bto%252BModulate%252Bthe%252BPK%25252C%252BPD%25252C%252Band%252BSafety%252BProfiles%26aulast%3DGilmore%26aufirst%3DJohn%2BL.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29062020%26date%3D25012021%26volume%3D64%26issue%3D3%26spage%3D1454%26epage%3D1480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zili Xiao, Michael G. Yang, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, David Marcoux, Kim W. McIntyre, Tracy L. Taylor, Hong Shi, Paul C. Levesque, Anthony M. Marino, Georgia Cornelius, Arvind Mathur, Ding Ren Shen, Mary Ellen Cvijic, Lois D. Lehman-McKeeman, Huadong Sun, Jenny H. Xie, Percy H. Carter, <span class="NLM_string-name hlFld-ContribAuthor">Alaric J. Dyckman</span>. </span><span class="cited-content_cbyCitation_article-title">Aryl Ether-Derived Sphingosine-1-Phosphate Receptor (S1P1) Modulators: Optimization of the PK, PD, and Safety Profiles. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (9)
                                     , 1766-1772. <a href="https://doi.org/10.1021/acsmedchemlett.0c00333" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00333</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00333%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAryl%252BEther-Derived%252BSphingosine-1-Phosphate%252BReceptor%252B%252528S1P1%252529%252BModulators%25253A%252BOptimization%252Bof%252Bthe%252BPK%25252C%252BPD%25252C%252Band%252BSafety%252BProfiles%26aulast%3DXiao%26aufirst%3DZili%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16062020%26date%3D11082020%26date%3D14082020%26date%3D11082020%26volume%3D11%26issue%3D9%26spage%3D1766%26epage%3D1772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Federica  Cirillo</span>, <span class="hlFld-ContribAuthor ">Marco  Piccoli</span>, <span class="hlFld-ContribAuthor ">Andrea  Ghiroldi</span>, <span class="hlFld-ContribAuthor ">Michelle M.  Monasky</span>, <span class="hlFld-ContribAuthor ">Paola  Rota</span>, <span class="hlFld-ContribAuthor ">Paolo  La Rocca</span>, <span class="hlFld-ContribAuthor ">Adriana  Tarantino</span>, <span class="hlFld-ContribAuthor ">Sara  D'Imperio</span>, <span class="hlFld-ContribAuthor ">Paola  Signorelli</span>, <span class="hlFld-ContribAuthor ">Carlo  Pappone</span>, <span class="hlFld-ContribAuthor ">Luigi  Anastasia</span>. </span><span class="cited-content_cbyCitation_article-title">The antithetic role of ceramide and sphingosine‐1‐phosphate in cardiac dysfunction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2021,</strong> <em>236 </em>
                                    (7)
                                     , 4857-4873. <a href="https://doi.org/10.1002/jcp.30235" title="DOI URL">https://doi.org/10.1002/jcp.30235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.30235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.30235%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DThe%252Bantithetic%252Brole%252Bof%252Bceramide%252Band%252Bsphingosine%2525E2%252580%2525901%2525E2%252580%252590phosphate%252Bin%252Bcardiac%252Bdysfunction%26aulast%3DCirillo%26aufirst%3DFederica%26date%3D2021%26date%3D2021%26volume%3D236%26issue%3D7%26spage%3D4857%26epage%3D4873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sébastien  Bihorel</span>, <span class="hlFld-ContribAuthor ">Shalabh  Singhal</span>, <span class="hlFld-ContribAuthor ">Diane  Shevell</span>, <span class="hlFld-ContribAuthor ">Huadong  Sun</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, <span class="hlFld-ContribAuthor ">Shenita  Basdeo</span>, <span class="hlFld-ContribAuthor ">Ang  Liu</span>, <span class="hlFld-ContribAuthor ">Santanu  Dutta</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Ludwig</span>, <span class="hlFld-ContribAuthor ">Hannah  Huang</span>, <span class="hlFld-ContribAuthor ">Kuan‐ju  Lin</span>, <span class="hlFld-ContribAuthor ">Aberra  Fura</span>, <span class="hlFld-ContribAuthor ">John  Throup</span>, <span class="hlFld-ContribAuthor ">Ihab G.  Girgis</span>. </span><span class="cited-content_cbyCitation_article-title">Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2021,</strong> <em>10 </em>
                                    (1)
                                     , 8-21. <a href="https://doi.org/10.1002/cpdd.878" title="DOI URL">https://doi.org/10.1002/cpdd.878</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.878&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.878%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DPopulation%252BPharmacokinetic%252BAnalysis%252Bof%252BBMS%2525E2%252580%252590986166%25252C%252Ba%252BNovel%252BSelective%252BSphingosine%2525E2%252580%2525901%2525E2%252580%252590Phosphate%2525E2%252580%2525901%252BReceptor%252BModulator%25252C%252Band%252BExposure%2525E2%252580%252590Response%252BAssessment%252Bof%252BLymphocyte%252BCounts%252Band%252BHeart%252BRate%252Bin%252BHealthy%252BParticipants%26aulast%3DBihorel%26aufirst%3DS%25C3%25A9bastien%26date%3D2021%26date%3D2020%26volume%3D10%26issue%3D1%26spage%3D8%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shalabh  Singhal</span>, <span class="hlFld-ContribAuthor ">Ihab G.  Girgis</span>, <span class="hlFld-ContribAuthor ">Jenny  Xie</span>, <span class="hlFld-ContribAuthor ">Santanu  Dutta</span>, <span class="hlFld-ContribAuthor ">Diane E.  Shevell</span>, <span class="hlFld-ContribAuthor ">John  Throup</span>. </span><span class="cited-content_cbyCitation_article-title">The safety and pharmacokinetics of a novel, selective S1P1R modulator in healthy participants. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (4)
                                     , 411-422. <a href="https://doi.org/10.1080/13543784.2020.1742322" title="DOI URL">https://doi.org/10.1080/13543784.2020.1742322</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1742322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1742322%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DThe%252Bsafety%252Band%252Bpharmacokinetics%252Bof%252Ba%252Bnovel%25252C%252Bselective%252BS1P1R%252Bmodulator%252Bin%252Bhealthy%252Bparticipants%26aulast%3DSinghal%26aufirst%3DShalabh%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D4%26spage%3D411%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Incorporation of aryl and heteroaryl side chains.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 6-Substituted-((1<i>R</i>,3<i>S</i>)-1-amino-3-(5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NaBH<sub>4</sub>, MeOH, 91%; (b) CDI, dioxane, 87%; (c) LiHMDS, (2-(<i>tert</i>-butoxy)-2-oxoethyl)zinc(II) bromide, THF; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, Q-phos, 80 °C, 85%; (e) TFA, DCM; (f) oxalyl chloride; (g) ethylene, AlCl<sub>3</sub>, DCM, 92%; (h) LDA, DMPU; (i) PhN(Tf)<sub>2</sub>, THF, −78 to 0 °C, 60% (2 steps); (j) LiHMDS, Co(acac)<sub>3</sub>, THF/NMP, RMgBr, −40 °C or CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, TEA, alkyne; (k) Pd(OH)<sub>2</sub>, MeOH, H<sub>2</sub>; (l) Chiral SFC separation; (m) 1 N NaOH, dioxane.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Alternate Synthesis of <b>14a</b> and <b>15a</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(OAc)<sub>2</sub>, P(<i>o</i>-Tol)<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O/MeCN, 80 °C; (b) 10% Pd/C, MeOH, H<sub>2</sub>; (c) H<sub>2</sub>SO<sub>4</sub>, 4 h, then MeOH; (d) 10% Pd/C, MeOH, H<sub>2</sub>, 55% yield from <b>4</b>; (e) LiBH<sub>4</sub>, THF, 60 °C, 90%; (f) Chiral SFC separation; (g) TsCl, pyridine, 80–95%; (h) CuBr-DMS, RMgCl, Et<sub>2</sub>O, 93%; (i) 1 N NaOH, dioxane, 57%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 6-Substituted-heterophenethyl Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LiBH<sub>4</sub>, THF, 60 °C, 90%; (b) Swern oxidation, 84%; (c) K<sub>2</sub>CO<sub>3</sub>, dimethyl (1-diazo-2-oxopropyl)phosphonate, 82%; (d) chiral SFC separation, 30–35% of <b>20a</b> and <b>20b</b>; (e) ArBr, Pd(amphos)Cl<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, MeCN, 80 °C, 40–50%; (f) 10% Pd(OH)<sub>2</sub>, MeOH, H<sub>2</sub>, 95%; (g) 1 N NaOH, dioxane; (h) 1-phenyl-1<i>H</i>-tetrazole-5-thiol, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 90%; (i) H<sub>2</sub>O<sub>2</sub>, ammonium molybdate tetrahydrate, 0 °C, 99%; (j) pyrazole aldehydes, KHMDS, 30–40% .</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Reduction in beating rate of human iPSC derived cardiomyocytes in the presence of full S1P<sub>1</sub> agonists with varying S1P<sub>3</sub> agonist profiles versus partial S1P<sub>1</sub> agonists sparing of S1P<sub>3</sub> (average of two experiments).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Efficacy of <b>14a</b> (BMS-986166: 0.1 and 0.5 mg/kg) and <b>1</b> (FTY: 1.0 mg/kg) vs vehicle in a mouse experimental autoimmune encephalomyelitis model (EAE), clinical score (A), and histological evaluation (B). Mice (<i>n</i> = 10/group) were administered <b>14a</b> PO/QD starting on day 0 at the time of immunization with MOG-peptide (myelin oligodendrocyte glycoprotein). Vehicle: PEG300. *<i>p</i> value <0.05 compared to vehicle treatment group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Effect of compounds in lysophosphatidylcholine (LPC)-induced demyelination model. Immunohistochemical staining showing myelination of organotypic cerebellar slices in vehicle (A), in slices incubated overnight with LPC (B), and in slices incubated overnight with LPC followed by treatment with <b>1-P</b> (C) or <b>14a-P</b> (D) for 7 days. Remyelination is induced by subsequent treatment. Myelination index of <b>1-P</b> and <b>14a-P</b> after overnight incubation with LPC followed by 7 days of treatment (E). <sup>a</sup>Incubated with 0.5 mg/mL LPC overnight; *<i>p</i> value 0.05 vs LPS; ANOVA followed by Dunnett test, <i>n</i> = 3–5.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/medium/jm-2018-016956_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy of <b>14a</b> (0.1 and 0.5 mg/kg) and mCTLA4Ig (1.0 mg/kg) vs vehicle in a collagen induced arthritis model (CIA), clinical score (A), and histological evaluation (B). ***<i>p</i> < 0.001 vs vehicle; One-Way ANOVA with Dunnett’s test. <i>N</i> = 10 in each group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-5/acs.jmedchem.8b01695/20190308/images/large/jm-2018-016956_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01695&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i78">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 37 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Billich, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bornancin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechtcheriakova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urtz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumruker, T.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">47408</span>– <span class="NLM_lpage">47415</span>, <span class="refDoi"> DOI: 10.1074/jbc.M307687200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1074%2Fjbc.M307687200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=13129923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47408-47415&author=A.+Billichauthor=F.+Bornancinauthor=P.+Devayauthor=D.+Mechtcheriakovaauthor=N.+Urtzauthor=T.+Baumruker&title=Phosphorylation+of+the+immunomodulatory+drug+FTY720+by+sphingosine+kinases&doi=10.1074%2Fjbc.M307687200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases</span></div><div class="casAuthors">Billich, Andreas; Bornancin, Frederic; Devay, Piroska; Mechtcheriakova, Diana; Urtz, Nicole; Baumruker, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">47408-47415</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The immunomodulatory drug FTY720 is phosphorylated in vivo, and the resulting FTY720 phosphate as a ligand for sphingosine-1-phosphate receptors is responsible for the unique biol. effects of the compd.  So far, phosphorylation of FTY720 by murine sphingosine kinase (SPHK) 1a had been documented.  We found that, while FTY720 is also phosphorylated by human SPHK1, the human type 2 isoform phosphorylates the drug 30-fold more efficiently, because of a lower Km of FTY720 for SPHK2.  Similarly, murine SPHK2 was more efficient than SPHK1a.  Among splice variants of the human SPHKs, an N-terminally extended SPHK2 isoform was even more active than SPHK2 itself.  Further SPHK superfamily members, namely ceramide kinase and a "SPHK-like" protein, failed to phosphorylate sphingosine and FTY720.  Thus, only SPHK1 and 2 appear to be capable of phosphorylating FTY720.  Using selective assay conditions, SPHK1 and 2 activities in murine tissues were measured.  While activity of SPHK2 toward sphingosine was generally lower than of SPHK1, FTY720 phosphorylation was higher under conditions favoring SPHK2.  In human endothelial cells, while activity of SPHK1 toward sphingosine was 2-fold higher than of SPHK2, FTY720 phosphorylation was 7-fold faster under SPHK2 assay conditions.  Finally, FTY720 was poorly phosphorylated in human blood as compared with rodent blood, in line with the low activity of SPHK1 and in particular of SPHK2 in human blood.  To conclude, both SPHK1 and 2 are capable of phosphorylating FTY720, but SPHK2 is quant. more important than SPHK1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrR5e-dVWnBT7Vg90H21EOLACvtfcHk0lhuJIuQRTT5Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpt1Cqtr0%253D&md5=26820503680682863dc76a69ea02fc7e</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M307687200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M307687200%26sid%3Dliteratum%253Aachs%26aulast%3DBillich%26aufirst%3DA.%26aulast%3DBornancin%26aufirst%3DF.%26aulast%3DDevay%26aufirst%3DP.%26aulast%3DMechtcheriakova%26aufirst%3DD.%26aulast%3DUrtz%26aufirst%3DN.%26aulast%3DBaumruker%26aufirst%3DT.%26atitle%3DPhosphorylation%2520of%2520the%2520immunomodulatory%2520drug%2520FTY720%2520by%2520sphingosine%2520kinases%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47408%26epage%3D47415%26doi%3D10.1074%2Fjbc.M307687200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Albert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller-Hartwieg, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knecht, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streiff, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welzenbach, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zécri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francotte, E.</span></span> <span> </span><span class="NLM_article-title">Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">5373</span>– <span class="NLM_lpage">5377</span>, <span class="refDoi"> DOI: 10.1021/jm050242f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050242f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=5373-5377&author=R.+Albertauthor=K.+Hinterdingauthor=V.+Brinkmannauthor=D.+Gueriniauthor=C.+Muller-Hartwiegauthor=H.+Knechtauthor=C.+Simeonauthor=M.+Streiffauthor=T.+Wagnerauthor=K.+Welzenbachauthor=F.+Z%C3%A9criauthor=M.+Zollingerauthor=N.+Cookeauthor=E.+Francotte&title=Novel+immunomodulator+FTY720+is+phosphorylated+in+rats+and+humans+to+form+a+single+stereoisomer.+Identification%2C+chemical+proof%2C+and+biological+characterization+of+the+biologically+active+species+and+its+enantiomer&doi=10.1021%2Fjm050242f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans To Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer</span></div><div class="casAuthors">Albert, Rainer; Hinterding, Klaus; Brinkmann, Volker; Guerini, Danilo; Mueller-Hartwieg, Constanze; Knecht, Helmut; Simeon, Corinne; Streiff, Markus; Wagner, Trixie; Welzenbach, Karl; Zecri, Frederic; Zollinger, Markus; Cooke, Nigel; Francotte, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5373-5377</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In vivo phosphorylation of FTY720 (1) in rats and humans resulted exclusively in the biol. active (S)-configured enantiomer, which was proven by an ex vivo o-phthaldialdehyde derivatization protocol esp. elaborated for phosphates of 1.  Starting from the prochiral amino alc. 1, racemic and enantiomerically pure phosphates of 1 were synthesized.  Pure enantiomers were obtained after purifn. of a partially protected key intermediate on an enantioselective support.  The abs. stereochem. was detd. by x-ray diffraction.  Data on human and rat studies are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh0U1_F0bQtLVg90H21EOLACvtfcHk0ljG-BZIzjWsTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVWisr4%253D&md5=34b956ad7d7e60c2013e66320a88560e</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fjm050242f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050242f%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DMuller-Hartwieg%26aufirst%3DC.%26aulast%3DKnecht%26aufirst%3DH.%26aulast%3DSimeon%26aufirst%3DC.%26aulast%3DStreiff%26aufirst%3DM.%26aulast%3DWagner%26aufirst%3DT.%26aulast%3DWelzenbach%26aufirst%3DK.%26aulast%3DZ%25C3%25A9cri%26aufirst%3DF.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DCooke%26aufirst%3DN.%26aulast%3DFrancotte%26aufirst%3DE.%26atitle%3DNovel%2520immunomodulator%2520FTY720%2520is%2520phosphorylated%2520in%2520rats%2520and%2520humans%2520to%2520form%2520a%2520single%2520stereoisomer.%2520Identification%252C%2520chemical%2520proof%252C%2520and%2520biological%2520characterization%2520of%2520the%2520biologically%2520active%2520species%2520and%2520its%2520enantiomer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D5373%26epage%3D5377%26doi%3D10.1021%2Fjm050242f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartung, H.</span></span> <span> </span><span class="NLM_article-title">Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis</span>. <i>Clin. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">101</span>, <span class="refDoi"> DOI: 10.1097/WNF.0b013e3181cbf825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1097%2FWNF.0b013e3181cbf825" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2010&pages=91-101&author=J.+Chunauthor=H.+Hartung&title=Mechanism+of+action+of+oral+fingolimod+%28FTY720%29+in+multiple+sclerosis&doi=10.1097%2FWNF.0b013e3181cbf825"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1097%2FWNF.0b013e3181cbf825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FWNF.0b013e3181cbf825%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DHartung%26aufirst%3DH.%26atitle%3DMechanism%2520of%2520action%2520of%2520oral%2520fingolimod%2520%2528FTY720%2529%2520in%2520multiple%2520sclerosis%26jtitle%3DClin.%2520Neuropharmacol.%26date%3D2010%26volume%3D33%26spage%3D91%26epage%3D101%26doi%3D10.1097%2FWNF.0b013e3181cbf825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mandala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajdu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergstrom, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quackenbush, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shei, G.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Card, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keohane, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenbach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupprecht, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">346</span>– <span class="NLM_lpage">349</span>, <span class="refDoi"> DOI: 10.1126/science.1070238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1126%2Fscience.1070238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=11923495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2002&pages=346-349&author=S.+Mandalaauthor=R.+Hajduauthor=J.+Bergstromauthor=E.+Quackenbushauthor=J.+Xieauthor=J.+Milliganauthor=R.+Thorntonauthor=G.-J.+Sheiauthor=D.+Cardauthor=C.+A.+Keohaneauthor=M.+Rosenbachauthor=J.+Haleauthor=C.+L.+Lynchauthor=K.+Rupprechtauthor=W.+Parsonsauthor=H.+Rosen&title=Alteration+of+lymphocyte+trafficking+by+sphingosine-1-phosphate+receptor+agonists&doi=10.1126%2Fscience.1070238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists</span></div><div class="casAuthors">Mandala, Suzanne; Hajdu, Richard; Bergstrom, James; Quackenbush, Elizabeth; Xie, Jenny; Milligan, James; Thornton, Rosemary; Shei, Gan-Ju; Card, Deborah; Keohane, Carolann; Rosenbach, Mark; Hale, Jeffrey; Lynch, Christopher L.; Rupprecht, Kathleen; Parsons, William; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue">5566</span>),
    <span class="NLM_cas:pages">346-349</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Blood lymphocyte nos., essential for the development of efficient immune responses, are maintained by recirculation through secondary Lymphoid organs.  We show that lymphocyte trafficking is altered by the lysophospholipid sphingosine-1-phosphate (S1P) and by a phosphoryl metabolite of the immunosuppressive agent FTY720.  Both species were high-affinity agonists of at least four of the five S1P receptors.  These agonists produce lymphopenia in blood and thoracic duct lymph by sequestration of lymphocytes in lymph nodes, but not spleen.  S1P receptor agonists induced emptying of lymphoid sinuses by retention of lymphocytes on the abluminal side of sinus-lining endothelium and inhibition of egress into lymph.  Inhibition of lymphocyte recirculation by activation of S1P receptors may result in therapeutically useful immunosuppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPvwG_lLsA8LVg90H21EOLACvtfcHk0ljG-BZIzjWsTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtVWhsrc%253D&md5=b57cbcffe41d144e701dbd42459cf38a</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.1070238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1070238%26sid%3Dliteratum%253Aachs%26aulast%3DMandala%26aufirst%3DS.%26aulast%3DHajdu%26aufirst%3DR.%26aulast%3DBergstrom%26aufirst%3DJ.%26aulast%3DQuackenbush%26aufirst%3DE.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DMilligan%26aufirst%3DJ.%26aulast%3DThornton%26aufirst%3DR.%26aulast%3DShei%26aufirst%3DG.-J.%26aulast%3DCard%26aufirst%3DD.%26aulast%3DKeohane%26aufirst%3DC.%2BA.%26aulast%3DRosenbach%26aufirst%3DM.%26aulast%3DHale%26aufirst%3DJ.%26aulast%3DLynch%26aufirst%3DC.%2BL.%26aulast%3DRupprecht%26aufirst%3DK.%26aulast%3DParsons%26aufirst%3DW.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DAlteration%2520of%2520lymphocyte%2520trafficking%2520by%2520sphingosine-1-phosphate%2520receptor%2520agonists%26jtitle%3DScience%26date%3D2002%26volume%3D296%26spage%3D346%26epage%3D349%26doi%3D10.1126%2Fscience.1070238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottens, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hof, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prieschl, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumruker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiestand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foster, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollinger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span> <span> </span><span class="NLM_article-title">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>277</i></span>,  <span class="NLM_fpage">21453</span>– <span class="NLM_lpage">21457</span>, <span class="refDoi"> DOI: 10.1074/jbc.C200176200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1074%2Fjbc.C200176200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=11967257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=21453-21457&author=V.+Brinkmannauthor=M.+D.+Davisauthor=C.+E.+Heiseauthor=R.+Albertauthor=S.+Cottensauthor=R.+Hofauthor=C.+Brunsauthor=E.+Prieschlauthor=T.+Baumrukerauthor=P.+Hiestandauthor=C.+A.+Fosterauthor=M.+Zollingerauthor=K.+R.+Lynch&title=The+immune+modulator+FTY720+targets+sphingosine+1-phosphate+receptors&doi=10.1074%2Fjbc.C200176200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The immune modulator FTY720 targets sphingosine 1-phosphate receptors</span></div><div class="casAuthors">Brinkmann, Volker; Davis, Michael D.; Heise, Christopher E.; Albert, Rainer; Cottens, Sylvain; Hof, Robert; Bruns, Christian; Prieschl, Eva; Baumruker, Thomas; Hiestand, Peter; Foster, Carolyn A.; Zollinger, Markus; Lynch, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">21453-21457</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis.  In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation.  FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms.  Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compd. is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis.  Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6zyZnHOYNbVg90H21EOLACvtfcHk0ljG-BZIzjWsTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xkslyqtb4%253D&md5=b59856fffa9ebae7fb8182d18daa025f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1074%2Fjbc.C200176200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.C200176200%26sid%3Dliteratum%253Aachs%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DDavis%26aufirst%3DM.%2BD.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DAlbert%26aufirst%3DR.%26aulast%3DCottens%26aufirst%3DS.%26aulast%3DHof%26aufirst%3DR.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPrieschl%26aufirst%3DE.%26aulast%3DBaumruker%26aufirst%3DT.%26aulast%3DHiestand%26aufirst%3DP.%26aulast%3DFoster%26aufirst%3DC.%2BA.%26aulast%3DZollinger%26aufirst%3DM.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26atitle%3DThe%2520immune%2520modulator%2520FTY720%2520targets%2520sphingosine%25201-phosphate%2520receptors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D21453%26epage%3D21457%26doi%3D10.1074%2Fjbc.C200176200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span>. <i>Annu. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1146/annurev-immunol-020711-075011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1146%2Fannurev-immunol-020711-075011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22149932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=69-94&author=J.+G.+Cysterauthor=S.+R.+Schwab&title=Sphingosine-1-phosphate+and+lymphocyte+egress+from+lymphoid+organs&doi=10.1146%2Fannurev-immunol-020711-075011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Cyster, Jason G.; Schwab, Susan R.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">69-94</span>CODEN:
                <span class="NLM_cas:coden">ARIMDU</span>;
        ISSN:<span class="NLM_cas:issn">0732-0582</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Much has been learned about how cells enter lymphoid tissues.  But how do they leave.  Sphingosine-1-phosphate (S1P) has emerged over the past decade as a central mediator of lymphocyte egress.  In this review, we summarize the current understanding of how S1P promotes exit from the secondary lymphoid organs and thymus.  We review what is known about addnl. requirements for emigration and summarize the mostly distinct requirements for exit from the bone marrow.  Egress from lymphoid organs is limited during immune responses, and we examine how this regulation works.  There is accumulating evidence for roles of S1P in directing immune cell behavior within lymphoid tissues.  How such actions can fit together with the egress-promoting role of S1P is discussed.  Finally, we examine current understanding of how FTY720, a drug that targets S1P receptors and is approved for the treatment of multiple sclerosis, causes immune suppression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhvMroRvgkZrVg90H21EOLACvtfcHk0ljH56h9p5yhuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVKmtLY%253D&md5=c9f9ef63f2248594b0f9ce4d06024bba</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1146%2Fannurev-immunol-020711-075011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-immunol-020711-075011%26sid%3Dliteratum%253Aachs%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26atitle%3DSphingosine-1-phosphate%2520and%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DAnnu.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D30%26spage%3D69%26epage%3D94%26doi%3D10.1146%2Fannurev-immunol-020711-075011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vendataraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaud, J.</span></span> <span> </span><span class="NLM_article-title">The vascular S1P gradient: cellular sources and biological significance</span>. <i>Biochim. Biophys. Acta, Mol. Cell Biol. Lipids</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1781</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">482</span>, <span class="refDoi"> DOI: 10.1016/j.bbalip.2008.07.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.bbalip.2008.07.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=18674637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1781&publication_year=2008&pages=477-482&author=T.+Hlaauthor=K.+Vendataramanauthor=J.+Michaud&title=The+vascular+S1P+gradient%3A+cellular+sources+and+biological+significance&doi=10.1016%2Fj.bbalip.2008.07.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The vascular S1P gradient-Cellular sources and biological significance</span></div><div class="casAuthors">Hla, Timothy; Venkataraman, Krishnan; Michaud, Jason</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular and Cell Biology of Lipids</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1781</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">477-482</span>CODEN:
                <span class="NLM_cas:coden">BBMLFG</span>;
        ISSN:<span class="NLM_cas:issn">1388-1981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P), a product of sphingomyelin metab., is enriched in the circulatory system whereas it is estd. to be much lower in interstitial fluids of tissues.  This concn. gradient, termed the vascular S1P gradient appears to form as a result of substrate availability and the action of metabolic enzymes.  S1P levels in blood and lymph are estd. to be in the μM range.  In the immune system, the S1P gradient is needed as a spatial cue for lymphocyte and hematopoietic cell trafficking.  During inflammatory reactions in which enhanced vascular permeability occurs, a burst of S1P becomes available to its receptors in the extravascular compartment, which likely contributes to the tissue reactions.  Thus, the presence of the vascular S1P gradient is thought to contribute to physiol. and pathol. conditions.  From an evolutionary perspective, S1P receptors may have co-evolved with the advent of a closed vascular system and the trafficking paradigms for hematopoietic cells to navigate in and out of the vascular system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosbyXvTWrRf7Vg90H21EOLACvtfcHk0ljH56h9p5yhuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVKjtbrF&md5=a9c4420dff6764f71060b18149669767</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2Fj.bbalip.2008.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbalip.2008.07.003%26sid%3Dliteratum%253Aachs%26aulast%3DHla%26aufirst%3DT.%26aulast%3DVendataraman%26aufirst%3DK.%26aulast%3DMichaud%26aufirst%3DJ.%26atitle%3DThe%2520vascular%2520S1P%2520gradient%253A%2520cellular%2520sources%2520and%2520biological%2520significance%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Biol.%2520Lipids%26date%3D2008%26volume%3D1781%26spage%3D477%26epage%3D482%26doi%3D10.1016%2Fj.bbalip.2008.07.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span> <span> </span><span class="NLM_article-title">Finding a way out: lymphocyte egress from lymphoid organs</span>. <i>Nat. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1301</span>, <span class="refDoi"> DOI: 10.1038/ni1545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fni1545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=18026082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=1295-1301&author=S.+R.+Schwabauthor=J.+G.+Cyster&title=Finding+a+way+out%3A+lymphocyte+egress+from+lymphoid+organs&doi=10.1038%2Fni1545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Finding a way out: lymphocyte egress from lymphoid organs</span></div><div class="casAuthors">Schwab, Susan R.; Cyster, Jason G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Immunology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1295-1301</span>CODEN:
                <span class="NLM_cas:coden">NIAMCZ</span>;
        ISSN:<span class="NLM_cas:issn">1529-2908</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The egress of lymphocytes from the thymus and secondary lymphoid organs into circulatory fluids is essential for normal immune function.  The discovery that a small-mol. inhibitor of lymphocyte exit, FTY720, is a ligand for sphingosine 1-phosphate (S1P) receptors led to studies demonstrating that S1P receptor type 1 (S1P1) is needed in T cells and B cells for their egress from lymphoid organs.  S1P exists in higher concns. in blood and lymph than in lymphoid organs, and this differential is also required for lymphocyte exit.  Transcriptional and post-translational mechanisms regulate S1P1 and thus the egress of lymphocytes.  In this review we discuss the body of evidence supporting a model in which lymphocyte egress is promoted by encounter with S1P at exit sites.  We relate this model to work examg. the effects of S1P receptor agonists on endothelium.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWY-Rk111SmLVg90H21EOLACvtfcHk0ljH56h9p5yhuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajtr7J&md5=ccf7ef06130d3ebd218707ac92618f36</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1038%2Fni1545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fni1545%26sid%3Dliteratum%253Aachs%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26atitle%3DFinding%2520a%2520way%2520out%253A%2520lymphocyte%2520egress%2520from%2520lymphoid%2520organs%26jtitle%3DNat.%2520Immunol.%26date%3D2007%26volume%3D8%26spage%3D1295%26epage%3D1301%26doi%3D10.1038%2Fni1545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goetzl, E. J.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1038/nri1650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fnri1650" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=15999095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=560-570&author=H.+Rosenauthor=E.+J.+Goetzl&title=Sphingosine+1-phosphate+and+its+receptors%3A+an+autocrine+and+paracrine+network&doi=10.1038%2Fnri1650"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network</span></div><div class="casAuthors">Rosen, Hugh; Goetzl, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">560-570</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Sphingosine 1-phosphate (S1P) is a biol. active lysophospholipid that transmits signals through a family of G-protein-coupled receptors to control cellular differentiation and survival, as well as the vital functions of several types of immune cell.  In this Review article, the authors discuss recent results that indicate that S1P and its receptors are required for the emigration of thymocytes from the thymus, the trafficking of lymphocytes in secondary lymphoid organs and the migration of B cells into splenic follicles.  In an autocrine manner, through interactions with different G-protein-coupled receptors, S1P also enhances optimal mast-cell migration and release of pro-inflammatory mediators in allergic reactions.  S1P-S1P-receptor regulatory systems might therefore be novel targets for the therapy of diverse immunol. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6-Zo0R14YILVg90H21EOLACvtfcHk0lhcI7XeMj7cpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlsl2itr4%253D&md5=b680f6c9e29d407579ab7f056209d853</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1038%2Fnri1650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri1650%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DH.%26aulast%3DGoetzl%26aufirst%3DE.%2BJ.%26atitle%3DSphingosine%25201-phosphate%2520and%2520its%2520receptors%253A%2520an%2520autocrine%2520and%2520paracrine%2520network%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2005%26volume%3D5%26spage%3D560%26epage%3D570%26doi%3D10.1038%2Fnri1650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pappu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwab, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelissen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Regard, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camerer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cyster, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, S. R.</span></span> <span> </span><span class="NLM_article-title">Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">298</span>, <span class="refDoi"> DOI: 10.1126/science.1139221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1126%2Fscience.1139221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17363629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2007&pages=295-298&author=R.+Pappuauthor=S.+R.+Schwabauthor=I.+Cornelissenauthor=J.+P.+Pereiraauthor=J.+B.+Regardauthor=Y.+Xuauthor=E.+Camererauthor=Y.-W.+Zhengauthor=Y.+Huangauthor=J.+G.+Cysterauthor=S.+R.+Coughlin&title=Promotion+of+lymphocyte+egress+into+blood+and+lymph+by+distinct+sources+of+sphingosine-1-phosphate&doi=10.1126%2Fscience.1139221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate</span></div><div class="casAuthors">Pappu, Rajita; Schwab, Susan R.; Cornelissen, Ivo; Pereira, Joao P.; Regard, Jean B.; Xu, Ying; Camerer, Eric; Zheng, Yao-Wu; Huang, Yong; Cyster, Jason G.; Coughlin, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">5822</span>),
    <span class="NLM_cas:pages">295-298</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Lymphocytes require sphingosine-1-phosphate (S1P) receptor-1 to exit lymphoid organs, but the source(s) of extracellular S1P and whether S1P directly promotes egress are unknown.  By using mice in which the two kinases that generate S1P were conditionally ablated, we find that plasma S1P is mainly hematopoietic in origin, with erythrocytes a major contributor, whereas lymph S1P is from a distinct radiation-resistant source.  Lymphocyte egress from thymus and secondary lymphoid organs was markedly reduced in kinase-deficient mice.  Restoration of S1P to plasma rescued egress to blood but not lymph, and the rescue required lymphocyte expression of S1P-receptor-1.  Thus, sep. sources provide S1P to plasma and lymph to help lymphocytes exit the low-S1P environment of lymphoid organs.  Disruption of compartmentalized S1P signaling is a plausible mechanism by which S1P-receptor-1 agonists function as immunosuppressives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMH4WVYwTIX7Vg90H21EOLACvtfcHk0lhcI7XeMj7cpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVeku70%253D&md5=6c658296c3b1d34543c193987092506b</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1126%2Fscience.1139221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1139221%26sid%3Dliteratum%253Aachs%26aulast%3DPappu%26aufirst%3DR.%26aulast%3DSchwab%26aufirst%3DS.%2BR.%26aulast%3DCornelissen%26aufirst%3DI.%26aulast%3DPereira%26aufirst%3DJ.%2BP.%26aulast%3DRegard%26aufirst%3DJ.%2BB.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DCamerer%26aufirst%3DE.%26aulast%3DZheng%26aufirst%3DY.-W.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DCyster%26aufirst%3DJ.%2BG.%26aulast%3DCoughlin%26aufirst%3DS.%2BR.%26atitle%3DPromotion%2520of%2520lymphocyte%2520egress%2520into%2520blood%2520and%2520lymph%2520by%2520distinct%2520sources%2520of%2520sphingosine-1-phosphate%26jtitle%3DScience%26date%3D2007%26volume%3D316%26spage%3D295%26epage%3D298%26doi%3D10.1126%2Fscience.1139221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tobias, K.</span></span> <span> </span><span class="NLM_article-title">Oral fingolomid for the treatment of patients with relapsing forms of multiple sclerosis</span>. <i>Int. J. Clin. Pract.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">887</span>– <span class="NLM_lpage">895</span>, <span class="refDoi"> DOI: 10.1111/j.1742-1241.2011.02721.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fj.1742-1241.2011.02721.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=21679286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2011&pages=887-895&author=B.+Singerauthor=A.+P.+Rossauthor=K.+Tobias&title=Oral+fingolomid+for+the+treatment+of+patients+with+relapsing+forms+of+multiple+sclerosis&doi=10.1111%2Fj.1742-1241.2011.02721.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis</span></div><div class="casAuthors">Singer, B.; Ross, A. P.; Tobias, K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Clinical Practice</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">887-895</span>CODEN:
                <span class="NLM_cas:coden">IJCPF9</span>;
        ISSN:<span class="NLM_cas:issn">1742-1241</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine 1-phosphate receptor modulator, is the first oral treatment approved by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).  The aim of this review was to provide a concise, comprehensive overview of the clin. relevant mechanism of action, efficacy and safety information available for fingolimod.  Key data were derived from two international, Phase III, double-blind, randomised trials (TRANSFORMS and FREEDOMS) performed over 12 and 24 mo, resp., which evaluated fingolimod 0.5 and 1.25 mg daily in 1703 patients with relapsing forms of MS.  In TRANSFORMS, there was a 52% redn. in the annualised relapse rate (ARR) with fingolimod 0.5 mg vs. 30 μg i.m. interferon beta-1a (0.16 vs. 0.33; p < 0.001) at 1 yr.  In FREEDOMS, there was a 55% decrease in ARR at 2 years with fingolimod 0.5 mg vs. placebo (0.18 vs. 0.40; p < 0.001).  Risk of disability progression, confirmed at 3 mo, was also reduced by 30% over the 2-yr study period with fingolimod vs. placebo (p = 0.02).  Significantly fewer new or enlarged lesions on T2-weighted images were seen in both studies (TRANSFORMS, p = 0.002 vs. interferon beta-1a at 1 yr; FREEDOMS, p < 0.001 vs. placebo at 2 years).  Overall, fingolimod 0.5 mg was well tolerated by patients.  Transient, generally asymptomatic bradycardia and infrequent atrioventricular block were seen with the administration of the first dose.  Macular edema and serious infections occurred infrequently.  Reversible, asymptomatic elevations of liver enzymes could also occur.  As the first approved oral disease-modifying treatment, fingolimod offers patients a convenient alternative to regular self-injection for the treatment of relapsing forms of MS.  In addn. to high efficacy with a relatively acceptable safety profile, fingolimod provides a therapy with a new mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKs1Biiz177Vg90H21EOLACvtfcHk0lhcI7XeMj7cpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpsV2hsbY%253D&md5=8be8ad56fc253ddccb59597c041b9ff8</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-1241.2011.02721.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-1241.2011.02721.x%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DA.%2BP.%26aulast%3DTobias%26aufirst%3DK.%26atitle%3DOral%2520fingolomid%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520relapsing%2520forms%2520of%2520multiple%2520sclerosis%26jtitle%3DInt.%2520J.%2520Clin.%2520Pract.%26date%3D2011%26volume%3D65%26spage%3D887%26epage%3D895%26doi%3D10.1111%2Fj.1742-1241.2011.02721.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Hernandez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataraman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claffey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and action of the immunomodulatory FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">47281</span>– <span class="NLM_lpage">47290</span>, <span class="refDoi"> DOI: 10.1074/jbc.M306896200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1074%2Fjbc.M306896200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=47281-47290&author=T.+Sanchezauthor=T.+Estrada-Hernandezauthor=J.-H.+Paikauthor=M.-T.+Wuauthor=K.+Venkataramanauthor=V.+Brinkmannauthor=K.+Claffeyauthor=T.+Hla&title=Phosphorylation+and+action+of+the+immunomodulatory+FTY720+inhibits+vascular+endothelial+cell+growth+factor-induced+vascular+permeability&doi=10.1074%2Fjbc.M306896200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M306896200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M306896200%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez%26aufirst%3DT.%26aulast%3DEstrada-Hernandez%26aufirst%3DT.%26aulast%3DPaik%26aufirst%3DJ.-H.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DVenkataraman%26aufirst%3DK.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DClaffey%26aufirst%3DK.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DPhosphorylation%2520and%2520action%2520of%2520the%2520immunomodulatory%2520FTY720%2520inhibits%2520vascular%2520endothelial%2520cell%2520growth%2520factor-induced%2520vascular%2520permeability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D47281%26epage%3D47290%26doi%3D10.1074%2Fjbc.M306896200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A.</span></span> <span> </span><span class="NLM_article-title">Modulators of sphingosine-1-phosphate pathway biology: recent advances in the discovery and development of sphingosine-1-phosphate-1 receptor agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5267</span>– <span class="NLM_lpage">5289</span>, and references cited therein <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01575</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01575" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ohsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5267-5289&author=A.+Dyckman&title=Modulators+of+sphingosine-1-phosphate+pathway+biology%3A+recent+advances+in+the+discovery+and+development+of+sphingosine-1-phosphate-1+receptor+agonists&doi=10.1021%2Facs.jmedchem.6b01575"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives</span></div><div class="casAuthors">Dyckman, Alaric J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5267-5289</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The sphingoid base derived class of lipids (sphingolipids) is a family of interconverting mols. that play key roles in numerous structural and signaling processes.  The biosynthetic pathway of the sphingolipids affords many opportunities for therapeutic intervention: targeting the ligands directly, targeting the various proteins involved in the interconversion of the ligands, or targeting the receptors that respond to the ligands.  The focus of this article is on the most advanced of the sphingosine-related therapeutics, agonists of sphingosine-1-phosphate receptor 1 (S1P1).  The diverse structural classes of S1P1 agonists will be discussed and the status of compds. of clin. relevance will be detailed.  An examn. of how potential safety concerns are being navigated with compds. currently under clin. evaluation is followed by a discussion of the novel methods being explored to identify next-generation S1P1 agonists with improved safety profiles.  Finally, therapeutic opportunities for sphingosine-related targets outside of S1P1 are touched upon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNNydOixG1FbVg90H21EOLACvtfcHk0lgzq4TGdhdiFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ohsr4%253D&md5=254a3b0960cff5c3268df13a326b887e</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01575%26sid%3Dliteratum%253Aachs%26aulast%3DDyckman%26aufirst%3DA.%26atitle%3DModulators%2520of%2520sphingosine-1-phosphate%2520pathway%2520biology%253A%2520recent%2520advances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520sphingosine-1-phosphate-1%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5267%26epage%3D5289%26doi%3D10.1021%2Facs.jmedchem.6b01575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerrero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, H.</span></span> <span> </span><span class="NLM_article-title">Sphingosine 1-phosphate receptor agonists: a patent review (2010–2012)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">841</span>, and references cited therein <span class="refDoi"> DOI: 10.1517/13543776.2013.783022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1517%2F13543776.2013.783022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=23541049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=817-841&author=E.+Robertsauthor=M.+Guerreroauthor=M.+Urbanoauthor=H.+Rosen&title=Sphingosine+1-phosphate+receptor+agonists%3A+a+patent+review+%282010%E2%80%932012%29&doi=10.1517%2F13543776.2013.783022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Sphingosine 1-phosphate receptor agonists: a patent review (2010 - 2012)</span></div><div class="casAuthors">Roberts, Edward; Guerrero, Miguel; Urbano, Mariangela; Rosen, Hugh</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">817-841</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: The sphingosine-1-phosphate (S1P)-driven signaling regulates fundamental biol. functions, including cell proliferation, angiogenesis, endothelial cell chemotaxis, immune cell trafficking and mitogenesis.  A large body of research has been focusing on the development of immunosuppressive S1P1 receptor (S1P1-R) agonist mols.  The S1P1,3 - 5-R pan-agonist fingolimod (FTY720) has been approved by the FDA for the treatment of relapsing-remitting multiple sclerosis.  However, FTY720 is now contraindicated in patients with compromised cardiac function.  Although the main adverse effect bradycardia has been linked to the S1P3-R activation, cardiovascular liabilities persist with more selective S1P1-R agonists that have entered clin. trials.  In contrast to the S1P1-R, the therapeutic application of the S1P2 - 5-Rs remains poorly explored.  Areas covered: This review provides the patent literature from 2010 to date on S1P-R agonist mols. and their relevant biol. properties.  Expert opinion: Limited progress has been made on agonists at S1P4,5-R subtypes, with some families of S1P5-R agonists showing promising results in animal models of age-related cognitive disorders.  A discrete no. of reviewed mols. are S1P1-R agonists with a promising clin. outlook in transplantation, inflammation, cancer and autoimmune settings.  Further preclin. and clin. studies will det. whether the new developed S1P1-R agonists do indeed improve the safety profile of FTY720.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIrASpSMDS37Vg90H21EOLACvtfcHk0lgzq4TGdhdiFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCks7o%253D&md5=405b6350b777d3040e2be21adf85d440</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1517%2F13543776.2013.783022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2013.783022%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DE.%26aulast%3DGuerrero%26aufirst%3DM.%26aulast%3DUrbano%26aufirst%3DM.%26aulast%3DRosen%26aufirst%3DH.%26atitle%3DSphingosine%25201-phosphate%2520receptor%2520agonists%253A%2520a%2520patent%2520review%2520%25282010%25E2%2580%25932012%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2013%26volume%3D23%26spage%3D817%26epage%3D841%26doi%3D10.1517%2F13543776.2013.783022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kappos, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polman, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radue, E. W.</span></span> <span> </span><span class="NLM_article-title">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>355</i></span>,  <span class="NLM_fpage">1124</span>– <span class="NLM_lpage">1140</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa052643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1056%2FNEJMoa052643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=16971719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=1124-1140&author=L.+Kapposauthor=J.+Antelauthor=G.+Comiauthor=X.+Montalbanauthor=P.+O%E2%80%99Connorauthor=C.+H.+Polmanauthor=T.+Haasauthor=A.+A.+Kornauthor=G.+Karlssonauthor=E.+W.+Radue&title=Oral+fingolimod+%28FTY720%29+for+relapsing+multiple+sclerosis&doi=10.1056%2FNEJMoa052643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Oral fingolimod (FTY720) for relapsing multiple sclerosis</span></div><div class="casAuthors">Kappos, Ludwig; Antel, Jack; Comi, Giancarlo; Montalban, Xavier; O'Connor, Paul; Polman, Chris H.; Haas, Tomas; Korn, Alexander A.; Karlsson, Goeril; Radue, Ernst W.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1124-1140</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.  We randomly assigned 281 patients to receive oral fingolimod, at a dose of 1.25 mg or 5.0 mg, or a placebo once daily, and we followed these patients for 6 mo with magnetic resonance imaging (MRI) and clin. evaluations (core study, months 0 to 6).  The primary end point was the total no. of gadolinium-enhanced lesions recorded on T1-weighted MRI at monthly intervals for 6 mo.  In an extension study in which the investigators and patients remained unaware of the dose assignments (months 7 to 12), patients who received placebo underwent randomization again to one of the fingolimod doses.  A total of 255 patients completed the core study.  The median total no. of gadolinium-enhanced lesions on MRI was lower with 1.25 mg of fingolimod (1 lesion, P < 0.001) and 5.0 mg of fingolimod (3 lesions, P = 0.006) than with placebo (5 lesions).  The annualized relapse rate was 0.77 in the placebo group, as compared with 0.35 in the group given 1.25 mg of fingolimod (P = 0.009) and 0.36 in the group given 5.0 mg of fingolimod (P = 0.01).  For the 227 patients who completed the extension study, the no. of gadolinium-enhanced lesions and relapse rates remained low in the groups that received continuous fingolimod, and both measures decreased in patients who switched from placebo to fingolimod.  Adverse events included nasopharyngitis, dyspnea, headache, diarrhea, and nausea.  Clin. asymptomatic elevations of alanine aminotransferase levels were more frequent with fingolimod (10 to 12%, vs. 1% in the placebo group).  One case of the posterior reversible encephalopathy syndrome occurred in the 5.0-mg group.  Fingolimod was also assocd. with an initial redn. in the heart rate and a modest decrease in the forced expiratory vol. in 1 s.  In this proof-of-concept study, fingolimod reduced the no. of lesions detected on MRI and clin. disease activity in patients with multiple sclerosis.  Evaluation in larger, longer-term studies is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA4MSvDIuvV7Vg90H21EOLACvtfcHk0lg-FxkA2Wjnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsFKku78%253D&md5=2a84e8f5fb92091782406da9dcbc1453</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa052643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa052643%26sid%3Dliteratum%253Aachs%26aulast%3DKappos%26aufirst%3DL.%26aulast%3DAntel%26aufirst%3DJ.%26aulast%3DComi%26aufirst%3DG.%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DPolman%26aufirst%3DC.%2BH.%26aulast%3DHaas%26aufirst%3DT.%26aulast%3DKorn%26aufirst%3DA.%2BA.%26aulast%3DKarlsson%26aufirst%3DG.%26aulast%3DRadue%26aufirst%3DE.%2BW.%26atitle%3DOral%2520fingolimod%2520%2528FTY720%2529%2520for%2520relapsing%2520multiple%2520sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D1124%26epage%3D1140%26doi%3D10.1056%2FNEJMoa052643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">David, O. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovarik, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmouder, R. L.</span></span> <span> </span><span class="NLM_article-title">Clinical pharmacokinetics of fingolimod</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2165/11596550-000000000-00000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.2165%2F11596550-000000000-00000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22149256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2012&pages=15-28&author=O.+J.+Davidauthor=J.+M.+Kovarikauthor=R.+L.+Schmouder&title=Clinical+pharmacokinetics+of+fingolimod&doi=10.2165%2F11596550-000000000-00000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical pharmacokinetics of fingolimod</span></div><div class="casAuthors">David, Olivier J.; Kovarik, John M.; Schmouder, Robert L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-28</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis</span>)
        </div><div class="casAbstract">A review.  Fingolimod (FTY720), a sphingosine 1-phosphate receptor modulator, is the first in a new class of therapeutic compds. and is the first oral therapy approved for the treatment of relapsing forms of multiple sclerosis (MS).  Fingolimod is a structural analog of endogenous sphingosine and undergoes phosphorylation to produce fingolimod phosphate, the active moiety.  Fingolimod targets MS via effects on the immune system, and evidence from animal models indicates that it may also have actions in the central nervous system.  In phase III studies in patients with relapsing-remitting MS, fingolimod has demonstrated efficacy superior to that of an approved first-line therapy, i.m. interferon-β-1a, as well as placebo, with benefits extending across clin. and magnetic resonance imaging measures.  The pharmacokinetic profiles of fingolimod and fingolimod phosphate have been extensively investigated in studies in healthy volunteers, renal transplant recipients (the indication for which fingolimod was initially under clin. development, but the development was subsequently discontinued) and MS patients.  Results from these studies have demonstrated that fingolimod is efficiently absorbed, with an oral bioavailability of >90%, and its absorption is unaffected by dietary intake, therefore it can be taken without regard to meals.  Fingolimod and fingolimod phosphate have a half-life of 6-9 days, and steady-state pharmacokinetics are reached after 1-2 mo of daily dosing.  The long half-life of fingolimod, together with its slow absorption, means that fingolimod has a fiat concn. profile over time with once-daily dosing.  Fingolimod and fingolimod phosphate show dose-proportional exposure in single- and multiple-dose studies over a range of 0.125-5 mg; hence, there is a predictable relationship between dose and systemic exposure.  Furthermore, fingolimod and fingolimod phosphate exhibit low to moderate intersubject pharmacokinetic variability.  Fingolimod is extensively metabolized, with biotransformation occurring via three main pathways: (i) reversible phosphorylation to fingolimod phosphate; (ii) hydroxylation and oxidn. to yield a series of inactive carboxylic acid metabolites; and (iii) formation of non-polar ceramides.  Fingolimod is largely cleared through metab. by cytochrome P 450 (CYP) 4F2.  Since few drugs are metabolized by CYP4F2, fingolimod would be expected to have a relatively low potential for drug-drug interactions.  This is supported by data from in vitro studies indicating that fingolimod and fingolimod phosphate have little or no capacity to inhibit and no capacity to induce other major drug-metabolizing CYP enzymes at therapeutically relevant steady-state blood concns.  Population pharmacokinetic evaluations indicate that CYP3A inhibitors and CYP3A inducers have no effect or only a weak effect on the pharmacokinetics of fingolimod and fingolimod phosphate.  However, blood concns. of fingolimod and fingolimod phosphate are increased moderately when fingolimod is coadministered with ketoconazole, an inhibitor of CYP4F2.  The pharmacokinetics of fingolimod are unaffected by renal impairment or mild-to-moderate hepatic impairment.  However, exposure to fingolimod is increased in patients with severe hepatic impairment.  No clin. relevant effects of age, sex or ethnicity on the pharmacokinetics of fingolimod have been obsd.  Fingolimod is thus a promising new therapy for eligible patients with MS, with a predictable pharmacokinetic profile that allows effective once-daily oral dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoxIUshcr8m7Vg90H21EOLACvtfcHk0lg-FxkA2Wjnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xit1OqtLg%253D&md5=a1a6d271470f6c297892ef00f0fe6ec6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F11596550-000000000-00000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F11596550-000000000-00000%26sid%3Dliteratum%253Aachs%26aulast%3DDavid%26aufirst%3DO.%2BJ.%26aulast%3DKovarik%26aufirst%3DJ.%2BM.%26aulast%3DSchmouder%26aufirst%3DR.%2BL.%26atitle%3DClinical%2520pharmacokinetics%2520of%2520fingolimod%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2012%26volume%3D51%26spage%3D15%26epage%3D28%26doi%3D10.2165%2F11596550-000000000-00000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gergely, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traebert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinterding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooke, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenewegen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vitaliti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sing, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luttringer, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crumb, W. J.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallstrom, E.</span></span> <span> </span><span class="NLM_article-title">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">1035</span>– <span class="NLM_lpage">1047</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02061.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fj.1476-5381.2012.02061.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22646698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2012&pages=1035-1047&author=P.+Gergelyauthor=B.+Nuesslein-Hildesheimauthor=D.+Gueriniauthor=V.+Brinkmannauthor=M.+Traebertauthor=C.+Brunsauthor=S.+Panauthor=N.+S.+Grayauthor=K.+Hinterdingauthor=N.+G.+Cookeauthor=A.+Groenewegenauthor=A.+Vitalitiauthor=T.+Singauthor=O.+Luttringerauthor=J.+Yangauthor=A.+Gardinauthor=N.+Wangauthor=W.+J.+Crumbauthor=M.+Saltzmanauthor=M.+Rosenbergauthor=E.+Wallstrom&title=The+selective+sphingosine+1-phosphate+receptor+modulator+BAF312+redirects+lymphocyte+distribution+and+has+species-specific+effects+on+heart+rate&doi=10.1111%2Fj.1476-5381.2012.02061.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate</span></div><div class="casAuthors">Gergely, P.; Nuesslein-Hildesheim, B.; Guerini, D.; Brinkmann, V.; Traebert, M.; Bruns, C.; Pan, S.; Gray, N. S.; Hinterding, K.; Cooke, N. G.; Groenewegen, A.; Vitaliti, A.; Sing, T.; Luttringer, O.; Yang, J.; Gardin, A.; Wang, N.; Crumb, W. J., Jr.; Saltzman, M.; Rosenberg, M.; Wallstrom, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1035-1047</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose BAF312 is a next-generation sphingosine 1-phosphate (S1P) receptor modulator, selective for S1P1 and S1P5 receptors.  S1P1 receptors are essential for lymphocyte egress from lymph nodes and a drug target in immune-mediated diseases.  Here, we have characterized the immunomodulatory potential of BAF312 and the S1P receptor-mediated effects on heart rate using preclin. and human data.  Exptl. Approach BAF312 was tested in a rat exptl. autoimmune encephalomyelitis (EAE) model.  Electrophysiol. recordings of G-protein-coupled inwardly rectifying potassium (GIRK) channels were carried out in human atrial myocytes.  A Phase I multiple-dose trial studied the pharmacokinetics, pharmacodynamics and safety of BAF312 in 48 healthy subjects.  Key Results BAF312 effectively suppressed EAE in rats by internalizing S1P1 receptors, rendering them insensitive to the egress signal from lymph nodes.  In healthy volunteers, BAF312 caused preferential decreases in CD4+ T cells, Tnaive, Tcentral memory and B cells within 4-6 h.  Cell counts returned to normal ranges within a week after stopping treatment, in line with the elimination half-life of BAF312.  Despite sparing S1P3 receptors (assocd. with bradycardia in mice), BAF312 induced rapid, transient (day 1 only) bradycardia in humans.  BAF312-mediated activation of GIRK channels in human atrial myocytes can fully explain the bradycardia.  Conclusion and Implications This study illustrates species-specific differences in S1P receptor specificity for first-dose cardiac effects.  Based on its profound but rapidly reversible inhibition of lymphocyte trafficking, BAF312 may have potential as a treatment for immune-mediated diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr42VfW58NMyLVg90H21EOLACvtfcHk0lg-FxkA2Wjnug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKkt7bE&md5=0034be62fb68b10abefff50f0220be2a</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02061.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02061.x%26sid%3Dliteratum%253Aachs%26aulast%3DGergely%26aufirst%3DP.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DGuerini%26aufirst%3DD.%26aulast%3DBrinkmann%26aufirst%3DV.%26aulast%3DTraebert%26aufirst%3DM.%26aulast%3DBruns%26aufirst%3DC.%26aulast%3DPan%26aufirst%3DS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DHinterding%26aufirst%3DK.%26aulast%3DCooke%26aufirst%3DN.%2BG.%26aulast%3DGroenewegen%26aufirst%3DA.%26aulast%3DVitaliti%26aufirst%3DA.%26aulast%3DSing%26aufirst%3DT.%26aulast%3DLuttringer%26aufirst%3DO.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DGardin%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCrumb%26aufirst%3DW.%2BJ.%26aulast%3DSaltzman%26aufirst%3DM.%26aulast%3DRosenberg%26aufirst%3DM.%26aulast%3DWallstrom%26aufirst%3DE.%26atitle%3DThe%2520selective%2520sphingosine%25201-phosphate%2520receptor%2520modulator%2520BAF312%2520redirects%2520lymphocyte%2520distribution%2520and%2520has%2520species-specific%2520effects%2520on%2520heart%2520rate%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D167%26spage%3D1035%26epage%3D1047%26doi%3D10.1111%2Fj.1476-5381.2012.02061.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G.
M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification and preclinical pharmacology of clinical candidate ((1<i>R</i>,3<i>S</i>)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986104) - a differentiated S1P<sub>1</sub> receptor modulator</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">288</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00448</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00448" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=283-288&author=T.+G.%0AM.+Dharauthor=H.-Y.+Xiaoauthor=J.+Xieauthor=L.+D.+Lehman-McKeemanauthor=D.-R.+Wuauthor=M.+Dabrosauthor=X.+Yangauthor=T.+L.+Taylorauthor=X.+D.+Zhouauthor=E.+M.+Heimrichauthor=R.+Thomasauthor=K.+W.+McIntyreauthor=B.+Warrackauthor=H.+Shiauthor=P.+C.+Levesqueauthor=J.+L.+Zhuauthor=J.+Hennanauthor=P.+Balimaneauthor=Z.+Yangauthor=A.+Marinoauthor=G.+Corneliusauthor=C.+D%27Arienzoauthor=A.+Mathurauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+Salter-cidauthor=J.+C.+Barrishauthor=P.+C.+Carterauthor=A.+J.+Dyckman&title=Identification+and+preclinical+pharmacology+of+clinical+candidate+%28%281R%2C3S%29-1-amino-3-%28%28R%29-6-hexyl-5%2C6%2C7%2C8-tetrahydronaphthalen-2-yl%29cyclopentyl%29methanol+%28BMS-986104%29+-+a+differentiated+S1P1+receptor+modulator&doi=10.1021%2Facsmedchemlett.5b00448"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00448%26sid%3Dliteratum%253Aachs%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXiao%26aufirst%3DH.-Y.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DZhou%26aufirst%3DX.%2BD.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DZhu%26aufirst%3DJ.%2BL.%26aulast%3DHennan%26aufirst%3DJ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%2527Arienzo%26aufirst%3DC.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520and%2520preclinical%2520pharmacology%2520of%2520clinical%2520candidate%2520%2528%25281R%252C3S%2529-1-amino-3-%2528%2528R%2529-6-hexyl-5%252C6%252C7%252C8-tetrahydronaphthalen-2-yl%2529cyclopentyl%2529methanol%2520%2528BMS-986104%2529%2520-%2520a%2520differentiated%2520S1P1%2520receptor%2520modulator%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D283%26epage%3D288%26doi%3D10.1021%2Facsmedchemlett.5b00448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dabros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D'Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Identification of potent tricyclic prodrug S1P<sub>1</sub> receptor modulators</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">725</span>– <span class="NLM_lpage">729</span>, <span class="refDoi"> DOI: 10.1039/C6MD00539J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1039%2FC6MD00539J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=725-729&author=D.+Marcouxauthor=H.-Y.+Xiaoauthor=T.+G.+M.+Murali+Dharauthor=J.+Xieauthor=L.+D.+Lehman-McKeemanauthor=D.-R.+Wuauthor=M.+Dabrosauthor=X.+Yangauthor=T.+L.+Taylorauthor=X.+D.+Zhouauthor=E.+M.+Heimrichauthor=R.+Thomasauthor=K.+W.+McIntyreauthor=H.+Shiauthor=P.+C.+Levesqueauthor=H.+Sunauthor=Z.+Yangauthor=A.+Marinoauthor=G.+Corneliusauthor=C.+D%27Arienzoauthor=A.+Guptaauthor=B.+Pragalathanauthor=R.+Rampullaauthor=A.+Mathurauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+Salter-cidauthor=L.+J.+Lombardoauthor=P.+C.+Carterauthor=A.+J.+Dyckman&title=Identification+of+potent+tricyclic+prodrug+S1P1+receptor+modulators&doi=10.1039%2FC6MD00539J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=10.1039%2FC6MD00539J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6MD00539J%26sid%3Dliteratum%253Aachs%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DXiao%26aufirst%3DH.-Y.%26aulast%3DMurali%2BDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DDabros%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DZhou%26aufirst%3DX.%2BD.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DThomas%26aufirst%3DR.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%2527Arienzo%26aufirst%3DC.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DSalter-cid%26aufirst%3DL.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DIdentification%2520of%2520potent%2520tricyclic%2520prodrug%2520S1P1%2520receptor%2520modulators%26jtitle%3DMedChemComm%26date%3D2017%26volume%3D8%26spage%3D725%26epage%3D729%26doi%3D10.1039%2FC6MD00539J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharel, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffter, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kennedy, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, T. L.</span></span> <span> </span><span class="NLM_article-title">Asymmetric synthesis of conformationally constrained fingolimod analogues--discovery of an orally active sphingosine 1-phosphate receptor type-1 agonist and receptor type-3 antagonist</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6428</span>– <span class="NLM_lpage">6435</span>, <span class="refDoi"> DOI: 10.1021/jm7010172</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7010172" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6428-6435&author=R.+Zhuauthor=A.+H.+Snyderauthor=Y.+Kharelauthor=L.+Schaffterauthor=Q.+Sunauthor=P.+C.+Kennedyauthor=K.+R.+Lynchauthor=T.+L.+Macdonald&title=Asymmetric+synthesis+of+conformationally+constrained+fingolimod+analogues%2D%2Ddiscovery+of+an+orally+active+sphingosine+1-phosphate+receptor+type-1+agonist+and+receptor+type-3+antagonist&doi=10.1021%2Fjm7010172"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=10.1021%2Fjm7010172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7010172%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DSnyder%26aufirst%3DA.%2BH.%26aulast%3DKharel%26aufirst%3DY.%26aulast%3DSchaffter%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DKennedy%26aufirst%3DP.%2BC.%26aulast%3DLynch%26aufirst%3DK.%2BR.%26aulast%3DMacdonald%26aufirst%3DT.%2BL.%26atitle%3DAsymmetric%2520synthesis%2520of%2520conformationally%2520constrained%2520fingolimod%2520analogues--discovery%2520of%2520an%2520orally%2520active%2520sphingosine%25201-phosphate%2520receptor%2520type-1%2520agonist%2520and%2520receptor%2520type-3%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6428%26epage%3D6435%26doi%3D10.1021%2Fjm7010172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit15d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheppeck, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haque, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhopadhyay, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarde, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levesque, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Discovery and structure activity relationship (SAR) of a series of ethanolamine-based direct acting agonists of sphingosine-1-phosphate (S1P1)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6248</span>– <span class="NLM_lpage">6264</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00373</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00373" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6248-6264&author=J.+L.+Gilmoreauthor=J.+E.+Sheppeckauthor=S.+H.+Wattersonauthor=L.+Haqueauthor=P.+Mukhopadhyayauthor=A.+J.+Tebbenauthor=M.+A.+Galellaauthor=D.+R.+Shenauthor=M.+Yardeauthor=M.+E.+Cvijicauthor=V.+Borowskiauthor=K.+M.+Gilloolyauthor=T.+Taylorauthor=K.+W.+McIntyreauthor=B.+Warrackauthor=P.+C.+Levesqueauthor=J.+P.+Liauthor=G.+Corneliusauthor=C.+J.+D%E2%80%99Arienzoauthor=A.+M.+Marinoauthor=P.+V.+Balimaneauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=W.+J.+Pittsauthor=P.+H.+Carterauthor=J.+Xieauthor=A.+J.+Dyckman&title=Discovery+and+structure+activity+relationship+%28SAR%29+of+a+series+of+ethanolamine-based+direct+acting+agonists+of+sphingosine-1-phosphate+%28S1P1%29&doi=10.1021%2Facs.jmedchem.6b00373"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15d&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00373%26sid%3Dliteratum%253Aachs%26aulast%3DGilmore%26aufirst%3DJ.%2BL.%26aulast%3DSheppeck%26aufirst%3DJ.%2BE.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DHaque%26aufirst%3DL.%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DYarde%26aufirst%3DM.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DLevesque%26aufirst%3DP.%2BC.%26aulast%3DLi%26aufirst%3DJ.%2BP.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DMarino%26aufirst%3DA.%2BM.%26aulast%3DBalimane%26aufirst%3DP.%2BV.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DDiscovery%2520and%2520structure%2520activity%2520relationship%2520%2528SAR%2529%2520of%2520a%2520series%2520of%2520ethanolamine-based%2520direct%2520acting%2520agonists%2520of%2520sphingosine-1-phosphate%2520%2528S1P1%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6248%26epage%3D6264%26doi%3D10.1021%2Facs.jmedchem.6b00373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="note"><p class="first last">Protein sequence alignment shows sphinosine kinase (SK) and sphingosine-1-phosphate phosphatase (SGPP) share high homology between rat and human, with 77–79% for SK1, 79–80% for SK2, 81% for SGPP1, and 82–85% for SGPP2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konopacki, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fix-Stenzel, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grongsaard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cusack, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffter, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henry, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoffel, R. H.</span></span> <span> </span><span class="NLM_article-title">Scalable synthesis and isolation of the four stereoisomers of methyl 1-amino-3-(4-bromophenyl)cyclopentanecarboxylate, useful intermediates for the synthesis of S1P1 receptor agonists</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">4886</span>– <span class="NLM_lpage">4889</span>, <span class="refDoi"> DOI: 10.1021/jo900376b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo900376b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2009&pages=4886-4889&author=G.+A.+Wallaceauthor=T.+D.+Gordonauthor=M.+E.+Hayesauthor=D.+B.+Konopackiauthor=S.+F.+Fix-Stenzelauthor=X.+Zhangauthor=P.+Grongsaardauthor=K.+P.+Cusackauthor=L.+M.+Schaffterauthor=R.+F.+Henryauthor=R.+H.+Stoffel&title=Scalable+synthesis+and+isolation+of+the+four+stereoisomers+of+methyl+1-amino-3-%284-bromophenyl%29cyclopentanecarboxylate%2C+useful+intermediates+for+the+synthesis+of+S1P1+receptor+agonists&doi=10.1021%2Fjo900376b"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjo900376b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo900376b%26sid%3Dliteratum%253Aachs%26aulast%3DWallace%26aufirst%3DG.%2BA.%26aulast%3DGordon%26aufirst%3DT.%2BD.%26aulast%3DHayes%26aufirst%3DM.%2BE.%26aulast%3DKonopacki%26aufirst%3DD.%2BB.%26aulast%3DFix-Stenzel%26aufirst%3DS.%2BF.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGrongsaard%26aufirst%3DP.%26aulast%3DCusack%26aufirst%3DK.%2BP.%26aulast%3DSchaffter%26aufirst%3DL.%2BM.%26aulast%3DHenry%26aufirst%3DR.%2BF.%26aulast%3DStoffel%26aufirst%3DR.%2BH.%26atitle%3DScalable%2520synthesis%2520and%2520isolation%2520of%2520the%2520four%2520stereoisomers%2520of%2520methyl%25201-amino-3-%25284-bromophenyl%2529cyclopentanecarboxylate%252C%2520useful%2520intermediates%2520for%2520the%2520synthesis%2520of%2520S1P1%2520receptor%2520agonists%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2009%26volume%3D74%26spage%3D4886%26epage%3D4889%26doi%3D10.1021%2Fjo900376b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silveira, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braga, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenardao, E. J.</span></span> <span> </span><span class="NLM_article-title">Synthetic approaches to 2-tetralones</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">8295</span>– <span class="NLM_lpage">8328</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2004.06.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.tet.2004.06.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmvV2gsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=8295-8328&author=C.+C.+Silveiraauthor=A.+L.+Bragaauthor=T.+S.+Kaufmanauthor=E.+J.+Lenardao&title=Synthetic+approaches+to+2-tetralones&doi=10.1016%2Fj.tet.2004.06.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic approaches to 2-tetralones</span></div><div class="casAuthors">Silveira, Claudio C.; Braga, Antonio L.; Kaufman, Teodoro S.; Lenardao, Eder J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">8295-8328</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review discusses a variety of methods for the prepn. of substituted 2-tetralones; the review discusses methods of prepg. 2-tetralones either by construction of the tetralone ring system or by functionalization of a previously obtained naphthalene or tetralone ring system.  The assembly of 2-tetralones by reactions such as the cyclization of α-diazocarbonyl compds., the copper-mediated cyclization of iodonium ylides, Friedel-Crafts alkylation and acylation reactions, cyclizations of β-ketosulfoxides, nucleophilic substitution of ruthenium-complexed arenes, the oxidative cyclization of δ-aryl-β-dicarbonyl compds., cyclization of silyl enol ethers onto radical cations, α-arylation reactions, benzyne cycloaddns., carbopalladation of arom. nitriles and acetylenes, and Dieckmann condensations are discussed.  Methods of prepg. 2-tetralones from either 1-tetralones or naphthols by carbonyl transposition, hydroboration and oxidn., redn., or ionic hydrogenation are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTfe2eaaFdhbVg90H21EOLACvtfcHk0ljG6cc9NN_EZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmvV2gsLw%253D&md5=47a6c66bc6d8c7c7ade29c344725ca09</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2004.06.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2004.06.080%26sid%3Dliteratum%253Aachs%26aulast%3DSilveira%26aufirst%3DC.%2BC.%26aulast%3DBraga%26aufirst%3DA.%2BL.%26aulast%3DKaufman%26aufirst%3DT.%2BS.%26aulast%3DLenardao%26aufirst%3DE.%2BJ.%26atitle%3DSynthetic%2520approaches%2520to%25202-tetralones%26jtitle%3DTetrahedron%26date%3D2004%26volume%3D60%26spage%3D8295%26epage%3D8328%26doi%3D10.1016%2Fj.tet.2004.06.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sonogashira, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tohda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hagihara, N.</span></span> <span> </span><span class="NLM_article-title">A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, iodoarenes and bromopyridines</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4467</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1016/S0040-4039(00)91094-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2FS0040-4039%2800%2991094-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1975&pages=4467-4470&author=K.+Sonogashiraauthor=Y.+Tohdaauthor=N.+Hagihara&title=A+convenient+synthesis+of+acetylenes%3A+catalytic+substitutions+of+acetylenic+hydrogen+with+bromoalkenes%2C+iodoarenes+and+bromopyridines&doi=10.1016%2FS0040-4039%2800%2991094-3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2991094-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252991094-3%26sid%3Dliteratum%253Aachs%26aulast%3DSonogashira%26aufirst%3DK.%26aulast%3DTohda%26aufirst%3DY.%26aulast%3DHagihara%26aufirst%3DN.%26atitle%3DA%2520convenient%2520synthesis%2520of%2520acetylenes%253A%2520catalytic%2520substitutions%2520of%2520acetylenic%2520hydrogen%2520with%2520bromoalkenes%252C%2520iodoarenes%2520and%2520bromopyridines%26jtitle%3DTetrahedron%2520Lett.%26date%3D1975%26volume%3D16%26spage%3D4467%26epage%3D4470%26doi%3D10.1016%2FS0040-4039%2800%2991094-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compound <b>18b</b> was unambiguously assigned ((<i>S</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate by X-ray crystal structure. Crystallographic data for the structures <b>18b</b> reported in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1876258. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-336-033; e-mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="7d19180d120e14093d1e1e191e531e1c10531c1e530816">[email protected]</a>). The absolute and relative stereochemistry of <b>18a</b> was assigned ((<i>R</i>)-6-((5<i>R</i>,7<i>S</i>)-2-oxo-3-oxa-1-azaspiro[4.4]nonan-7-yl)-1,2,3,4-tetrahydronaphthalen-2-yl)methyl 4-methylbenzenesulfonate based on the results for the crystal structure of <b>18b</b>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compound <b>14a</b> was unambiguously assigned ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>S</i>)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol by X-ray crystal structure. Crystallographic data for the structures <b>14a</b> reported in this paper has been deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1876257. Copies of the data can be obtained free of charge on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223-336-033; e-mail: <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="1b7f7e6b7468726f5b78787f7835787a76357a78356e70">[email protected]</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">The absolute and relative stereochemistry of compounds <b>9a</b>/<b>9b</b>, <b>10a</b>/<b>10b</b>, and <b>20a</b>/<b>20b</b> were assigned by chiral HPLC analysis using material with known stereochemistry synthesized using <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. This analysis indicated that <b>9a</b> has the <i>S</i> configuration and <b>9b</b> has the <i>R</i> configuration at the benzyl attachment point. This analysis indicated that <b>10a</b> has the R configuration and <b>10b</b> has the <i>S</i> configuration at the phenethyl attachment point. This analysis indicated that <b>20a</b> has the <i>R</i> configuration and <b>20b</b> has the <i>S</i> configuration at the alkyne attachment point.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blakemore, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocieński, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morley, A.</span></span> <span> </span><span class="NLM_article-title">A stereoselective synthesis of <i>trans</i>-1,2-disubstituted alkenes based on the condensation of aldehydes with metallated 1-phenyl-1<i>H</i>-tetrazol-5-yl sulfones</span>. <i>Synlett</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1998</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.1055/s-1998-1570</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1055%2Fs-1998-1570" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=26-28&author=P.+R.+Blakemoreauthor=W.+J.+Coleauthor=P.+J.+Kocie%C5%84skiauthor=A.+Morley&title=A+stereoselective+synthesis+of+trans-1%2C2-disubstituted+alkenes+based+on+the+condensation+of+aldehydes+with+metallated+1-phenyl-1H-tetrazol-5-yl+sulfones&doi=10.1055%2Fs-1998-1570"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1055%2Fs-1998-1570&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1998-1570%26sid%3Dliteratum%253Aachs%26aulast%3DBlakemore%26aufirst%3DP.%2BR.%26aulast%3DCole%26aufirst%3DW.%2BJ.%26aulast%3DKocie%25C5%2584ski%26aufirst%3DP.%2BJ.%26aulast%3DMorley%26aufirst%3DA.%26atitle%3DA%2520stereoselective%2520synthesis%2520of%2520trans-1%252C2-disubstituted%2520alkenes%2520based%2520on%2520the%2520condensation%2520of%2520aldehydes%2520with%2520metallated%25201-phenyl-1H-tetrazol-5-yl%2520sulfones%26jtitle%3DSynlett%26date%3D1998%26volume%3D1998%26spage%3D26%26epage%3D28%26doi%3D10.1055%2Fs-1998-1570" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siow, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wattenberg, B. W.</span></span> <span> </span><span class="NLM_article-title">An assay system for measuring the acute production of sphingosine 1-phosphate in intact monolayers</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">184</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2007.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.ab.2007.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17884005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2007&pages=184-193&author=D.+L.+Siowauthor=B.+W.+Wattenberg&title=An+assay+system+for+measuring+the+acute+production+of+sphingosine+1-phosphate+in+intact+monolayers&doi=10.1016%2Fj.ab.2007.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">An assay system for measuring the acute production of sphingosine 1-phosphate in intact monolayers</span></div><div class="casAuthors">Siow, Deanna L.; Wattenberg, Binks W.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">184-193</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Sphingosine kinase (SK) is a signaling enzyme that phosphorylates sphingosine to produce sphingosine 1-phosphate.  Sphingosine and sphingosine 1-phosphate (S1P) belong to a class of bioactive sphingolipid metabolites that are crit. in a no. of cellular processes, yet often have opposing biol. functions.  The intracellular localization of sphingosine kinase has been demonstrated in multiple studies to be a crit. aspect of its signaling function.  To date, assays of sphingosine kinase activity have been developed for measuring activity in lysates, where the effects of localization are lost.  Here the authors outline a system in which the rate of prodn. of S1P can be measured in intact cells using exogenously added radiolabeled ATP instead of tritiated sphingosine.  The surprising ability of ATP to enter unpermeabilized monolayers is one aspect that makes this assay simple, efficient, and inexpensive, yet sensitive enough to measure endogenous enzyme activity.  The assay is well behaved in terms of kinetics and substrate dependence.  Overall, this assay is ideal for future studies to identify changes in S1P prodn. in intact cells such as those that result from the differential intracellular targeting of sphingosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8eyI_ZniaG7Vg90H21EOLACvtfcHk0ljG6cc9NN_EZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1GlurjO&md5=475c29aeca26fb40069e565efef7b273</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2007.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2007.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DSiow%26aufirst%3DD.%2BL.%26aulast%3DWattenberg%26aufirst%3DB.%2BW.%26atitle%3DAn%2520assay%2520system%2520for%2520measuring%2520the%2520acute%2520production%2520of%2520sphingosine%25201-phosphate%2520in%2520intact%2520monolayers%26jtitle%3DAnal.%2520Biochem.%26date%3D2007%26volume%3D371%26spage%3D184%26epage%3D193%26doi%3D10.1016%2Fj.ab.2007.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barnett, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, L. B.</span></span> <span> </span><span class="NLM_article-title">Biomarkers in acute lung injury – marking forward progress</span>. <i>Crit. Care Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">661</span>– <span class="NLM_lpage">683</span>, <span class="refDoi"> DOI: 10.1016/j.ccc.2011.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.ccc.2011.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=21742222" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslWrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2011&pages=661-683&author=N.+Barnettauthor=L.+B.+Ware&title=Biomarkers+in+acute+lung+injury+%E2%80%93+marking+forward+progress&doi=10.1016%2Fj.ccc.2011.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers in Acute Lung Injury-Marking Forward Progress</span></div><div class="casAuthors">Barnett, Nicolas; Ware, Lorraine B.</div><div class="citationInfo"><span class="NLM_cas:title">Critical Care Clinics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">661-683</span>CODEN:
                <span class="NLM_cas:coden">CCCLEH</span>;
        ISSN:<span class="NLM_cas:issn">0749-0704</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  This article reviews the state of the art regarding biomarkers for prediction, diagnosis, and prognosis in acute lung injury.  Biomarkers and the goals of biomarker research are defined.  Progress along 4 general routes is examd.  First, the results of wide-ranging existing protein biomarkers are reported.  Second, newer biomarkers awaiting or with strong potential for validation are described.  Third, progress in the fields of genomics and proteomics is reported.  Finally, given the complexity and no. of potential biomarkers, the results of combining clin. predictors with protein and other biomarkers to produce better prognostic and diagnostic indexes are examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDQHoERr7RdrVg90H21EOLACvtfcHk0ljxyQo5me2diw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslWrs7w%253D&md5=bada458495b6ae9da2b57f1d72ee37d8</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.ccc.2011.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccc.2011.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DBarnett%26aufirst%3DN.%26aulast%3DWare%26aufirst%3DL.%2BB.%26atitle%3DBiomarkers%2520in%2520acute%2520lung%2520injury%2520%25E2%2580%2593%2520marking%2520forward%2520progress%26jtitle%3DCrit.%2520Care%2520Clin.%26date%3D2011%26volume%3D27%26spage%3D661%26epage%3D683%26doi%3D10.1016%2Fj.ccc.2011.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Shea, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontaine, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tager, A.</span></span> <span> </span><span class="NLM_article-title">Prolonged exposure to sphingosine 1–phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung lnjury</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">662</span>– <span class="NLM_lpage">673</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2009-0345OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1165%2Frcmb.2009-0345OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=20081052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=662-673&author=B.+S.+Sheaauthor=S.+F.+Brooksauthor=B.+A.+Fontaineauthor=J.+Chunauthor=A.+D.+Lusterauthor=A.+Tager&title=Prolonged+exposure+to+sphingosine+1%E2%80%93phosphate+receptor-1+agonists+exacerbates+vascular+leak%2C+fibrosis%2C+and+mortality+after+lung+lnjury&doi=10.1165%2Frcmb.2009-0345OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26aR"><div class="casContent"><span class="casTitleNuber">26a</span><div class="casTitle"><span class="NLM_cas:atitle">Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury</span></div><div class="casAuthors">Shea, Barry S.; Brooks, Sarah F.; Fontaine, Benjamin A.; Chun, Jerold; Luster, Andrew D.; Tager, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">662-673</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">Sphingosine 1-phosphate (S1P) is a key endogenous regulator of the response to lung injury, maintaining endothelial barrier integrity through interaction with one of its receptors, S1P1.  The short-term administration of S1P or S1P1 receptor agonists enhances endothelial monolayer barrier function in vitro, and attenuates injury-induced vascular leak in the lung and other organ systems in vivo.  Although S1P1 agonists bind to and activate S1P1, several of these agents also induce receptor internalization and degrdn., and may therefore act as functional antagonists of S1P1 after extended exposure.  Here we report on the effects of prolonged exposure to these agents in bleomycin-induced lung injury.  We demonstrate that repeated administration of S1P1 agonists dramatically worsened lung injury after bleomycin challenge, as manifested by increased vascular leak and mortality.  Consistent with these results, prolonged exposure to S1P1 agonists in vitro eliminated the ability of endothelial cell monolayers to respond appropriately to the barrier-protective effects of S1P, indicating a loss of normal S1P-S1P1 signaling.  As bleomycin-induced lung injury progressed, continued exposure to S1P1 agonists also resulted in increased pulmonary fibrosis.  These data indicate that S1P1 agonists can act as functional antagonists of S1P1 on endothelial cells in vivo, which should be considered in developing these agents as therapies for vascular leak syndromes.  Our findings also support the hypothesis that vascular leak is an important component of the fibrogenic response to lung injury, and suggest that targeting the S1P-S1P1 pathway may also be an effective therapeutic strategy for fibrotic lung diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpG8d_yM8ZpErVg90H21EOLACvtfcHk0ljxyQo5me2diw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2jtr%252FM&md5=1b0c0384272545d0ca4dfb3c4df0c8c9</span></div><a href="/servlet/linkout?suffix=cit26a&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2009-0345OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2009-0345OC%26sid%3Dliteratum%253Aachs%26aulast%3DShea%26aufirst%3DB.%2BS.%26aulast%3DBrooks%26aufirst%3DS.%2BF.%26aulast%3DFontaine%26aufirst%3DB.%2BA.%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26aulast%3DTager%26aufirst%3DA.%26atitle%3DProlonged%2520exposure%2520to%2520sphingosine%25201%25E2%2580%2593phosphate%2520receptor-1%2520agonists%2520exacerbates%2520vascular%2520leak%252C%2520fibrosis%252C%2520and%2520mortality%2520after%2520lung%2520lnjury%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2010%26volume%3D43%26spage%3D662%26epage%3D673%26doi%3D10.1165%2Frcmb.2009-0345OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Sammani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Vinasco, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzapoiazova, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singleton, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evenoski, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Husain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moitra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, J. G. N.</span></span> <span> </span><span class="NLM_article-title">Differential effects of sphingosine 1-phosphate on airway and vascular barrier function in the murine lung</span>. <i>Am. J. Respir. Cell Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">402</span>, <span class="refDoi"> DOI: 10.1165/rcmb.2009-0223OC</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1165%2Frcmb.2009-0223OC" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=19749179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2010&pages=394-402&author=S.+Sammaniauthor=L.+Moreno-Vinascoauthor=T.+Mirzapoiazovaauthor=P.+A.+Singletonauthor=E.+T.+Chiangauthor=C.+L.+Evenoskiauthor=T.+Wangauthor=B.+Mathewauthor=A.+Husainauthor=J.+Moitraauthor=X.+Sunauthor=L.+Nunezauthor=J.+R.+Jacobsonauthor=S.+M.+Dudekauthor=V.+Natarajanauthor=J.+G.+N.+Garcia&title=Differential+effects+of+sphingosine+1-phosphate+on+airway+and+vascular+barrier+function+in+the+murine+lung&doi=10.1165%2Frcmb.2009-0223OC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26bR"><div class="casContent"><span class="casTitleNuber">26b</span><div class="casTitle"><span class="NLM_cas:atitle">Differential effects of sphingosine 1-phosphate receptors on airway and vascular barrier function in the murine lung</span></div><div class="casAuthors">Sammani, Saad; Moreno-Vinasco, Liliana; Mirzapoiazova, Tamara; Singleton, Patrick A.; Chiang, Eddie T.; Evenoski, Carrie L.; Wang, Ting; Mathew, Biji; Husain, Aliya; Moitra, Jaideep; Sun, Xiaoguang; Nunez, Luis; Jacobson, Jeffrey R.; Dudek, Steven M.; Natarajan, Viswanathan; Garcia, Joe G. N.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory Cell and Molecular Biology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">394-402</span>CODEN:
                <span class="NLM_cas:coden">AJRBEL</span>;
        ISSN:<span class="NLM_cas:issn">1044-1549</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">The therapeutic options for ameliorating the profound vascular permeability, alveolar flooding, and organ dysfunction that accompanies acute inflammatory lung injury (ALI) remain limited.  Extending our previous finding that the i.v. administration of the sphingolipid angiogenic factor, sphingosine 1-phosphate (S1P), attenuates inflammatory lung injury and vascular permeability via ligation of S1PR1, we det. that a direct intratracheal or i.v. administration of S1P, or a selective S1P receptor (S1PR1) agonist (SEW-2871), produces highly concn.-dependent barrier-regulatory responses in the murine lung.  The intratracheal or i.v. administration of S1P or SEW-2871 at < 0.3 mg/kg was protective against LPS-induced murine lung inflammation and permeability.  However, intratracheal delivery of S1P at 0.5 mg/kg (for 2 h) resulted in significant alveolar-capillary barrier disruption (with a 42% increase in bronchoalveolar lavage protein), and produced rapid lethality when delivered at 2 mg/kg.  Despite the greater selectivity for S1PR1, intratracheally delivered SEW-2871 at 0.5 mg/kg also resulted in significant alveolar-capillary barrier disruption, but was not lethal at 2 mg/kg.  Consistent with the S1PR1 regulation of alveolar/vascular barrier function, wild-type mice pretreated with the S1PR1 inverse agonist, SB-649146, or S1PR1+/- mice exhibited reduced S1P/SEW-2871-mediated barrier protection after challenge with LPS.  In contrast, S1PR2-/- knockout mice as well as mice with reduced S1PR3 expression (via silencing S1PR3-contg. nanocarriers) were protected against LPS-induced barrier disruption compared with control mice.  These studies underscore the potential therapeutic effects of highly selective S1PR1 receptor agonists in reducing inflammatory lung injury, and highlight the crit. role of the S1P delivery route, S1PR1 agonist concn., and S1PR1 expression in target tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr268-TV7Sk97Vg90H21EOLACvtfcHk0ljxyQo5me2diw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qsbzE&md5=b65a25010b114f0ddcec189d2c540e65</span></div><a href="/servlet/linkout?suffix=cit26b&amp;dbid=16384&amp;doi=10.1165%2Frcmb.2009-0223OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1165%252Frcmb.2009-0223OC%26sid%3Dliteratum%253Aachs%26aulast%3DSammani%26aufirst%3DS.%26aulast%3DMoreno-Vinasco%26aufirst%3DL.%26aulast%3DMirzapoiazova%26aufirst%3DT.%26aulast%3DSingleton%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DE.%2BT.%26aulast%3DEvenoski%26aufirst%3DC.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DMathew%26aufirst%3DB.%26aulast%3DHusain%26aufirst%3DA.%26aulast%3DMoitra%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DNunez%26aufirst%3DL.%26aulast%3DJacobson%26aufirst%3DJ.%2BR.%26aulast%3DDudek%26aufirst%3DS.%2BM.%26aulast%3DNatarajan%26aufirst%3DV.%26aulast%3DGarcia%26aufirst%3DJ.%2BG.%2BN.%26atitle%3DDifferential%2520effects%2520of%2520sphingosine%25201-phosphate%2520on%2520airway%2520and%2520vascular%2520barrier%2520function%2520in%2520the%2520murine%2520lung%26jtitle%3DAm.%2520J.%2520Respir.%2520Cell%2520Mol.%2520Biol.%26date%3D2010%26volume%3D43%26spage%3D394%26epage%3D402%26doi%3D10.1165%2Frcmb.2009-0223OC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hocke, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellwig, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutbier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schonrock, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tschernig, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmiedl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hippenstiel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">N’Guessan, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosseau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suttorp, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witzenrath, M.</span></span> <span> </span><span class="NLM_article-title">The sphingosine-1–phosphate receptor agonist FTY720 dose dependently affected endothelial integrity <i>in vitro</i> and aggravated ventilator-induced lung injury in mice</span>. <i>Pulm. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">377</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1016/j.pupt.2011.01.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.pupt.2011.01.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=21419858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjvVGksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=377-385&author=H.+C.+Mullerauthor=A.+C.+Hockeauthor=K.+Hellwigauthor=B.+Gutbierauthor=H.+Petersauthor=S.+M.+Schonrockauthor=T.+Tschernigauthor=A.+Schmiedlauthor=S.+Hippenstielauthor=P.+D.+N%E2%80%99Guessanauthor=S.+Rosseauauthor=N.+Suttorpauthor=M.+Witzenrath&title=The+sphingosine-1%E2%80%93phosphate+receptor+agonist+FTY720+dose+dependently+affected+endothelial+integrity+in+vitro+and+aggravated+ventilator-induced+lung+injury+in+mice&doi=10.1016%2Fj.pupt.2011.01.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26cR"><div class="casContent"><span class="casTitleNuber">26c</span><div class="casTitle"><span class="NLM_cas:atitle">The Sphingosine-1 Phosphate receptor agonist FTY720 dose dependently affected endothelial integrity in vitro and aggravated ventilator-induced lung injury in mice</span></div><div class="casAuthors">Muller Holger Christian; Hocke Andreas Christian; Hellwig Katharina; Gutbier Birgitt; Peters Harm; Schonrock Stefanie Maria; Tschernig Thomas; Schmiedl Andreas; Hippenstiel Stefan; N'Guessan Philippe Dje; Rosseau Simone; Suttorp Norbert; Witzenrath Martin</div><div class="citationInfo"><span class="NLM_cas:title">Pulmonary pharmacology & therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">377-85</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lung barrier protection by Sphingosine-1 Phosphate (S1P) has been demonstrated experimentally, but recent evidence suggests barrier disruptive properties of high systemic S1P concentrations.  The S1P analog FTY720 recently gained an FDA approval for treatment of multiple sclerosis.  In case of FTY720 treated patients experiencing multiple organ dysfunction syndrome the drug may accumulate due to liver failure, and the patients may receive ventilator therapy.  Whereas low doses of FTY720 enhanced endothelial barrier function, data on effects of increased FTY720 concentrations are lacking.  We measured transcellular electrical resistance (TER) of human umbilical vein endothelial cell (HUVEC) monolayers, performed morphologic analysis and measured apoptosis by TUNEL staining and procaspase-3 degradation in HUVECs stimulated with FTY720 (0.01-100 μM).  Healthy C57BL/6 mice and mice ventilated with 17 ml/kg tidal volume and 100% oxygen for 2 h were treated with 0.1 or 2 mg/kg FTY720 or solvent, and lung permeability, oxygenation and leukocyte counts in BAL and blood were quantified.  Further, electron microscopic analysis of lung tissue was performed.  We observed barrier protective effects of FTY720 on HUVEC cell layers at concentrations up to 1 μM while higher concentrations induced irreversible barrier breakdown accompanied by induction of apoptosis.  Low FTY720 concentrations (0.1 mg/kg) reduced lung permeability in mechanically ventilated mice, but 2 mg/kg FTY720 increased pulmonary vascular permeability in ventilated mice accompanied by endothelial apoptosis, while not affecting permeability in non-ventilated mice.  Moreover, hyperoxic mechanical ventilation sensitized the pulmonary vasculature to a barrier disrupting effect of FTY720, resulting in worsening of ventilator induced lung injury.  In conclusion, the current data suggest FTY720 induced endothelial barrier dysfunction, which was probably caused by proapoptotic effects and enhanced by mechanical ventilation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRnm0D5Ux3vzbt7lRqEFUJVfW6udTcc2eahMmAaUEbGQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjvVGksw%253D%253D&md5=1389da129056ace3a9166de853e0a3e1</span></div><a href="/servlet/linkout?suffix=cit26c&amp;dbid=16384&amp;doi=10.1016%2Fj.pupt.2011.01.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pupt.2011.01.017%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DH.%2BC.%26aulast%3DHocke%26aufirst%3DA.%2BC.%26aulast%3DHellwig%26aufirst%3DK.%26aulast%3DGutbier%26aufirst%3DB.%26aulast%3DPeters%26aufirst%3DH.%26aulast%3DSchonrock%26aufirst%3DS.%2BM.%26aulast%3DTschernig%26aufirst%3DT.%26aulast%3DSchmiedl%26aufirst%3DA.%26aulast%3DHippenstiel%26aufirst%3DS.%26aulast%3DN%25E2%2580%2599Guessan%26aufirst%3DP.%2BD.%26aulast%3DRosseau%26aufirst%3DS.%26aulast%3DSuttorp%26aufirst%3DN.%26aulast%3DWitzenrath%26aufirst%3DM.%26atitle%3DThe%2520sphingosine-1%25E2%2580%2593phosphate%2520receptor%2520agonist%2520FTY720%2520dose%2520dependently%2520affected%2520endothelial%2520integrity%2520in%2520vitro%2520and%2520aggravated%2520ventilator-induced%2520lung%2520injury%2520in%2520mice%26jtitle%3DPulm.%2520Pharmacol.%2520Ther.%26date%3D2011%26volume%3D24%26spage%3D377%26epage%3D385%26doi%3D10.1016%2Fj.pupt.2011.01.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit26d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Oo, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thangada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezaul, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaho, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, S.-I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span> <span> </span><span class="NLM_article-title">Engagement of S1P(1)-degradative mechanisms leads to vascular leak in mice</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">2290</span>– <span class="NLM_lpage">2300</span>, <span class="refDoi"> DOI: 10.1172/JCI45403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1172%2FJCI45403" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2011&pages=2290-2300&author=M.+L.+Ooauthor=S.-H.+Changauthor=S.+Thangadaauthor=M.-T.+Wuauthor=K.+Rezaulauthor=V.+Blahoauthor=S.-I.+Hwangauthor=D.+K.+Hanauthor=T.+Hla&title=Engagement+of+S1P%281%29-degradative+mechanisms+leads+to+vascular+leak+in+mice&doi=10.1172%2FJCI45403"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26d&amp;dbid=16384&amp;doi=10.1172%2FJCI45403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI45403%26sid%3Dliteratum%253Aachs%26aulast%3DOo%26aufirst%3DM.%2BL.%26aulast%3DChang%26aufirst%3DS.-H.%26aulast%3DThangada%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DM.-T.%26aulast%3DRezaul%26aufirst%3DK.%26aulast%3DBlaho%26aufirst%3DV.%26aulast%3DHwang%26aufirst%3DS.-I.%26aulast%3DHan%26aufirst%3DD.%2BK.%26aulast%3DHla%26aufirst%3DT.%26atitle%3DEngagement%2520of%2520S1P%25281%2529-degradative%2520mechanisms%2520leads%2520to%2520vascular%2520leak%2520in%2520mice%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2011%26volume%3D121%26spage%3D2290%26epage%3D2300%26doi%3D10.1172%2FJCI45403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyon, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, S. E.</span></span> <span> </span><span class="NLM_article-title">The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening</span>. <i>Br. J. Pharamacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">304</span>– <span class="NLM_lpage">317</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2012.02118.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fj.1476-5381.2012.02118.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22845396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2013&pages=304-317&author=J.+M.+Khanauthor=A.+R.+Lyonauthor=S.+E.+Harding&title=The+case+for+induced+pluripotent+stem+cell-derived+cardiomyocytes+in+pharmacological+screening&doi=10.1111%2Fj.1476-5381.2012.02118.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening</span></div><div class="casAuthors">Khan, Jaffar M.; Lyon, Alexander R.; Harding, Sian E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">304-317</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The current drug screening models are deficient, particularly in detecting cardiac side effects.  Human stem cell-derived cardiomyocytes could aid both early cardiotoxicity detection and novel drug discovery.  Work over the last decade has generated human embryonic stem cells as potentially accurate sources of human cardiomyocytes, but ethical constraints and poor efficacy in establishing cell lines limit their use.  Induced pluripotent stem cells do not require the use of human embryos and have the added advantage of producing patient-specific cardiomyocytes, allowing both generic and disease- and patient-specific pharmacol. screening, as well as drug development through disease modeling.  A crit. question is whether sufficient stds. have been achieved in the reliable and reproducible generation of "adult-like" cardiomyocytes from human fibroblast tissue to progress from validation to safe use in practice and drug discovery.  This review will highlight the need for a new exptl. system, assess the validity of human induced pluripotent stem cell-derived cardiomyocytes and explore what the future may hold for their use in pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoF1oDJmQ4dyLVg90H21EOLACvtfcHk0lhaZEWDccWxTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFSgt7w%253D&md5=86a904e75a13cdc3282b35f5e6a6b2d3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.02118.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.02118.x%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DJ.%2BM.%26aulast%3DLyon%26aufirst%3DA.%2BR.%26aulast%3DHarding%26aufirst%3DS.%2BE.%26atitle%3DThe%2520case%2520for%2520induced%2520pluripotent%2520stem%2520cell-derived%2520cardiomyocytes%2520in%2520pharmacological%2520screening%26jtitle%3DBr.%2520J.%2520Pharamacol.%26date%3D2013%26volume%3D169%26spage%3D304%26epage%3D317%26doi%3D10.1111%2Fj.1476-5381.2012.02118.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, G. L.</span>; <span class="NLM_string-name">Bhaskaran, V.</span>; <span class="NLM_string-name">Lecureux, L.</span>; <span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span> <span> </span><span class="NLM_article-title">Sphingosine-1-Phosphate Receptor 1 (S1PR1) Agonists Cause Proliferative and Pro-fibrotic Changes in Rat Lung</span>. Presented at <span class="NLM_publisher-name">Society of Toxicology Meeting</span>, <span class="NLM_publisher-loc">Baltimore, MD</span>, March 12–16, <span class="NLM_year">2017</span>; paper  <span class="NLM_fpage">1668</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=1668&author=G.+L.+Gong&author=V.+Bhaskaran&author=L.+Lecureux&author=L.+D.+Lehman-McKeeman&title=Sphingosine-1-Phosphate+Receptor+1+%28S1PR1%29+Agonists+Cause+Proliferative+and+Pro-fibrotic+Changes+in+Rat+Lung"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DG.%2BL.%26atitle%3DSphingosine-1-Phosphate%2520Receptor%25201%2520%2528S1PR1%2529%2520Agonists%2520Cause%2520Proliferative%2520and%2520Pro-fibrotic%2520Changes%2520in%2520Rat%2520Lung%26pub%3DSociety%2520of%2520Toxicology%2520Meeting%26date%3D2017%26spage%3D1668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Camm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkmann, V.</span></span> <span> </span><span class="NLM_article-title">Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications</span>. <i>Am. Heart J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">632</span>– <span class="NLM_lpage">644</span>, <span class="refDoi"> DOI: 10.1016/j.ahj.2014.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1016%2Fj.ahj.2014.06.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=25440790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFSjtbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2014&pages=632-644&author=J.+Cammauthor=T.+Hlaauthor=R.+Bakshiauthor=V.+Brinkmann&title=Cardiac+and+vascular+effects+of+fingolimod%3A+mechanistic+basis+and+clinical+implications&doi=10.1016%2Fj.ahj.2014.06.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications</span></div><div class="casAuthors">Camm, John; Hla, Timothy; Bakshi, Rajesh; Brinkmann, Volker</div><div class="citationInfo"><span class="NLM_cas:title">American Heart Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">632-644</span>CODEN:
                <span class="NLM_cas:coden">AHJOA2</span>;
        ISSN:<span class="NLM_cas:issn">0002-8703</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Fingolimod, a sphingosine-1-phosphate receptor (S1PR) modulator, was the first oral disease-modifying therapy approved for relapsing forms of multiple sclerosis; it reduces autoreactive lymphocytes' egress from lymphoid tissues by down-regulating S1PRs.  Sphingosine-1-phosphate signaling is implicated in a range of physiol. functions, and S1PRs are expressed differentially in various tissues, including the cardiovascular system.  Modulation of S1PRs on cardiac cells provides an explanation for the transient effects of fingolimod on heart rate and atrioventricular conduction at initiation of fingolimod therapy, and for the mild but more persistent effects on blood pressure obsd. in some patients on long-term treatment.  This review describes the nontherapeutic actions of fingolimod in the context of sphingosine-1-phosphate signaling in the cardiovascular system, as well as providing a summary of the assocd. clin. implications useful to physicians considering initiation of fingolimod therapy in patients.  A transient redn. in heart rate (mean decrease of 8 beats per min) and, less commonly, a temporary delay in atrioventricular conduction obsd. in some patients when initiating fingolimod therapy are both due to activation of S1PR subtype 1 on cardiac myocytes.  These effects are a reflection of fingolimod first acting as a full S1PR agonist and thereafter functioning as an S1PR antagonist after down-regulation of S1PR subtype 1 at the cell surface.  For most individuals, first-dose effects of fingolimod are asymptomatic, but all patients need to be monitored for at least 6 h after the first dose, in accordance with the label recommendations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovWJ_QWgnozbVg90H21EOLACvtfcHk0ljQc4or0Qdn3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFSjtbvF&md5=1e9ea571e48690f02a8cc5310636fd66</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.ahj.2014.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ahj.2014.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DCamm%26aufirst%3DJ.%26aulast%3DHla%26aufirst%3DT.%26aulast%3DBakshi%26aufirst%3DR.%26aulast%3DBrinkmann%26aufirst%3DV.%26atitle%3DCardiac%2520and%2520vascular%2520effects%2520of%2520fingolimod%253A%2520mechanistic%2520basis%2520and%2520clinical%2520implications%26jtitle%3DAm.%2520Heart%2520J.%26date%3D2014%26volume%3D168%26spage%3D632%26epage%3D644%26doi%3D10.1016%2Fj.ahj.2014.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrill, J. E.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo pharmacological models to assess demyelination and remyelination</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">55</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1038/npp.2008.145</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fnpp.2008.145" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=18800062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7vN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=55-73&author=J.+E.+Merrill&title=In+vitro+and+in+vivo+pharmacological+models+to+assess+demyelination+and+remyelination&doi=10.1038%2Fnpp.2008.145"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">In Vitro and In Vivo Pharmacological Models to Assess Demyelination and Remyelination</span></div><div class="casAuthors">Merrill, Jean E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-73</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In making a selection of cellular tools and animal models for generating screening assays in the search for new drugs, one needs to take into consideration the practicality of their use in the drug discovery process.  Conducting high-throughput primary screens using libraries of small mols., close to 1 million members in size, requires the generation of large nos. of cells which are easily acquired, reliably enriched, and reproducibly responsive to std. pos. controls.  These cells need to be similar in form and function to their counterparts in human disease.  In vitro assays that can be mechanized by using robots can therefore save time and costs.  In selecting in vivo models, consideration must be given to the species and strain of animal chosen, the appropriateness of the model to human disease, the extent of animal husbandry required during the in-life pharmacol. assessment, the tech. aspects of generating the model and harvesting the tissues for analyses, the cost of research tools in terms of time and money (demyelinating and remyelinating agents, amt. of compd. to be generated), and the length of time required for drug testing in the model.  A consideration of the translational aspects of the in vivo model compared to those used in the clinic is also important.  These themes will be developed with examples for drug discovery in the field of CNS demyelination and repair, specifically as it pertains to multiple sclerosis.  Neuropsychopharmacol. (2009) 34, 55-73; doi:10.1038/npp.2008.145; published online 17 Sept. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjK7BPEmVTWLVg90H21EOLACvtfcHk0ljQc4or0Qdn3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVyru7vN&md5=fe9c0fc0d6d677612b081621bf32ea42</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.145&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.145%26sid%3Dliteratum%253Aachs%26aulast%3DMerrill%26aufirst%3DJ.%2BE.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520pharmacological%2520models%2520to%2520assess%2520demyelination%2520and%2520remyelination%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D55%26epage%3D73%26doi%3D10.1038%2Fnpp.2008.145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dev, K. K.</span></span> <span> </span><span class="NLM_article-title">S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">382</span>– <span class="NLM_lpage">392</span>, <span class="refDoi"> DOI: 10.1002/glia.22272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1002%2Fglia.22272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=22108845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A280%3ADC%252BC387mvFeltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2012&pages=382-392&author=G.+K.+Sheridanauthor=K.+K.+Dev&title=S1P1+receptor+subtype+inhibits+demyelination+and+regulates+chemokine+release+in+cerebellar+slice+cultures&doi=10.1002%2Fglia.22272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures</span></div><div class="casAuthors">Sheridan Graham K; Dev Kumlesh K</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">382-92</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Sphingosine-1-phosphate receptors (S1PRs) are drug targets for the compound FTY720, which is the first oral therapy developed for treatment of relapsing-remitting multiple sclerosis.  S1PRs play a variety of functional roles in the differentiation, proliferation, survival and/or migration of neurons and glia.  In this study, rat organotypic cerebellar slice cultures were used to assess whether S1PRs play a role in demyelination induced by lysolecithin (LPC).  The data demonstrated that FTY720 and SEW2871 (a S1P1R-specific agonist) inhibited LPC-induced demyelination as assessed by myelin basic protein (MBP) immunofluorescence.  Treatment with both drugs for 48 h also induced an increase in S1P1R expression in astrocytes.  Moreover, FTY720 and SEW2871 inhibited the release of several chemokines in conditions of LPC-induced demyelination, including LIX (CXCL5), MIP-1alpha, and MIP-3alpha.  Taken together, the data suggest that activation of S1P1Rs prevents LPC-induced demyelination via a mechanism involving a reduction of chemotactic chemokine release.  The study supports the concept that FTY720 attenuates demyelination by not only preventing S1PR-mediated T cell migration into the CNS but also by limiting cytokine communication between cells of the immune system and the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0i22J0AjP3DMsgLhIoICsfW6udTcc2ebHx4DqCiMTOrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387mvFeltA%253D%253D&md5=17308ee161b253fb4a7ad341edbe6534</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fglia.22272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.22272%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DG.%2BK.%26aulast%3DDev%26aufirst%3DK.%2BK.%26atitle%3DS1P1%2520receptor%2520subtype%2520inhibits%2520demyelination%2520and%2520regulates%2520chemokine%2520release%2520in%2520cerebellar%2520slice%2520cultures%26jtitle%3DGlia%26date%3D2012%26volume%3D60%26spage%3D382%26epage%3D392%26doi%3D10.1002%2Fglia.22272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mi, S.</span></span> <span> </span><span class="NLM_article-title">Dissecting demyelination</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1351</span>– <span class="NLM_lpage">1354</span>, <span class="refDoi"> DOI: 10.1038/nn1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1038%2Fnn1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17965654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1ajsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2007&pages=1351-1354&author=R.+H.+Millerauthor=S.+Mi&title=Dissecting+demyelination&doi=10.1038%2Fnn1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32aR"><div class="casContent"><span class="casTitleNuber">32a</span><div class="casTitle"><span class="NLM_cas:atitle">Dissecting demyelination</span></div><div class="casAuthors">Miller, Robert H.; Mi, Sha</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1351-1354</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The loss of central nervous system myelin and the failure of remyelination by oligodendrocytes contribute to the functional impairment that characterizes diseases such as multiple sclerosis.  Why myelin repair fails in multiple sclerosis is currently unclear; however, new understanding of the generation of oligodendrocytes and myelination during development, as well as an increasing understanding of the bases of successful remyelination, are providing new insights and therapeutic targets.  We propose that successful myelin repair of the adult CNS recapitulates a sequence of stages that generally correlate with those seen during development, whereas unsuccessful myelin repair results from the perturbation of a crit. process in any one of several sequential events.  Defining the rate-limiting steps and most vulnerable aspects at each stage of myelin repair will provide logical targets for therapeutic intervention in demyelinating diseases such as multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxyvKG-czMIrVg90H21EOLACvtfcHk0ljel_JIkhCUdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1ajsbbJ&md5=2f95a264434d134c678dace5c77c1bc2</span></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=10.1038%2Fnn1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1995%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DR.%2BH.%26aulast%3DMi%26aufirst%3DS.%26atitle%3DDissecting%2520demyelination%26jtitle%3DNat.%2520Neurosci.%26date%3D2007%26volume%3D10%26spage%3D1351%26epage%3D1354%26doi%3D10.1038%2Fnn1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Slowik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarner, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, M.</span></span> <span> </span><span class="NLM_article-title">The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>172</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1111/bph.12938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=10.1111%2Fbph.12938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=25220526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=80-92&author=A.+Slowikauthor=T.+Schmidtauthor=C.+Beyerauthor=S.+Amorauthor=T.+Clarnerauthor=M.+Kipp&title=The+sphingosine+1-phosphate+receptor+agonist+FTY720+is+neuroprotective+after+cuprizone-induced+CNS+demyelination&doi=10.1111%2Fbph.12938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32bR"><div class="casContent"><span class="casTitleNuber">32b</span><div class="casTitle"><span class="NLM_cas:atitle">The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination</span></div><div class="casAuthors">Slowik, A.; Schmidt, T.; Beyer, C.; Amor, S.; Clarner, T.; Kipp, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-92</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Modulation of the sphingosine 1-phosphate receptor is an approved treatment for relapsing multiple sclerosis because of its anti-inflammatory effect of retaining lymphocytes within the lymph nodes.  Here, we evaluated the potential of an agonist at this receptor, FTY720 (fingolimod), to activate the promyelinating pathways within the brain to encourage remyelination and neuroprotection.  Exptl. Approach : In this study, we used the cuprizone model in male C57BL/6 mice and tested the promyelinating and neuroprotective effects of FTY720 after acute and chronic toxin-induced exptl. demyelination.  We used histol., immunohistochem. and gene expression methods.  Key Results : The midline of the corpus callosum was severely demyelinated after acute and chronic cuprizone-induced demyelination.  Robust endogenous remyelination was evident after acute, but impaired after chronic, demyelination.  FTY720 treatment modestly accelerated myelin recovery after acute but not chronic cuprizone exposure.  Markers of gliosis (astrocyte and microglia activation) were not affected by FTY720 treatment.  Remarkably, the accumulation of amyloid precursor protein-pos. spheroids in axons was less distinct in FTY720-treated animals, indicating that this compd. alleviated ongoing axonal damage.  Conclusions and Implications : We show that even during endogenous remyelination, axonal degeneration continued at a low level, accumulating over time.  This continuous neurodegenerative process was ameliorated by FTY720 treatment.  FTY720 preserved CNS integrity by direct interaction with brain resident cells, the actions of which are still to be defined.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRi-heBO2_H7Vg90H21EOLACvtfcHk0ljel_JIkhCUdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsL3J&md5=ee2c20b31e7a7e0766cc604621c070de</span></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=10.1111%2Fbph.12938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12938%26sid%3Dliteratum%253Aachs%26aulast%3DSlowik%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DT.%26aulast%3DBeyer%26aufirst%3DC.%26aulast%3DAmor%26aufirst%3DS.%26aulast%3DClarner%26aufirst%3DT.%26aulast%3DKipp%26aufirst%3DM.%26atitle%3DThe%2520sphingosine%25201-phosphate%2520receptor%2520agonist%2520FTY720%2520is%2520neuroprotective%2520after%2520cuprizone-induced%2520CNS%2520demyelination%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D80%26epage%3D92%26doi%3D10.1111%2Fbph.12938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, T. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcoux, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borowski, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balimane, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornelius, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warrack, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pragalathan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cvijic, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehman-McKeeman, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyckman, A. J.</span></span> <span> </span><span class="NLM_article-title">Assymetric hydroboration approach to the scalable synthesis of ((1<i>R</i>,3<i>S</i>)-1-amino-3-((<i>R</i>)-6-hexyl-5,6,7,8-tetrahydronaphalen-2-yl)cyclopentyl)methanol (BMS-986104) as a potent S1P receptor modulator</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">11138</span>– <span class="NLM_lpage">11147</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01433</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01433" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=11138-11147&author=M.+G.+Yangauthor=Z.+Xiaoauthor=T.+G.+M.+Dharauthor=H.-Y.+Xiaoauthor=J.+L.+Gilmoreauthor=D.+Marcouxauthor=J.+H.+Xieauthor=K.+W.+McIntyreauthor=T.+L.+Taylorauthor=V.+Borowskiauthor=E.+M.+Heimrichauthor=Y.-W.+Liauthor=J.+Fengauthor=A.+Fernandesauthor=Z.+Yangauthor=P.+Balimaneauthor=A.+Marinoauthor=G.+Corneliusauthor=B.+Warrackauthor=A.+Mathurauthor=D.-R.+Wuauthor=P.+Liauthor=A.+Guptaauthor=B.+Pragalathanauthor=D.+R.+Shenauthor=M.+E.+Cvijicauthor=L.+D.+Lehman-McKeemanauthor=L.+Salter-cidauthor=J.+C.+Barrishauthor=P.+C.+Carterauthor=A.+J.+Dyckman&title=Assymetric+hydroboration+approach+to+the+scalable+synthesis+of+%28%281R%2C3S%29-1-amino-3-%28%28R%29-6-hexyl-5%2C6%2C7%2C8-tetrahydronaphalen-2-yl%29cyclopentyl%29methanol+%28BMS-986104%29+as+a+potent+S1P+receptor+modulator&doi=10.1021%2Facs.jmedchem.6b01433"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01433%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DM.%2BG.%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DDhar%26aufirst%3DT.%2BG.%2BM.%26aulast%3DXiao%26aufirst%3DH.-Y.%26aulast%3DGilmore%26aufirst%3DJ.%2BL.%26aulast%3DMarcoux%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DJ.%2BH.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DBorowski%26aufirst%3DV.%26aulast%3DHeimrich%26aufirst%3DE.%2BM.%26aulast%3DLi%26aufirst%3DY.-W.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFernandes%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DBalimane%26aufirst%3DP.%26aulast%3DMarino%26aufirst%3DA.%26aulast%3DCornelius%26aufirst%3DG.%26aulast%3DWarrack%26aufirst%3DB.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DPragalathan%26aufirst%3DB.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DCvijic%26aufirst%3DM.%2BE.%26aulast%3DLehman-McKeeman%26aufirst%3DL.%2BD.%26aulast%3DSalter-cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BC.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26atitle%3DAssymetric%2520hydroboration%2520approach%2520to%2520the%2520scalable%2520synthesis%2520of%2520%2528%25281R%252C3S%2529-1-amino-3-%2528%2528R%2529-6-hexyl-5%252C6%252C7%252C8-tetrahydronaphalen-2-yl%2529cyclopentyl%2529methanol%2520%2528BMS-986104%2529%2520as%2520a%2520potent%2520S1P%2520receptor%2520modulator%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D11138%26epage%3D11147%26doi%3D10.1021%2Facs.jmedchem.6b01433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rozelle, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy results from pivotal clinical trials with abatacept</span>. <i>Clin. Exp. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">S30</span>– <span class="NLM_lpage">S34</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=17977486" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=S30-S34&author=A.+L.+Rozelleauthor=M.+C.+Genovese&title=Efficacy+results+from+pivotal+clinical+trials+with+abatacept"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRozelle%26aufirst%3DA.%2BL.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DEfficacy%2520results%2520from%2520pivotal%2520clinical%2520trials%2520with%2520abatacept%26jtitle%3DClin.%2520Exp.%2520Rheumatol.%26date%3D2007%26volume%3D25%26spage%3DS30%26epage%3DS34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bihorel, S.</span>; <span class="NLM_string-name">Singhal, S.</span>; <span class="NLM_string-name">Shevell, D.</span>; <span class="NLM_string-name">Sun, H.</span>; <span class="NLM_string-name">Xie, J.</span>; <span class="NLM_string-name">Basdeo, S.</span>; <span class="NLM_string-name">Liu, A.</span>; <span class="NLM_string-name">Dutta, S.</span>; <span class="NLM_string-name">Huang, H.</span>; <span class="NLM_string-name">Lin, K.</span>; <span class="NLM_string-name">Throup, J.</span>; <span class="NLM_string-name">Girgis, I.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetic analysis of BMS-986166, a novel selective sphingosine-1-phosphate 1 receptor modulator, and exposure-response assessment of its effects on lymphocyte counts and heart rate in healthy participants unpublished results</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Bihorel%2C+S.%3B+Singhal%2C+S.%3B+Shevell%2C+D.%3B+Sun%2C+H.%3B+Xie%2C+J.%3B+Basdeo%2C+S.%3B+Liu%2C+A.%3B+Dutta%2C+S.%3B+Huang%2C+H.%3B+Lin%2C+K.%3B+Throup%2C+J.%3B+Girgis%2C+I.+Population+pharmacokinetic+analysis+of+BMS-986166%2C+a+novel+selective+sphingosine-1-phosphate+1+receptor+modulator%2C+and+exposure-response+assessment+of+its+effects+on+lymphocyte+counts+and+heart+rate+in+healthy+participants+unpublished+results."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DBihorel%26aufirst%3DS.%26atitle%3DPopulation%2520pharmacokinetic%2520analysis%2520of%2520BMS-986166%252C%2520a%2520novel%2520selective%2520sphingosine-1-phosphate%25201%2520receptor%2520modulator%252C%2520and%2520exposure-response%2520assessment%2520of%2520its%2520effects%2520on%2520lymphocyte%2520counts%2520and%2520heart%2520rate%2520in%2520healthy%2520participants%2520unpublished%2520results" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, H.-Y.</span>; <span class="NLM_string-name">Dyckman, A. J.</span>; <span class="NLM_string-name">Xiao, Z.</span>; <span class="NLM_string-name">Yang, M. G.</span>; <span class="NLM_string-name">Dhar, T. G. M.</span>; <span class="NLM_string-name">Gilmore, J. L.</span>; <span class="NLM_string-name">Marcoux, D.</span></span>; <span> </span><span class="NLM_article-title">Substituted Bicyclic Compounds</span>. U.S. Pat. Appl. <span class="NLM_patent">0052888</span>, World Patent <span class="NLM_patent">WO201628959</span><span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=H.-Y.+Xiao&author=A.+J.+Dyckman&author=Z.+Xiao&author=M.+G.+Yang&author=T.+G.+M.+Dhar&author=J.+L.+Gilmore&author=D.+Marcoux&title=Substituted+Bicyclic+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DH.-Y.%26atitle%3DSubstituted%2520Bicyclic%2520Compounds%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacIntyre, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rance, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wastall, P.</span></span> <span> </span><span class="NLM_article-title">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=9336307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;key=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=46-58&author=R.+Obachauthor=J.+Baxterauthor=T.+E.+Listonauthor=B.+M.+Silberauthor=B.+C.+Jonesauthor=F.+MacIntyreauthor=D.+J.+Ranceauthor=P.+Wastall&title=The+prediction+of+human+pharmacokinetic+parameters+from+preclinical+and+in+vitro+metabolism+data"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data</span></div><div class="casAuthors">Obach, R. Scott; Baxter, James G.; Liston, Theodore E.; Silber, B. Michael; Jones, Barry C.; Macintyre, Flona; Rance, David J.; Wastall, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">46-58</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 35 refs.  We describe a comprehensive retrospective anal. in which the abilities of several methods by which human pharmacokinetic parameters are predicted from preclin. pharmacokinetic data and/or in vitro metab. data were assessed.  The prediction methods examd. included both methods from the scientific literature as well as some described in this report for the first time.  Four methods were examd. for their ability to predict human vol. of distribution.  Three were highly predictive, yielding, on av., predictions that were within 60% to 90% of actual values.  Twelve methods were assessed for their utility in predicting clearance.  The most successful allometric scaling method yielded clearance predictions that were, on av., within 80% of actual values.  The best methods in which in vitro metab. data from human liver microsomes were scaled to in vivo clearance values yielded predicted clearance values that were, on av., within 70% to 80% of actual values.  Human t1/2 was predicted by combining predictions of human vol. of distribution and clearance.  The best t1/2 prediction methods successfully assigned compds. to appropriate dosing regimen categories (e.g., once daily, twice daily and so forth) 70% to 80% of the time.  In addn., correlations between human t1/2 and t1/2 values from preclin. species were also generally successful (72-87%) when used to predict human dosing regimens.  In summary, this retrospective anal. has identified several approaches by which human pharmacokinetic data can be predicted from preclin. data.  Such approaches should find utility in the drug discovery and development processes in the identification and selection of compds. that will possess appropriate pharmacokinetic characteristics in humans for progression to clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppAngniZ4izLVg90H21EOLACvtfcHk0lgZ4_uzVXQsKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmslCltr0%253D&md5=68d1910d925e26ec4a8ef23043ffb1ed</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%26aulast%3DBaxter%26aufirst%3DJ.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DSilber%26aufirst%3DB.%2BM.%26aulast%3DJones%26aufirst%3DB.%2BC.%26aulast%3DMacIntyre%26aufirst%3DF.%26aulast%3DRance%26aufirst%3DD.%2BJ.%26aulast%3DWastall%26aufirst%3DP.%26atitle%3DThe%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%2520from%2520preclinical%2520and%2520in%2520vitro%2520metabolism%2520data%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1997%26volume%3D283%26spage%3D46%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i76"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01695">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_82616"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01695">10.1021/acs.jmedchem.8b01695</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">X-ray crystallographic structures of <b>18b</b> and <b>14a</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_001.pdf">jm8b01695_si_001.pdf (3.31 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01695/suppl_file/jm8b01695_si_002.csv">jm8b01695_si_002.csv (1.78 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01695&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-5%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01695" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01695" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c4c81abe3c10","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
